Role of stromal Caveolin-1 (CAV1) levels in breast cancer angiogenesis by Díez Sánchez, Alberto (dir.)
0 
 
Universidad Autónoma de Madrid 
Programa de Doctorado en Biociencias Moleculares 
 
  
 
Role of stromal Caveolin-1 (CAV1) 
levels in breast cancer angiogenesis 
 
Alberto Díez Sánchez  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Madrid, 2018 
1 
 
Departamento de Bioquímica 
Facultad de Medicina 
Universidad Autónoma de Madrid 
 
  
 
Role of stromal Caveolin-1 (CAV1) 
levels in breast cancer angiogenesis 
 
Doctorando: Alberto Díez Sánchez, Licenciado en Biotecnología 
Director: Miguel Ángel del Pozo Barriuso, MD, PhD. 
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC)  
 
 
 
 
 
 
 
 
 
 
 
Madrid, 2018 
 
5 
 
ACKNOWLEDGMENTS 
 
It is said that scientific knowledge is built on top of the shoulder of giants, in more practical 
terms, I consider all these people below my personal giants. 
First ones I encountered, were my parents and grandparents, everything I have achieved has 
been done on top of their previous efforts, to them I dedicate my most sincere gratitude for 
teaching this once lazy kid the value of effort. 
Next, I have to thank all those high-school teachers and university professors that during my 
education have been able to spark in me the sense of amazement derived from understanding 
how nature works. Special acknowledgments to my high school biology teacher Charo Díaz, 
who was able to amazingly convey and share her enthusiasm for her teachings, you are guilty 
of my choice for biological sciences. 
While instigating this interest was crucial in my career, a very different scenario was 
maintaining and nurturing it. Here I would like to thank all those good mentors I have come 
across during my short lab years: Luis Ángel Fernández (CNB), Marilyn G. Farquhar (UCSD), 
Mehul Shah (UCSD), Geir Bjørkøy (NTNU)... In this regard, I am especially grateful to my 
thesis director, Miguel Ángel del Pozo (CNIC), for giving me enough freedom to seek my own 
questions, make my own mistakes and having the patience of, afterward, dealing with them. 
On a day to day basis, I am grateful for the people that I have been sharing my bench floor 
with (both in Spain and in Norway); talking about, most usually, the disappointment of failing 
experiments and, less commonly, the excitement for a major breakthrough has made my 
passage through these thesis years much easier and funnier than anticipated. Finishing this 
period with a good feeling is because of you. 
In terms of heavy-lifting work, I am grateful for having Mauro, Inés, and Miguel by my side. All 
the work presented here today would not have been possible without your key contributions. I 
do not forget my collaborators, in image analysis (Xenia, Daniel, and Laura), high-content 
screening (Irene and Mariano) and bioinformatics analysis, your abilities do not cease to 
amaze me. 
On a personal level, I feel blessed with my lifelong neighborhood friends, not only because of 
the countless hours of fun that have made easier dealing with lab stress, but also for their 
continuous support.  Without deserving it, they have been calling me “doctor” even before 
starting my degree. This one is for you. 
6 
 
Last but not least, a very special thanks to Mara, my life partner, who has been lately dealing 
with my stress-related mood swings using an infinite amount of patience and unconditional 
love. You have made this possible and I cannot wait to have more of yourself for the years to 
come. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This doctoral thesis was made possible with the funding of Obra Social “la Caixa” 
7 
 
SUMMARY 
 
Tumors have been described as “wounds that never heal”; and non-tumoral surrounding cell 
populations involved in angiogenesis and response to injury, such as endothelial cells, immune 
cells and fibroblasts are actively engaged to support the aberrant growth and remodeling of 
the tumor mass, which conversely determine tumor architecture and behavior. These cells, 
along with extracellular matrix (ECM) components, define the tumor microenvironment or 
tumor stroma.  
While breast cancer progression was conceived for a long time to be largely dependent on 
aberrant mutations in tumor cells, stromal Cancer-Associated Fibroblasts (CAFs) have been 
demonstrated to modulate breast cancer growth, invasion, metastasis and therapeutic 
resistance. 
Caveolin-1 (CAV1), a prominent organizer of plasma membrane properties and function, 
exhibits extensive ties with many events defining tumor onset and progression. Although 
previous studies have shown CAV1 expression levels in CAFs to influence breast cancer 
growth and metastasis, the underlying driving mechanisms remain incompletely characterized. 
In this regard, ECM modification and metabolic reprogramming have been proposed as key 
aspects of a stromal CAV1-dependent role in tumor biology. 
This thesis research report aims to contribute to our understanding as to how CAV1 expression 
in stromal CAFs impact tumor angiogenesis, and thus tumor hypoxia, cancer aggressiveness 
and metastasis. 
The present work showcases evidence supporting a positive reciprocal feedback relationship 
between stromal CAV1 downregulation and endoplasmic reticulum (ER) stress, which can 
drive exacerbated proangiogenic signaling, causative of the generation of an aberrant and 
dysfunctional tumor vasculature. 
This report proposes defective angiogenesis and consequent hypoxia as major driving causes 
for increased aggressiveness of breast cancer in low stromal CAV1 tumors.  
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RESUMEN 
 
Los tumores podrían describirse como heridas que nunca terminan de curarse. En respuesta 
a esta agresión, se puede observar el reclutamiento de células del sistema inmune, de 
fibroblastos que intentan cerrar la lesión y de células endoteliales implicadas en la formación 
de nuevos vasos sanguíneos y linfáticos. Estas células, en conjunto con la matriz extracelular 
(ECM, Extracellular Matrix, por sus siglas en inglés) que las rodea, conforman lo que se 
conoce como microambiente o estroma tumoral.  
Durante décadas, la progresión y el comportamiento del cáncer de mama se concebían como 
procesos dependientes de las mutaciones que acaecían en las células tumorales. Sin 
embargo, recientemente varios estudios han demostrado que el microambiente tumoral en 
general, y los fibroblastos estromales asociados al tumor (CAFs, Cancer-Associated 
Fibroblasts, por sus siglas en inglés) en particular, son capaces de modular el crecimiento 
tumoral, la capacidad invasiva y el proceso metastático del cáncer de mama, así como la 
resistencia a determinadas terapias. 
Aunque estudios previos han demostrado que los niveles de la proteína Caveolina-1 (CAV1) 
que presentan los fibroblastos estromales (CAFs) tienen una influencia sobre la capacidad 
metastática y de crecimiento del cáncer de mama, el mecanismo responsable de esta 
habilidad moduladora está por resolver. Procesos como la modificación ejercida por estos 
CAFs sobre la ECM y su potencial para reprogramar el metabolismo tumoral se han postulado 
como piezas de este rompecabezas. 
Este trabajo describe como una bajada en la expresión de CAV1 en CAFs estromales 
orquestra la formación de una vasculatura tumoral disfuncional y aberrante que resulta en un 
incremento de la hipoxia, la agresividad y la capacidad metastática de estos tumores con bajos 
niveles de CAV1 estromal. Además, establece un círculo vicioso de retroalimentación positiva 
entre la menor expresión de CAV1 y la inducción de estrés reticular, que en última instancia 
es responsable de la activación de una señalización proangiogénica exacerbada que deriva 
en la formación de la vasculatura aberrante arriba mencionada. 
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NON-STANDARD ABBREVIATIONS AND ACRONYMS 
2-DG 2-Deoxyglucose 
ACTA2 Smooth Muscle Actin (aka αSMA) 
ADAMTS A Disintegrin and Metalloproteinase with Thrombospondin Motifs 
Ag Antigen 
aka Also Known As 
ANG Angiogenin 
ANGP1/2 Angiopoietin-1/2 (Protein) ANGPT1/2 (Gene/Transcript) 
ANOVA Analysis of Variance 
AR Androgen Receptor 
ATF4 / 6 Activating Transcription Factor 4 / 6 
AVCs Angiogenic Vascular Cells 
BLBC Basal-Like Breast Cancer 
BM Basement Membrane 
BMPs Bone Morphogenetic Proteins 
brCAN Breast cancer cell lines 
CAFs Cancer-Associated Fibroblasts (aka TAFs) 
CAFscr Breast CAFs transduced with a non-targeting lentivirus 
CAFshCAV1 Breast CAFs transduced with a CAV1 mRNA-targeting lentivirus 
CAV1 Caveolin-1 (protein/gene/transcript) 
CCDN1 Cyclin D1 
CCL2 C-C Motif Chemokine Ligand 2 (aka MCP-1) 
CCL5 Chemokine (C-C motif) ligand 5 
CD31 Platelet Endothelial Cell Adhesion Molecule (aka PECAM-1) 
CherryFP Cherry Fluorescent Protein (aka ChFP) 
CHOP C/EBP-Homologous Protein (aka DDIT3) 
CK Cytokeratin 
c-Met Tyrosine-protein kinase Met (aka HGFR) 
CMV Cytomegalovirus 
cPPT  Central Polypurine Tract 
CSCs Cancer Stem Cells 
CSD Caveolin Scaffolding Domain 
CSF-1 Colony Stimulating Factor 1 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
CXCL10 C-X-C Motif Chemokine Ligand 10 
CXCL12 Stromal Derived Growth Factor 1 (aka SDF1) 
CXCL8 Interleukin-8 (gene/transcript) 
CXCR1/2 C-X-C Motif Chemokine Receptor 1/2 
DCA Dichloroacetic Acid 
DCIS Ductal Carcinoma In Situ 
DCs Dendritic Cells 
DPP4 Dipeptidyl Peptidase 4 
ECAR Extracellular Acidification Ratio 
ECGM Endothelial Cell Growth Medium 
ECM Extracellular Matrix 
ECs Endothelial Cells 
EdU 5-ethynyl-2’-deoxyuridine 
EGF Epidermal Growth Factor    
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EGFR Epidermal Growth Factor Receptor 
eIF2α Eukaryotic Translation Initiation Factor 2A 
ELISA Enzyme-linked Immunosorbant Assay 
EMT Epithelial to Mesenchymal Transition 
EndMT Endothelial to Mesenchymal Transition 
EPCs Endothelial Progenitor Cells 
ER Estrogen Receptor (appears in breast cancer introduction) 
ER  Endoplasmic Reticulum (rest of the text) 
FACS Fluorescence Activated Cell Sorting 
FAP Fibroblast Activation Protein 
FBS Fetal Bovine Serum 
FGFs Fibroblast Growth Factors 
FSP1 Fibroblast Specific Protein 1 (aka S100A4) 
GFP Green Fluorescent Protein 
GLUT1 Glucose Transporter Type 1 (aka SLC2A1) 
GSH Glutathione 
GSH-EE Glutathione Ethyl Ester 
H&E Hematoxylin and Eosin 
HCS High Content Screening 
HER2 Human Epidermal Growth Factor Receptor 2 
HG High Glucose 
HGF Hepatocyte Growth Factor 
HIFs Hypoxia Inducible Factors 
HIF1A Hypoxia Inducible Factor 1 Alpha (aka HIF-1α)  
HK Hexokinase 
HR Hormone Receptor status in breast cancer 
HRAS Harvey Rat Sarcoma Viral Oncoprotein 
HRE Hypoxia Response Elements 
HUVEC Human Umbilical Vein Endothelial Cells  
IDC Invasive Ductal Carcinoma 
IFNγ Interferon Gamma 
IFP Interstitial Fluid Pressure 
IGF-1 Insulin-like Growth Factor 1 
IHC Immunohistochemistry 
IICs Immune Infiltrating Cells 
IL-1β Interleukin-1 Beta (protein), IL1B (gene/transcript) 
IL-6 Interleukin-6 (protein), IL6 (gene/transcript) 
IL-8 Interleukin-8 (protein), CXCL8 (gene/transcript) 
ILC Invasive Lobular Carcinoma 
IMG Intussusceptive microvascular growth  
IPA Ingenuity Pathway Analysis 
IRE1α Inositol-Requiring Enzyme 1 Alpha 
ISR Integrated Stress Response 
ITGA11 Integrin Subunit Alpha 11 
Ki67 Marker Of Proliferation Ki-67 
kDa Kilodalton 
LC3 Autophagy-Related Ubiquitin-Like Modifier LC3 
LCIS Lobular Carcinoma In Situ 
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LG Low Glucose 
logFC Log2 fold-change 
LTRs Long Terminal Repeats 
LYVE1 Lymphatic Vessel Endothelial Hyaluronan Receptor 1 
mAb  Monoclonal Antibody (aka MAB) 
MCP-1 Monocyte Chemoattractant Protein-1 (aka CCL2) 
MCS Multi Cloning Site 
MCT1 Monocarboxylate Transporter 1 
MDSCs Myeloid-Derived Suppressor Cells  
MEK Mitogen-Activated Protein Kinase Kinase 1 (aka MAP2K1) 
miR microRNA (aka miRNA) 
MMPs Matrix Metalloproteinases 
MOI Multiplicity of Infection 
MSCs Mesenchymal Stem Cells 
MT  Prefix for genes encoded by the mitochondrial genome 
mTOR  Mechanistic Target Of Rapamycin Kinase 
MW Molecular Weight 
NAFs Normal Activated Fibroblasts 
NDUFS1/2 NADH:Ubiquinone Oxidoreductase Core Subunit S1/2 
NFs Normal Fibroblasts 
NFκB Nuclear Factor Kappa B Subunit 1 
NK Natural Killer cell 
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice 
OCR Oxygen Consumption Rate 
OXPHOS Oxidative Phosphorylation 
P2A Porcine Teschovirus "self-cleaving" 2A peptide 
P62 Sequestosome 1 (aka SQSTM1) 
pAb  Polyclonal Antibody 
PARP Poly(ADP-Ribose) Polymerase 
PBS Phosphate Buffered Saline 
PCMV Cytomegalovirus promoter (aka CMV) 
pCR  Pathological Complete Response 
PD-1 Programmed Cell Death 1  
PDGFRβ Platelet-Derived Growth Factor Receptor Beta 
PDGFs Platelet-Derived Growth Factors 
PD-L1 Programmed Cell Death 1 Ligand 1 
PECAM1 Platelet And Endothelial Cell Adhesion Molecule 1 (aka CD31) 
PERK Pancreatic EIF2-Alpha Kinase 
PERKi Pancreatic EIF2-Alpha Kinase inhibitor 
PET-CT Positron Emission Tomography - Computed Tomography 
PFA Paraformaldehyde 
PFKFB3 6-Phosphofructo-2-Kinase/Fructose-2,6-biphosphatase 3 
PGK1 Phosphoglycerate Kinase 1 
PI3K Phosphatidylinositol-4,5-Bisphosphate 3-Kinase 
PIGF Phosphatidylinositol Glycan Anchor Biosynthesis Class F 
pO2 Partial Oxygen (O2) pressure 
PR Progesterone Receptor 
PuroR Puromycin resistance 
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qPCR  Quantitative Polymerase Chain Reaction 
RAF Raf-1 Proto-Oncogene, Serine/Threonine Kinase 
RAS Kirsten Rat Sarcoma Viral Oncogene Homolog (aka K-RAS) 
RE Restriction Enzyme 
RE8luc Far Red light emitting luciferase 
RER Rough Endoplasmic Reticulum 
RLUs Relative Luminescent Units 
RNASeq RNA sequencing 
ROBO Roundabout Guidance Receptor 
ROS Reactive Oxygen Species 
RPL / RPS Ribosomal Protein L family / Ribosomal Protein S family 
RRE Rev Response Elements 
sCAV1high Tumor xenografts with high levels of stromal CAV1 (from CAFscr) 
sCAV1low Tumor xenografts with low levels of stromal CAV1 (from CAFshCAV1) 
SD Standard Deviation 
SDF-1 Stromal Derived Growth Factor 1 (aka CXCL12) 
SDHA/B Succinate Dehydrogenase Complex Flavoprotein Subunit A/B 
SEM Standard Error Mean 
SERCA ATPase Sarcoplasmic/Endoplasmic Reticulum Ca2+ Transporting 2 
SHG Second Harmonic Generation 
SLIT Slit Guidance Ligand 
SPARC Secreted Protein Acidic And Rich In Cysteine (aka Osteonectin) 
SRC SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase 
SREs Steroid Response Elements 
STAT3 Signal Transducer And Activator Of Transcription 3 
TAFs Tumor-Associated Fibroblasts (aka CAFs) 
TAMs Tumor-Associated Macrophages 
TCs Tumor Cells (TNBC breast cancer cell lines in this case) 
TCsluc TNBC Cell Lines transduced with a luciferase-expressing lentivirus 
TGF-β Transforming Growth Factor Beta 
THBS1/2 Thrombospondin 1/2 
TIE2 TEK Receptor Tyrosine Kinase 
TIMPs Tissue Inhibitor Of Metalloproteinases 
TKIs Tyrosine Kinase Inhibitors 
TKs Tyrosine Kinases 
TME Tumor Microenvironment 
TNBC Triple Negative Breast Cancer 
TNF Tumor Necrosis Factor 
TPI1 Triosephosphate Isomerase 1 
Treg Regulatory T cells 
TSS Transcription Start Site 
UPR Unfolded Protein Response 
VASH1 Vasohibin 1 
VEGFA Vascular Endothelial Growth Factor (gene/transcript) VEGF-A (protein) 
VEGFR2 Vascular Endothelial Growth Factor Receptor 2 (protein/gene) 
WPRE Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element 
XBP1 X-Box Binding Protein 1 
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GLOSSARY OF MEDICAL TERMS 
Adapted from NCI Dictionary of Cancer Terms 
(These medical terms are highlighted in bold in the main text) 
Adjuvant therapy: Additional cancer treatment given after the primary treatment to lower the 
relapse occurrence. Adjuvant therapy may include chemotherapy, radiation therapy, hormone 
therapy, targeted therapy, or biological therapy. 
BRCAness: Used to define tumors with loss-of-function mutations in either BRCA1 or BRCA2 
or tumors that share molecular features of BRCA-mutant tumors such as a defect in double-
strand break repair (DSBR) by homologous recombination repair (HRR). 
Cancer Stage: Stage refers to the extent of cancer in an individual patient, such as how large 
the tumor is, and if it has spread. The TNM system is the most widely used cancer staging 
system: (i) T refers to the size and extent of the main primary tumor, (ii) N refers to the number 
of nearby lymph nodes that have cancer and (iii) M refers to presence of metastases in a 
secondary site. 
Disease-free survival: The length of time between first-line therapy and relapse, thus survival 
time without any signs or symptoms of disease. In clinical practice, measuring the disease-free 
survival is a useful tool to evaluate treatment efficacy. Also known as DFS or relapse-free 
survival (RFS). 
Immune-checkpoint inhibitors:  Drugs that block certain proteins made by some immune 
system cells, such as T cells, and some cancer cells. These proteins help keep immune 
responses in check and can keep T cells from killing cancer cells. When these proteins are 
blocked, the “brakes” on the immune system are released and T cells are able to kill cancer 
cells more efficiently. Examples of checkpoint proteins found on T cells or cancer cells include 
PD-1/PD-L1 and CTLA-4/B7-1/B7-2. Some immune checkpoint inhibitors are used to treat 
cancer. 
Incidence: The number of new cases of a disease diagnosed each year. 
Metronomic: Treatment in which low doses of drugs are given on a continuous or frequent, 
regular schedule (such as daily or weekly), usually over a long time. Metronomic chemotherapy 
causes less severe side effects than standard chemotherapy. Giving low doses of 
chemotherapy may stop the growth of new blood vessels that tumors need to grow.  
Neoadjuvant therapy: Treatment given as a first step to shrink a tumor before the main 
treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include 
chemotherapy, antiangiogenic therapy, radiation therapy, and hormone therapy. 
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Overall survival: The length of time from either the date of diagnosis or the start of treatment 
for a disease, such as cancer, that patients diagnosed with the disease are still alive. In a 
clinical trial, measuring the overall survival is one way to see how well a new treatment works. 
Also called OS. 
Pathologic complete response (pCR): The lack of all signs of cancer in tissue samples 
removed during surgery or biopsy after treatment with radiation or chemotherapy. To find out 
if there is a pathologic complete response, a pathologist checks the tissue samples under a 
microscope to see if there are still cancer cells left after the anticancer treatment. Knowing if 
the cancer is in pathologic complete response may help show how well treatment is working 
or if cancer will relapse. Also called pathologic complete remission. 
Tumor Grade: Tumor grade is the description of a tumor based on how abnormal the tumor 
cells and the tumor tissue look under a microscope. It is an indicator of how quickly a tumor is 
likely to grow and spread. If the cells of the tumor and the organization of the tumor’s tissue 
are close to those of normal cells and tissue, the tumor is called “well-differentiated” These 
tumors tend to grow and spread at a slower rate than tumors that are “undifferentiated” or 
“poorly differentiated,” which have abnormal-looking cells and may lack normal tissue 
structures. 
Predictive factor: A condition or finding that can be used to help predict whether a patient’s 
cancer will respond to a specific treatment. Predictive factor may also describe something that 
increases an individual’s risk of developing a condition or disease. 
Prevalence: Total number of people in a specific group who have (or had) a certain disease, 
condition, or risk factor (such as smoking or obesity) at a specific time point or during a given 
period of time. For example, the prevalence of breast cancer may show how many women in 
the U.S. were diagnosed with breast cancer within the past 10 years, including those who are 
receiving treatment and those who are considered cured and are still alive on a certain date. 
Prognosis: The likely outcome or course of a disease; the chance of recovery or recurrence. 
Relapse: The return of a disease or the signs and symptoms of a disease after a period of 
improvement. 
Sentinel lymph node: The first lymph node to which cancer is likely to spread from the primary 
tumor. When cancer spreads, the cancer cells may appear first in the sentinel node before 
spreading to other lymph nodes. 
Sentinel lymph node mapping: The use of dyes or radioactive substances to identify the first 
lymph node to which cancer is likely to spread from the primary tumor. 
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1. INTRODUCTION 
1.1 Breast Cancer: an overview 
More than 1.5 million women worldwide are diagnosed with breast cancer each year, making 
it the most common form of cancer in women1. It does not only show the highest incidence, 
but it is also the first cause of cancer death in women, both worldwide and in Spain2,3.  
Breast cancer prevalence, together with awareness-raising efforts, has given breast cancer a 
high public profile. Therefore, research into breast cancer’s treatments, early detection, and 
improved screening campaigns have been well funded. As a result, the survival rates for breast 
cancer have improved markedly over the decades4. 
However not all breast tumors are the same, and for some there are still not effective 
treatments, so nearly half-a-million women worldwide still die from this disease each year2. 
Recognizing breast cancer multiple subtypes by understanding the different phenotypic and 
molecular differences allow health professionals to stratify patients with distinct clinical 
implications5. An accurate classification turns out to be an efficient prognostic and predictive 
factor, both in terms of estimating the disease outcome (disease-free and overall survival) 
and the likelihood/lack of response to a specific treatment, respectively. 
Strikingly, once distant dissemination (metastasis) has developed, breast cancer remains 
largely incurable with a median survival of patients with metastatic breast cancer ranging from 
2 to 3 years6. One subtype with a particularly poor prognosis is Triple Negative Breast Cancer 
(TNBC). Here, the tumor cells lack the three receptors often leveraged for targeted treatment 
in breast cancer, leaving drug developers with little to aim at7,8. 
1.1.1 Breast Anatomy and Physiology 
The breast is a highly complex and plastic tissue subject to cyclical and sequential changes, 
mainly related to hormonal variations, happening at different stages in a woman’s life.  
It is composed of glandular and adipose tissue held together by a framework of fibers called 
Cooper’s ligaments. Each mammary gland located in the breast, termed lobe, is made of a 
series of milk-producing lobules. These lobes consist of clusters of lobules lined by an inner 
layer of milk-producing luminal epithelial cells, an intermediate layer of myoepithelial cells that 
provide structural support and assist in milk ejection during lactation, and an outer basement 
membrane9. The lobules continue into small ducts, showing the same structural and cellular 
organization, that finally merge into a unique duct draining each lobe. These ducts form a tree-
branch-like network that converges at the base of the nipple and are responsible for delivering 
the milk to the surface of the skin through tiny pores in the nipple10 (Fig. 1).  
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Breast cancer usually begins in the ducts that carry milk to the nipple or within the lobules11,12. 
During metastasis, cancer cells escape the primary tumor through the tumor vasculature and, 
preferentially, via the breast lymphatic system which is in charge of excess fluid drainage and 
white blood cell transport13,14. As many cancers do, breast cancer possesses an organ-specific 
pattern of dissemination, metastasizing to the lung, liver, bones, and brain15, which is enriched 
in one target organ or another depending on breast cancer subtype16. Ducts, lobules, and 
lymph nodes are key structures when determining the stage of a patient’s breast cancer. 
 
Figure 1. Breast anatomy and histology. Breast is composed of glandular and stromal tissue. 
Glandular tissue consists of lobes and ducts and the stroma includes the area in between lobes. Breast 
structures are presented at the macroscopic, lobular and cellular levels. 
1.1.2 Classification of Breast Cancers  
Breast cancer classification divides breast cancer into subtypes according to different criteria 
with the purpose of estimating the disease outcome (prognosis) or selecting the best treatment. 
Major criteria for classification include: histological type, tumor grade, tumor stage, receptor 
status and gene expression profile.   
1.1.2.1 Histopathological Features  
Histological type refers to the growth pattern of tumors, and whether they stay in situ (in its 
place of origin) or invade the surrounding tissues (Fig. 2). Among these non-invasive in situ 
lesions, we find: (i) Ductal Carcinoma In Situ (DCIS), a precancerous lesion that starts in the 
milk ducts and has not spread into any normal surrounding tissue, and (ii) Lobular Carcinoma 
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In Situ (LCIS), a collection of abnormal cells (neoplasia), that starts growing in the milk-
producing lobules at the end of breast ducts. Both, DCIS and LCIS are precancerous non-
invasive neoplasia, and thus are not considered malignant cancer17,18. Around 1 out of every 
5 new breast “cancer” cases are diagnosed as DCIS12 .  
Approximately 80% of breast carcinomas are Invasive Ductal Carcinoma (IDC), followed by 
Invasive Lobular Carcinomas (ILC) which account for approximately 10-15% of cases19. IDC 
and ILC are cancers that originated in the milk ducts or the lobules, respectively, but have 
broken through the basement membrane and spread into the surrounding tissues of the breast. 
 
Figure 2. Histopathological classification of lobular and ductal breast cancer. Invasion of cancer 
cells through the basement membrane marks the transformation from in situ lesions (LCIS/DCIS) into 
invasive carcinomas (ILC / IDC). 
1.1.2.2 Immunohistochemical Evaluation: Receptor Status 
Breast cancer prognosis and treatment protocols still rely primarily on receptor status 
assessment by immunohistochemistry (IHC) of three markers: estrogen receptor (ER), 
progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2)20,21. 
The presence of one or more of these receptors suggests that a treatment targeting these 
pathways might be effective. Targeted proliferation-inhibition therapies for HER2+ breast 
cancers include monoclonal antibodies (Trastuzumab and Pertuzumab) aimed at the HER2 
receptor and tyrosine kinase inhibitors (Lapatinib) that interrupt the EGFR and HER2 signaling 
pathways22. Hormone receptor (HR) positive breast tumors (ER+ and/or PR+) are treated with 
endocrine therapy, which slows or stops the growth of hormone-sensitive tumors by: (i) 
blocking the body’s ability to produce hormones or (ii) interfering with effects of hormones on 
breast cancer cells using estrogen receptor modulators (i.e. Tamoxifen) or antiestrogen drugs 
(i.e. Fulvestrant)23,24.  
Meanwhile, the absence of, or in the case of HER2, lack of overexpression of, all of these 
receptors (ER- PR- HER2-), termed Triple Negative Breast Cancer (TNBC), indicates a need 
for the more toxic, non-targeted, classical chemotherapy7,8. 
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Receptor status designation and Ki67 proliferation index (+ for high an - for low) largely 
correspond, but do not completely overlap, with more recent determinations of intrinsic 
molecular subtypes based on patterns of gene expression25,26.  
1.1.2.3 Gene Expression Profiling: Intrinsic Molecular Subtype 
Pivotal studies of gene expression, made possible by high-throughput analysis platforms (i.e. 
microarrays), have resulted in the classification of breast cancer according to intrinsic 
molecular subtypes: luminal A, luminal B, HER2-enriched, normal-like, and basal-like breast 
cancer (BLBC)25,26.  
These five intrinsic subtypes have been validated by other studies with varying numbers of 
genes included in the signature27. Among these studies, PAM50, a 50-gene classifier mostly 
based in hormone receptor, proliferative and myoepithelial/basal-related genes28, has been 
shown to be a significant prognostic and predictive factor for breast tumors in a clinical 
setting29–31. However these “gene signatures” are yet to be fully incorporated into clinical 
practice32–34. 
Table 1. Summary of breast cancer molecular intrinsic subtypes and IHC receptor status 
approximate equivalence with associated disease outcomes and prevalence. Slash (/) in between 
receptor status represents and/or (presence of both receptors/or just one of them). 
Intrinsic subtype IHC Receptor Status Outcome Prevalence35 
Luminal A ER+ / PR+ HER2- Ki67- Good 38.5% 
Luminal B 
ER+ / PR+ HER2- Ki67+ Intermediate 
19.8% 
ER+ / PR+ HER2+ Ki67+ Poor 
HER2-enriched ER- PR- HER2+ Poor 11.6% 
Basal-like (BLBC) ER- PR- HER2-, basal marker+ Poor 25.4% 
Normal-like ER+ / PR+ HER2- Ki67- Intermediate 4.7% 
 
These subtypes have been associated with different prognoses, with patients harboring 
luminal A tumors having the best prognosis, and patients with HER2-enriched and BLBC 
having the worst21. The poor prognosis of these two subtypes derives from a higher risk of 
early relapse among those patients with an incomplete eradication of tumor cells (or 
pathological complete response, pCR) after treatment36. Furthermore, patients can be 
separated by treatment protocols based on these subtypes25,26, since luminal and HER2 
enriched subtypes are amenable to targeted therapies, while patients with BLBC currently 
have only chemotherapy as an option28,37.  
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1.1.3 Triple Negative Breast Cancer (TNBC)  
The majority of TNBCs (95%) are classified histologically as Invasive Ductal Carcinomas 
(IDCs)38. Although it has been discussed that TNBC and BLBC are the same subtypes, not all 
TNBC express basal cells markers39. It is true that most TNBCs are classified as BLBCs 
(80.6%), but some also fall into HER2-enriched (10.2%), normal-like (4.7%), luminal B (3.5%) 
and luminal A (1.1%) categories40 (Fig. 3A). 
Behind its homogeneous nomenclature, TNBC is comprised of many different disease entities. 
Based on genetic expression profiling, TNBC has been categorized into six “TNBCtypes” 
associated with different potential treatments41: Basal-like 1 and 2 (BL-1, BL-2), 
Immunomodulatory (IM), a rare, histologically distinct form of TNBC associated with a 
favorable prognosis42, Mesenchymal (M) and Mesenchymal stem-like (MSL) showing 
signatures related to epithelial to mesenchymal transition (EMT), and Luminal Androgen 
Receptor (LAR), characterized by androgen receptor (AR) signaling and in vitro sensitiveness 
to AR antagonists (Fig. 3B). 
In regard to treatment options, TNBC 
patients with mutations in BRCA1/2 or other 
genes related to homologous recombination-
mediated DNA repair (“BRCAness”) may 
benefit from treatment with platinum 
compounds and PARP inhibitors aimed at 
inhibiting DNA repair mechanisms8. The 
majority of actionable genomic alterations, 
related to PI3K/mTOR or RAS/RAF/MEK 
pathways, tend to be rare in TNBC8. Still, 
immune-checkpoint inhibitors are a very 
promising therapeutic option in adjuvant and 
neoadjuvant therapy of early-stage and 
metastatic TNBC8,43. 
However, the only proven current method for 
systemic management of triple-negative 
breast cancer, for both early-stage and 
metastatic settings, is cytotoxic 
chemotherapy7,8. In patients who receive 
neoadjuvant chemotherapy and show pathological complete response (pCR) on resection, 
prognosis is very good. However, patients who do not show complete pCR have a worse 
prognosis with a higher incidence of recurrences8.  
Figure 3. TNBC molecular subtypes according to 
(A) PAM50 classification or (B) TNBCtype; UNS, 
unstable; UNCL, unclassified. 
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Despite optimal systemic chemotherapy, fewer than 30% of women with metastatic breast 
cancer survive 5 years after diagnosis, and virtually all women with metastatic TNBC will 
ultimately die of their disease44. Thus, there is an urgent need to find targeted therapies and 
stratify TNBC patients by treatment options.  
1.2 Tumor Microenvironment (TME) / Tumor Stroma 
Cancer progression was long conceived to be largely dependent on aberrant mutations in 
tumor cells. Therefore, a substantial share of cancer research has been focused on unveiling 
the dominant oncogenes and tumor suppressor genes whose respective malfunction serves 
to impart aberrant properties on normal cells45.  
However, a new understanding of tumor biology, where cancer cells are not the only active 
elements determining tumor progression, has emerged during the past decade46,47. Tumors 
develop within complex tissue environments, which they depend on for sustained growth, 
invasion, and metastasis. This environment, referred as tumor stroma or tumor 
microenvironment (TME), is supported by an extracellular matrix (ECM) where stromal cells, 
blood, and lymphatic vessels coexist and interact with tumor cells45–48 (Fig. 4).  
Due to the non-physiological nature of the tumor cells it harbors, TME exhibits altered 
homeostasis and aberrant immune responses, actively contributing to tumor behavior and 
progression49–51. Tumor onset is characterized by an unresolved inflammatory response52,53, 
where stromal cells accumulate and become activated in an attempt to normalize the situation. 
Nevertheless, their normal role in homeostasis maintenance turns dysfunctional and finally 
evolves to accommodate and support the growing tumor54. In this sense, tumors have been 
described as “wounds that never heal”55, thus cells involved in angiogenesis and the response 
to injury, such as angiogenic vascular cells (AVCs), infiltrating immune cells (IICs), and 
fibroblasts will be on-site constituting the stromal cell compartment of the TME.  
Cancer therapy is incorporating this paradigm and moving towards more integrative 
approaches, where personalized diagnostics and combinatorial therapeutics will target not only 
cancer cells but also stromal cells and pathways of the TME56,57. Furthermore, according to 
the key role of the TME in disease progression, stromal gene expression can provide valuable 
biomarkers able to predict clinical outcome in breast cancer patients58–61. 
Given the scope of this work and the fact that an immunodeficient NSG mice model62 has been 
used in the presented results, illustrative but not comprehensive examples of the roles that the 
immune system plays in the TME are presented.  Consequently, even though the TME also 
influences pre-metastatic niche formation and metastatic colonization of distant organs46, the 
focus is presented in the influence the TME has over primary tumor growth, invasion, and 
dissemination. 
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1.2.1 Immune Suppression and Tumor-Associated Macrophages (TAMs) 
A decisive step for the malignant progression of developing tumors is evasion and suppression 
of the host immune system45,46. Myeloid-Derived Suppressor Cells (MDSCs) and regulatory T 
cells (Treg) have the ability to modulate the immune response in cancer (Fig. 4): 
• MDSCs are mobilized during tumorigenesis and infiltrate growing tumors, where they 
disrupt immunosurveillance mechanisms, including T cell activation63, inhibition of 
natural killer (NK) cell cytotoxicity64 and antigen presentation by dendritic cells (DCs)65.  
• Treg cells also suppress tumor-associated antigen presentation and interfere with 
cytolytic granule release by NK cells66,67. In breast cancer, increased numbers of Treg 
cells are associated with reduced overall survival68. 
These “brakes” on the immune system have been recently targeted in a variety of cancers, 
including HR+ 69 and TNBC8,43 breast cancers, using immune checkpoint inhibitors 
(i.e. PD-1/PD-L1 and CTLA-4 targeting antibodies), in an attempt to restore immune system 
function and allow T cells to attack the tumor69,70. 
Tumor-Associated Macrophages (TAMs) are another important IIC regulator of tumorigenesis, 
facilitating cancer cell invasion at the leading edge of tumors, by secreting matrix-degrading 
metalloproteinases (MMPs), promoting angiogenesis (discussed later) and, particularly in 
breast cancer, promoting tumor cell growth via paracrine EGF – CSF-1 signalling71 (Fig. 4).  
 
Figure 4. Tumor microenvironment (TME) - derived effects (solid arrows) over tumor progression 
and possible origins (dashed arrows) of Cancer-Associated Fibroblasts (CAFs). TME-associated 
cells play diverse roles in tumor growth, invasion, angiogenesis and immune suppression. Figure 
adapted from46. 
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1.2.2 Cancer-Associated Fibroblasts (CAFs) 
Consistent with the idea of tumors as “wounds that do not heal”55, a predominant portion of the 
breast tumor stroma is occupied by specific fibroblasts termed Cancer-Associated Fibroblasts 
(CAFs)72,73, which through the secretion of metabolites, growth factors and chemokines, as 
well as the production and modification of ECM, have been demonstrated to contribute to the 
core and emergent hallmarks of cancer45,74 (Fig. 5). Among these hallmarks, CAFs have been 
reported to sustain proliferative signaling, activate invasion and metastasis, reprogram energy 
metabolism, help to evade tumor immune destruction and induce angiogenesis45,73,75–77. 
Although CAF influx into the tumor is hypothesized to be mediated by growth factors secretion 
(FGFs, PDGFs, and TGF-β) derived from cancer and immune infiltrating cells (IICs)78–80, a 
detailed model for CAFs recruitment and origin is still being unraveled75,81,82. 
In order to sustain proliferative signaling of cancer cells, CAFs express and secrete mitogenic 
growth factors, such as hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), 
stromal derived growth factor (SDF-1), EGF-family members, as well as various fibroblast 
growth factors (FGFs) with the ability of stimulating cancer cell proliferation72,77,83–86.  
 
Figure 5. Cancer-Associated Fibroblasts (CAFs) display key contributions to the hallmarks of 
cancer. Figure adapted from75. 
In addition to producing growth factors and other ECM cues, CAFs also favor cancer cell 
proliferation and survival by metabolically reprogramming the TME87. A series of studies 
suggest that CAFs are induced by cancer cells to switch on aerobic glycolysis, thereby 
secreting lactate and pyruvate, which in turn serves as fuel for cancer cell proliferation87,88. 
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This metabolic support phenotype, termed “Reverse Warburg effect”, is displayed by CAFs in 
which the scaffold protein Caveolin-1 (CAV1; see below) is downregulated, resulting in an 
activated TME that drives early tumor recurrence, metastasis and poor clinical outcome in 
breast cancer89,90. 
Beyond MDSCs and Tregs, CAFs also help the tumor avoid immune destruction by inhibiting 
cytotoxic T and NK cells, partly by secreting transforming growth factor-β (TGF-β), thus 
promoting an anti-inflammatory response that allows tumor growth and progression91. Once 
the primary tumor acquires the ability to evade host immune responses and cancer cells enter 
the circulation, metastatic dissemination is underway46. Prior to this event, cancer cells have 
to locally invade the surrounding tissues.  
One of the initiating steps of primary tumor invasion is epithelial to mesenchymal transition 
(EMT), during which tumor cells lose epithelial markers and acquire mesenchymal features 
that confer stem-like properties and a migratory phenotype92–94. In breast cancer, CAFs 
modulate the capability of tumors to invade locally: (i) by activating EMT programs in cancer 
cells via secretion of TGF-β95, (ii) by stimulating c-Met signaling via HGF production, which 
promotes both invasiveness and proliferation96 and (iii) by modifying the surrounding ECM both 
by exerting physical forces97–101, and by secreting matrix components72 and matrix modifying 
proteases102–105, a function also partially carried out by TAMs106,107.  
In addition to the aforementioned mechanism, CAFs also influence tumor growth, metastatic 
behavior, and immune cell infiltration via regulation of angiogenesis45,75,77, as discussed later.  
1.2.2.1 CAFs and the Extracellular Matrix (ECM)  
The importance of ECM properties for cancer progression is such that it affects the clinical 
prognosis and response to therapy of breast tumors58–60. In breast cancer, tumors can be 
stratified across four subclasses (ECM 1-4) based strictly on ECM composition, which is 
predictive of patient outcome108. Furthermore, increased breast density and fibrosis have been 
long linked with an increased predisposition to breast tumors109–111. 
As tumors grow and become invasive, the stromal content also increases. Periostin and 
tenascin C, produced in part by CAFs, are generally absent in normal adult mammary tissue, 
but they become expressed in breast tumors112–116.  
By exerting physical forces97–101 and secreting ECM proteins72 and ECM-remodeling 
enzymes102–105, CAFs can profoundly alter the architecture and physical properties of the ECM. 
The resulting increased stiffness and fibrosis have been proposed to: (i) induce a rise in 
interstitial fluid pressure (IFP), associated with an impaired delivery of therapeutics117 and (ii) 
facilitate tumor cell migration and dissemination97–101. Consequently, reducing interstitial 
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pressure in some tumors results in improved tumor hemodynamics and a more favorable 
distribution of cytotoxic drugs118–121.   
1.2.2.2 Cancer-Associated Fibroblasts (CAFs): Origin and Markers 
Despite being described as early as 1858 by Virchow122, fibroblasts remain a mysterious and 
heterogeneous cell population that is classified by what it is not rather than by what it is.  They 
are the non-vascular, non-epithelial and non-inflammatory cells of the connective tissue123 with 
a likely mesenchymal lineage origin75.  
Fibroblasts within healthy tissues most often exhibit spindle morphologies and are generally 
considered to have negligible metabolic and transcriptomic activity. Thus, they are speculated 
to be in a quiescent or resting state. Upon physical damage or acute/chronic inflammation of 
the functional organ parenchyma, these quiescent fibroblasts become “activated” as part of a 
coordinated wound healing response aimed at achieving tissue regeneration and repair124,125. 
Fibroblast activation in response to tissue injury results in a robust induction of protein 
synthesis activity or “secretory phenotype” producing72,81,125: 
• Inflammatory cytokines, such as TNF, IFNγ, IL-6, CCL5, and CXCL10, which results in 
the recruitment of immune cells in charge of removing damaged cell and debris by 
phagocytosis. In addition, some of these proinflammatory cytokines, along with CAF-
derived VEGF-A play a role in tissue neo-vascularization (angiogenesis). 
• Growth factors, such as TGFβ, HGF, FGF, EGF, and PDGF, which induce fibroblast 
and epithelial proliferation, associated with the scarring and re-epithelization processes 
aimed at tissue repair. 
• ECM components, such as fibronectin and collagens (I, III, IV, and V), aimed at 
repairing the damaged ECM scaffold. Accumulation of fibronectin and collagen I, along 
with fibroblast- and IICs-derived VEGF-A production also promote angiogenesis. 
• Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) 
involved in ECM remodeling. 
These normal activated fibroblasts (NAFs) also acquire contractile capabilities, which together 
with ECM deposition and modification, enable wound closure and production of connective 
tissue. This newly acquired contractility requires the induction of expression of the cytoskeletal 
smooth muscle actin protein α (αSMA, also known as ACTA2), which along with that of 
vimentin, is acquired through TGFβ-mediated signaling81,126. 
Altogether, the acquired synthetic and contractile abilities result in the aforementioned 
increased secretory and migratory functions that amplify NAFs activation, recruitment, and 
proliferation. Once the wound healing process is complete, the number of activated fibroblasts 
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decreases significantly owing to apoptosis or reprogramming, and the quiescent phenotype is 
restored127.  
In the case of persisting and sustained damaging stimuli, such as the development of cancer 
lesions, a chronic wound healing response, also known as tissue fibrosis, is triggered. As 
stated before, tumors can be considered as “wounds that never complete the healing 
process”55, exhibiting continuous repair activation. 
Fibroblast associated with this cancer scenario, are termed Cancer-Associated Fibroblasts 
(CAFs) or Tumor-Associated Fibroblasts (TAFs). They are present within the tumor stroma or 
TME in aberrantly high numbers as compared to normal tissue, and in addition to the functions 
associated with NAFs, they display distinct traits which significantly impact cancer progression 
(see above). 
It is unclear from where CAFs arise from during disease progression75,81,82,128. Studies have 
reported CAFs to arise from bone-marrow-derived precursors129, mesenchymal stem cells 
(MSCs)75,128, endothelial cells undergoing endothelial to mesenchymal transition (EndMT)130, 
resting tissue fibroblasts and possibly from epithelial tumor cells following EMT131,132 (Fig. 4). 
In line with this heterogeneity of possible origins, although many different markers can identify 
activated fibroblasts, none of them is specific for fibroblasts133. Such markers include fibroblast-
specific protein 1 (FSP1; also known as S100A4), αSMA, vimentin, platelet-derived growth 
factor receptor β (PDGFRβ), ITGA11 and fibroblast activation protein α (FAP)72,81,134.  
In this case, regression of CAFs to a quiescent state is hypothesized to be limited by epigenetic 
regulation135. In fact, breast tumor stromal cells (presumably CAFs) display unique epigenetic 
changes not observed in fibroblasts from normal mammary tissue136,137. 
1.3 Tumor Angiogenesis 
Although an oncogenic event may allow tumor cells to evade immune surveillance or may 
enhance their survival, the large-scale growth of a solid tumor ultimately requires a blood 
supply, a hypothesis dating back to 1971138. This blood is provided to the tumor through the 
formation of new blood vessels from preexisting ones, a process called angiogenesis. 
Angiogenesis, now accepted as a hallmark of cancer74, constitutes the response to a growing 
need for oxygen and nutrients from the bloodstream, without which tumors would succumb to 
dormancy46. Once a tumor lesion exceeds a few millimeters in diameter, hypoxia (inadequate 
oxygen supply) and nutrient deprivation, triggers the formation of an actively growing and 
infiltrative vascular network, a phenomenon known as “angiogenic switch”139,140. This switch is 
associated with the progression of pre-malignant stages of epithelial tumors (i.e. breast DCIS), 
where a basal lamina isolates the tumor from the vascularized surroundings to a malignant 
stage (i.e. breast IDC)141. 
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According to the revised model of sprouting angiogenesis142, in response to a proangiogenic 
stimulus, the endothelial cells (ECs), that constitute the blood vessel inner layer, become 
activated and induce both the remodeling of EC cell-to-cell junctions and the surrounding 
vascular basement membrane (BM), along with the detachment of pericytes (outer layer of 
perivascular support cells) (Fig. 6). These coordinated functions allow ECs at the leading edge 
of the sprout to form filopodia and migrate in the direction of the angiogenic stimulus. These 
migrating ECs, known as tip cells, are followed by endothelial stalk cells, which proliferate to 
elongate the vessel sprout, form a lumen and recruit pericytes for stabilization. In order to 
generate a perfused vessel, the tip cells of two migrating EC fronts contact and fuse 
(anastomose). Upon perfusion, blood vessel maturation ensues; ECs become quiescent 
phalanx cells, which deposit BM, and pericytes cover the newly formed vessel. 
In adults, most blood vessels are quiescent, and angiogenesis only occurs under specific 
conditions such as during the female reproductive cycle, after an exercise-induced increase in 
muscle mass143 or as a response to pathophysiological conditions, such as ischemia and 
wound healing144. 
 
Figure 6. Structural and dysfunctional blood vessel features present in tumor vasculature. 
In the case of tumor angiogenesis, owing to excessive and sustained proangiogenic 
signaling145–147, tumor vasculature very often acquires an aberrant morphology, characterized 
by excessive branching and blood vessel density, abundant and abnormal binges and blind 
ends, discontinuous EC lining, and defective BM and pericyte coverage148,149. These structural 
features, associated with impaired vascular maturation, are all indicative of poor vessel 
functionality, both in terms of low perfusion and increased permeability148,150 (Fig. 6).  
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As a consequence of the generation of this impaired vascular network, the tumor continues to 
be deprived of an adequate oxygen and nutrient supply, factors which along the non-resolved 
wound healing response contribute to aggravate vascular dysfunctionality by further promoting 
an aberrant proangiogenic signaling151–155. Subsequent intratumoral hypoxia, besides being a 
driver of tumor angiogenesis, contributes to cancer cell escape and metastasis by providing 
an aggressive selection pressure for resilient stem-like tumor cells that subsequently migrate 
away from the primary tumor46,73. 
1.3.1 Alternative Modes of Tumor Vascularization 
Although tumor vascularization has traditionally been defined as the sprouting of new vessels 
from pre-existing vessels (angiogenesis), new findings show that the blood vessels that 
support tumor growth or tumor rebound after therapy can also originate from: 
• Intussusceptive microvascular growth (IMG)156, a nonsprouting angiogenesis where the 
capillary wall extends into the lumen to split a single vessel in two has been reported in 
various tumor types, including breast cancer157–160.  
• Vascular co-option161,  the process by which cancer cells surround and hijack host tissue 
vessels resulting in their incorporation by the tumor. This mechanism mainly occurs in 
highly vascularized tissues such as liver, lungs, and brain162 and is also observed in 
metastatic growth in those organs163–167. 
• Postnatal vasculogenesis168, where endothelial progenitor cells (EPCs) are recruited from 
the bone marrow to sites of vascular damage present in the tumor169. EPC mobilization is 
mediated by various cytokines (VEGF-A and CXCL12/SDF-1) and proteolytic enzymes 
(MMP9) released from the tumor microenvironment170–172.  
• Cancer cells themselves, which either constitute vascular channels mimicking blood 
vessels (via vasculogenic mimicry173) or differentiate from cancer stem cells (CSCs) into 
functional ECs174,175 or pericytes176. 
1.3.2 Microenvironmental Regulation of Tumor Angiogenesis 
Given that tumor vascularization is critical for tumor growth and metastasis, understanding the 
tumor microenvironment pathways, cells and factors controlling this process is key to develop 
new tactics aimed at limiting cancer progression.  
1.3.2.1 Extracellular Matrix, Secreted Factors, and Metabolism 
Since its discovery and characterization177,178, mechanistic and inhibitor studies of tumor 
angiogenesis have largely focused on vascular endothelial growth factor (VEGF-A) by showing 
its role in the induction of sprouting (EC tip formation)179,180, vasodilation and increased vessel 
permeability150,181. However new concepts and insights in the angiogenesis field have emerged 
over the past years and original paradigms are being revisited182–185.  
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Despite the focus on VEGF-A, the role of various growth factors (i.e. PDGF-B120,186, TGF-β187, 
FGFs188,189, VEGF-B/C190, and ANGP1/2191), cytokines (i.e. IL-1β192, IL-6193, IL-8194–196, 
MCP-1/CCL2197,198, and SDF-1170,199,200), and proteases (MMP2/9, ADAMTS1/5/8)201 in the 
tumor faulty vascularization process has also been acknowledged.  
In addition, the tumor stroma is made of multiple ECM components that regulate the angiogenic 
process201,202. In this setting, integrins constitute the main cell-matrix adhesion molecules that 
integrate signals among the ECM and specific activated cytokine or growth factors receptors. 
This crosstalk can determine whether a cell is in the correct environment and will accordingly 
instruct it to survive, migrate or invade; in this regard optimal, angiogenic growth factor 
stimulation relies on integrin-mediated adhesion to an appropriate ECM protein203,204. 
On this subject, ECM composition, remodeling and physical properties have been reported to 
control tumor angiogenic potential and invasiveness by showing both pro-angiogenic and 
vascular stabilizing roles183. In tumors, the vascular BM, remodeled by MMP2/9 and MT1-
MMP, is frequently discontinuous and loosely associated with ECs and pericytes149,150, which 
contributes to increased vascular leakiness and facilitates tumor extravasation and 
metastasis205.  Besides the BM that surrounds the vessels, tumor stromal ECM regulates 
angiogenesis by: (i) acting as a depot for VEGF-A, FGFs, PDFGB and TGF-β, proangiogenic 
sequestered factors that are released in their bioactive form upon proteolytic processing of the 
ECM by proteases (i.e. MMPs)202,206, (ii) direct proangiogenic (fibronectin, periostin, tenascin 
C, and perlecan)207–210 or angiostatic (SPARC and THBS1)211,212 functions  exerted by ECM 
components and (iii) changing its biophysical and mechanical properties through matrix 
deposition, crosslinking and degradation, processes enhancing ECs migration and increasing 
tumor interstitial pressure (promoting inefficient drug delivery)117,120. 
Moreover, several new classes of angiogenesis regulators affecting various aspects of EC 
biology have been recently described, including: (i) Bone Morphogenetic Proteins (BMPs), with 
enhancing213,214 and suppresing215 roles in tumor angiogenesis depending on the family 
members involved, (ii) axonal guidance molecules (SLITs216, Semaphorins217 and 
Ephrins218,219), a group of signaling families regulating endothelial sprouting navigation, and 
(iii) miRNAs, also called angiomiRs220, short non-coding RNAs that negatively regulate the 
expression of angiogenesis-related genes at the post-transcriptional level221.  
Lastly, EC metabolism has lately been put forward as a determinant angiogenesis regulator, a 
recent concept indicating that angiogenesis is not only controlled by the balance between pro- 
and antiangiogenic factors222. Despite their proximity to blood oxygen, ECs from tumor vessels 
rely primarily on aerobic glycolysis to generate energy, in particular tips cells223. In this regard, 
glucose transporter (GLUT1) and glycolytic enzymes (PFKFB3) have been shown to be 
34 
 
regulated by proangiogenic factors (VEGF-A and FGF2) and to be involved in tip cell migration 
and stalk proliferation224,225. 
1.3.2.2 TME-Associated Cells in Angiogenesis 
Although hypoxic and nutrient-deprived cancer cells can be an important source of pro-
angiogenic factors, many signals originating from different tumor stromal cells sustain and 
regulate tumor vascularization; mainly IICs and CAFs. 
In the case of TAMs, high macrophage numbers are associated with increased vascular 
density and reduced survival in human tumors226–228. Its recruitment into the tumor, where they 
produce a series of proangiogenic factors (VEGF-A, PIGF, IL-1β, IL-6 and IL-8)229–231 and 
proteases (MMP2/9)232, is mediated by hypoxia-induced expression of CXCL-12/SDF-1 and 
Angiopoietin-2, which interact with CXCR4 and TIE2 TAMs receptors respectively233. 
Other angiogenesis-regulating IICs include: (i) neutrophils, recruited by CXCL chemokines, 
which play an important role during the early stages of tumor progression230,234 by producing 
VEGF-A, FGF2 and MMP9 in a STAT3-dependent manner235 and (ii) platelets, which are 
activated at sites of vascular hyperpermeability by contact with ECM and cancer cells236, where 
they become activated and secrete VEGF-A, FGF2, and PDGFs237. Besides directly promoting 
angiogenesis, platelets initiate a wound-healing response that recruits other IICs and CAFs, 
further fostering tumor vascularization238. The function of other IICs is reviewed elsewhere183. 
Aside from IICs, CAFs have a well-established proangiogenic function in tumors, where co-
implantation in xenografts enhances vascularization and accelerates growth72,239. Besides 
being a major source of tumor VEGF-A240, CAFs also support tumor angiogenesis by producing 
PDGF-C241, FGFs188,189, IL-8196 and recruiting ECs precursors and macrophages through 
CXCL12/SDF-1 secretion77. As promoters of the wound healing response in solid tumors75, 
CAFs also enhance and regulate angiogenesis by altering the composition207–210 and 
biomechanical properties242 of the ECM, as well as releasing latent factors during its 
modification202,206 (Fig. 4 and 5). 
1.3.3 Emergent Pathways Governing Tumor Vascularization 
Under intratumoral hypoxic conditions, hypoxia-inducible factors (HIFs) activate, translocate to 
the nucleus and bind to hypoxia response elements (HRE), resulting in the transcription of 
various genes involved in angiogenesis, metastasis, apoptosis, and glycolysis243. Besides HIFs 
activation, the highly evolutionarily conserved unfolded protein response (UPR), has recently 
been linked to the modulation of physiological and tumor vascularization244.  
Originally described as a consequence of misfolded protein accumulation, UPR can be 
triggered under stress conditions for the endoplasmic reticulum (ER), such as nutrient 
deprivation and hypoxia245–247, or independently. In the context of tumor angiogenesis, these 
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stressors can be alleviated by vascularization of the affected tissue. In this regard, activation 
of the three branches of the UPR, PERK-ATF4, IRE1α/XBP1 and ATF6, has been linked with 
proangiogenic signaling244 (Fig. 7). 
 
Figure 7. Unfolded protein response axes involved in proangiogenic factor production. From left 
to right, upon accumulation of misfolded proteins, hypoxia, low nutrient concentrations or other ER 
stressors: (A) PERK activates via dimerization/autophosphorylation, provoking a global translational 
attenuation by phosphorylating eIF2α; and favoring the translation of alternative open reading frames, 
such as active ATF4. ATF4 expression leads to CHOP induction, which reverses translation arrest by 
activating GADD34, or upon sustained stress leads to apoptosis.  (B) IRE1α oligomerizes and 
autophosphorylates, triggering the splicing of an XBP1 intron, resulting in the production of an active 
XBP-1s. Alternatively, upon severe stress, a pro-apoptotic TRAF2-ASK1-JNK1 cascade is activated. 
(C) Post-activation, ATF6 translocates to the Golgi where is cleaved by S1P and S2P proteases and the 
resulting active ATF6f is shuttled to the nucleus. Upon axis activation (A) ATF4, (B) XBP-1s or (C) ATF6f 
transcription factors, respectively, are shuttled into the nucleus where they induce the transcription of 
various angiogenic cues. Figure adapted from244. 
Transcription factors from all three branches of the UPR have consensus sites in the VEGF-A 
promoter and have been shown to bind and drive its transcription248. In addition to VEGF-A 
production, in vitro ER stress induction, and consequent UPR activation have also been shown 
to increase production of other proangiogenic factors such as IL-8, FGF2, and angiogenin 
(ANG)247,249,250. 
Both PERK-ATF4251–253 and IRE1α/XBP1254,255 axes, have been linked to tumor vascularization 
in vivo through the induction of VEGF-A, IL-1β, IL-6, and IL-8. Modulating ER stress thus 
results in an attractive target for alternative antiangiogenic therapies, for instance, preclinical 
studies have demonstrated the anti-angiogenic/-tumoral potential of targeting PERK256,257 and 
XBP1258 axes in TNBC and pancreatic cancer models, respectively. Other approved, and 
undergoing clinical trials, anti-angiogenic therapies are discussed in the next section. 
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1.3.4 Antiangiogenic Therapies  
Approval of the first antiangiogenic agent dates back to 2004; it was a humanized monoclonal 
antibody (mAb) targeting VEGF-A (Avastin®) prescribed for patients with metastatic colorectal 
cancer259. Since then, new adjuvant and neoadjuvant mono- and, generally combination 
therapies260,261, targeting VEGFs, FGFs, PDGFs, and angiopoietin-2 (ANGP2) or its receptors 
(VEGFRs, FGFRs, PDGFRs, and TIE2, respectively) have been developed, including mAbs, 
ligand traps, vascular disrupting agents, and tyrosine kinase inhibitors (TKIs)45,182,261,262. 
Nonetheless, clinical trials in breast cancer have offered mixed results,  thus it currently lacks 
an approved antiangiogenic therapy263. 
Based on the assumption that tumors deprived of their blood supply would succumb due to a 
lack of oxygen and nutrients, high hopes were placed on antiangiogenic therapy. However, the 
clinical application of antiangiogenic therapies targeting VEGF/VEGFR has demonstrated that 
the anticancer potential of these drugs is limited and associated with tumor resistance264,265 
and, in some cases, with an increase in cancer aggressiveness and metastasis266–269. 
 
Figure 8. Tumor vascular normalization versus regression depends on a fine equilibrium 
between pro- (in red) and anti- (in green) angiogenic cues. 
In this regard, tumors undergo a number of adaptations to survive the initial vascular regression 
and consequent acute hypoxia that follows angiogenesis blockade270. Therefore, these 
changes are aimed at either regenerating the tumor vasculature through alternative signaling 
pathways and cell effectors, or surviving in its absence, for instance: (i) metabolic 
reprogramming271–273, (ii) enforcement of compensatory alternative pro-angiogenic signals 
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(IL-8, PIGF, FGF2, CXCL12/SDF-1, and ANGP2)274–276, (iii) recruitment of myeloid-derived 
angiogenesis inducers (i.e. TAMs and neutrophils)277–279, (iv) activation of CAFs241 and (v) 
usage of angiogenesis-independent modes of tumor growth, such as IMG or vascular co-
option159,161,164. 
Besides being behind the induction of the adaptive changes already mentioned, tumor hypoxia 
is also responsible for the increase in cancer aggressiveness, chemo-/radiotherapy resistance, 
and metastasis46,73,280–284.  Overall, hypoxia induces an imbalance in the production of pro- and 
anti-angiogenic factors, which leads to the enhanced, fast and chaotic blood vessel 
formation145–147,155. This results in the generation of a hypoxic/faulty angiogenesis loop, where 
dysfunctional tumor vascularization and consequent hypoxia feed on one another152.  
In an attempt to tackle these issues and improve the efficacy of antiangiogenic therapies, the 
concept of vascular normalization versus vascular regression arose146,285. Vascular 
normalization advocates for the restoration of the balance between pro- and anti-angiogenic 
signals in the tumors, via low dose or metronomic antiangiogenic therapies, thus prompting 
selective pruning of immature dysfunctional vessels and stabilization of perfused ones266,286. 
Consequently, tumor blood flow improves, facilitating chemotherapy delivery, tumor 
oxygenation, and T-cell extravasation, which also opens new possibilities for either targeting 
tumor metabolism287 or combining chemotherapy and immune checkpoint inhibitors with 
vascular normalization therapies288 (Fig. 8).  
Lastly, even though new imaging techniques with targeted tracers to assess patient response 
to therapy have been developed289–291, validated markers for appropriately selecting individuals 
with cancer amenable for antiangiogenic therapy are still needed292,293. 
1.4 Caveolin-1 (CAV1): A Prognostic Marker? 
Given the importance of CAFs in the modulation of breast cancer growth, metastasis and 
response to therapy, understanding the molecular mechanisms driving CAFs behavior and 
finding CAFs markers for breast cancer patient stratification has been the focus of research 
recently58–61.  
Amidst these biomarkers, changes in the expression levels of Caveolin-1 (CAV1) in CAFs have 
been associated with the metabolic reprogramming of the tumor87,88,294 and the modification of 
the ECM architecture101, which in turn modulate breast cancer cell growth and metastasis. 
1.4.1 Caveolae: Specialized Membrane Microdomains 
CAV1 is a scaffolding protein with multiple binding partners that is a key structural 
component295–297, along with cavins298,299, of cell surface caveolae. Caveolae are non-planar 
lipid rafts that appear as 50-100nm plasma membrane invaginations under electron 
microscopy (EM) examination300,301 (Fig. 9). Caveolae are very heterogeneous both in terms 
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of membrane distribution302 and abundance in different cell types303. While endothelial, 
smooth-muscle, adipocyte and fibroblast cells display a high abundance of caveolae304, 
lymphocytes, neurons, and hepatocytes show low, but functionally important levels of 
caveolae305–307.  
Figure 9. Caveolae structural 
organization. EM micrographs (left, 
top to bottom) showing ultrastructure of 
caveolae in fibroblasts and complex 
arrangements of caveolae in cultured 
adipocytes and in skeletal muscle. 
Scale bar: 100 nm. Caveolae 
schematic representation (right). 
Reproduced with permission from303. 
As lipid rafts, caveolae constitute specialized membrane microdomains that pre-organize, 
sequester and compartmentalize signaling molecules for efficient signal transduction308. For 
instance, the GTPase HRAS309,310, SRC kinases311 and endothelial nitric oxide synthase 
(eNOS)312–314 signaling can be regulated by caveolae compartmentalization. 
Besides regulating signaling cascades through compartmentalization, caveolae are involved 
in: (i) detecting physical stimuli like shear stress and membrane tension (mechanosensing)303, 
(ii) clathrin-independent endocytosis303, (iii) calcium signaling, through the formation of 
junctional complexes coupling the plasma membrane with the endoplasmic reticulum (ER)315, 
and (iv) cholesterol transport316,317. 
In this regard, caveolar lipid rafts are enriched in cholesterol, along with saturated fatty acids 
and sphingolipids. Moreover, such is the importance of cholesterol, that not only it is essential 
for caveolae formation318, but also regulates CAV1 expression (by binding to steroid regulatory 
elements, SREs, of its promoter)316,319. In addition, CAV1 is a cholesterol-binding protein320 
that shuttles cholesterol between Golgi, the plasma membrane, and mitochondria. In fact, 
CAV1 deficiency leads to cholesterol accumulation in mitochondrial membranes, driving 
mitochondrial dysfunction and aerobic glycolysis317. 
1.4.2 Caveolin-1 (CAV1): Structure Related to Function 
In order to allow caveolae formation and carry out the aforementioned functions, CAV1 shows 
a very particular structure (Fig. 10). CAV1 is a 22 kDa integral membrane protein, with a 
putative hairpin domain embedded within the membrane and both the amino- and carboxy- 
terminus facing the cytoplasm. This unique configuration is due to the presence of an 
intramembrane domain (102–134 aa) that prevents CAV1 from completely spanning the 
plasma membrane in a traditional double-pass fashion321.  
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Figure 10. Domain organization 
of CAV1. Graphic representation 
of CAV1 domain organization. 
CAV1 palmitoylation (Palm) sites, 
involved in CAV1 targeting to lipid 
rafts are indicated in green, a 
Tyrosine phosphorylation (P) site 
(Y14) in orange, and the starting 
Methionine (M32) of CAV1β 
isoform is shown in black. 
Adapted from303.  
Other important domains include the oligomerization domain (61–102 aa), which mediates the 
homo-oligomerization of CAV1 necessary for caveolae formation322. The oligomerization 
domain also includes the Caveolin scaffolding domain (CSD), not only key for the interaction 
of CAV1 with caveolae-associated proteins such as eNOS, tyrosine kinases (TKs) and G-
protein subunits323, but also important for cholesterol binding324. 
Regarding its synthesis, CAV1 is produced in the rough endoplasmic reticulum (RER) as an 
integral membrane protein, then it traffics through the Golgi complex, where it associates with 
cholesterol and forms higher-order oligomers, to the cell surface via discrete carriers303. 
1.4.3 Caveolae and Caveolin-1 in Disease 
Although CAV1 and caveolae are dispensable for life and mice deficient for them are viable, 
lack of caveolae, either as a result of mutations or gene expression changes in CAV1, results 
in a variety of diseases, including muscular dystrophy, lipodystrophy, cardiovascular disease 
and cancer303,308,325.  
Even if CAV1 is involved in cancer progression, its role is still unclear. CAV1 deficiency leads 
to increased proliferation, tumorigenesis326–328 and metastasis90. However, a tumor-promoting 
role has been reported in prostate cancer329 and melanoma330. These contrasting observations 
could be explained by differences in which specific tumor compartment is affected by the CAV1 
loss (either cancer or stromal cells) and the diverse tumor stages reported.  
Regarding CAV1 levels in the tumor stroma, although multiple mechanisms have been 
proposed to explain the deregulation of CAV1 levels in CAFs, the reason behind these changes 
still remains a puzzle128,323. While some studies have associated loss of Caveolin-1 (CAV1) in 
CAFs with poor clinical outcomes in breast cancer in terms of decreased survival, early tumor 
recurrence, lymph node metastasis and resistance to tamoxifen89,90,331–334, exceptions have 
been reported101. CAV1 thus appears to have a complex role in tumor stroma, and further work 
is needed to justify the potential use of CAV1 for prognosis. 
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1B. AIMS & OBJECTIVES 
 
The general aim of the research embodied in this thesis report was to explore and contribute 
further knowledge regarding the impact of the expression levels of stromal CAV1, on breast 
cancer progression, and assess potential translational opportunities for future studies.  
In this regard, previous data had been obtained using mice models where either tumor cells or 
the stromal component were of murine origin. Precedent studies had shown how data derived 
from these systems offered mixed results when translated into a clinical setting.  
In an attempt to overcome these problems and define with greater precision cancer 
cell - stromal CAV1 interactions, both the stromal compartment (CAFs) and cancer cells of the 
presented tumor xenograft are of human origin. 
Our specific objectives were: 
1. To develop and validate strategies to functionally and mechanistically dissect the 
specific contribution of stromal CAV1 levels to tumor biology, both in vitro and in vivo. 
In order to do so, different tailored strategies for the perturbation of CAV1 protein 
expression in a selective manner were to be deployed and tested. 
2. To assess the functional impact on tumor growth and progression in vivo of such 
selective intervention of stromal CAV1, using state-of-the-art xenograft-based mouse 
models, which allow for the full characterization of established human breast cancer 
models, including the recapitulation of the metastatic process.  
3. To gain unbiased mechanistic insight on the contribution of stromal CAV1 protein 
levels, both to basic stromal cell biology as well as at systems-level tumor behavior. A 
core component of these studies was to be founded on detailed transcriptome profiling 
across different contexts (in vitro versus in vivo). 
4. To explore the therapeutic potential of pharmacological interventions leveraging the 
novel knowledge generated by our functional and molecular studies. 
5. To contribute functional screens for small molecules potentially capable of intervening 
CAV1 protein levels on cancer-associated fibroblasts (CAFs). 
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2. MATERIALS & METHODS 
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2. MATERIALS & METHODS 
2.1 Animal model 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NOD-SCID IL2rγnull 4; NSG) immunodeficient mice were 
purchased from Jackson Laboratory (Stock No: 005557; Bar Harbor, ME, USA) and housed 
under specific pathogen-free conditions in accordance with CNIC institutional guidelines. 
Experiments were performed in accordance with Spanish legislation on animal protection and 
were approved by the local governmental animal care committee (Protocol Proex 57/14). 
Breast cancer cell injections in the mammary fat pad were conducted on young female mice 
ranging from 8 to 10 weeks old. 
2.2 Cell lines and cell culture conditions 
Human breast cancer cell lines: MDA-MB-436 (ATCC® HTB-130™), MDA-MB-468 (ATCC® 
HTB-132™), MDA-MB-231 (ATCC® HTB-26™), HCC1937 (ATCC® CRL-2336™) and MCF7 
(ATCC® HTB-22™), Breast Cancer-Associated Fibroblast (CAF) cell lines: CCD-1068Sk 
(ATCC® CRL-2086™) and CCD-1069Sk (ATCC® CRL-2089™), prostate cancer PC-3 
(ATCC® CRL-1435™), and cervix cancer HeLa (ATCC® CCL-2™) cell lines were obtained 
from the American Type Culture Collection (ATCC; www.atcc.org). Human Umbilical Vein 
Endothelial Cells (HUVEC) were acquired from Lonza (Cat. No CC-2519) and cultured in 0.2% 
gelatin-coated flasks. Primary pancreatic CAFs (panCAF 1788 – 1790) were kindly provided 
by Dr. Manuel Hidalgo. 
2.3 Isolation and culture of primary human breast Cancer-Associated Fibroblasts 
(CAFs) 
To isolate the primary breast stromal fibroblasts used in this study, primary cancer tissues were 
obtained from female breast cancer patients335 at Instituto Europeo di Oncologia (IEO, Milan) 
with written consent from participants and with the approval of the Institutional Review Board 
of IEO. The breast cancer tissue specimens used for isolation of stromal fibroblasts were 
diagnosed as invasive ductal carcinoma with histological grade II and classified as luminal A 
subtype with estrogen receptor-negative/progesterone receptor-negative/human epidermal 
growth factor receptor 2-negative. These patients had undergone mastectomy but had not 
been treated with preoperatory neoadjuvant chemotherapy. The fresh tissues were diced and 
digested with 160 μg ml−1collagenase A (Sigma, Cat. No COLLA-RO) and 25 μg ml−1 
hyaluronidase (Sigma, Cat. No H1136) at 37 °C for 3 h. Then the cells were collected and 
cultured in complete DMEM on Corning™ BioCoat™ Collagen I coated flask (Corning™ Cat. 
No 356485) until cells grew into a confluent monolayer. After 2–3 passages, a unique 
homogeneity of stromal fibroblasts was formed. Fibroblasts were then infected with pLenti-
GFP (Cell Biolabs, Cat. No LTV-400) and sorted for a homogeneous positive population.  
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All cell types were cultured according to standard mammalian sterile tissue culture protocols 
and maintained in a humidified incubator at 37ºC and 5% CO2 atmosphere. 
2.4 Generation of CAFscr/CAFshCAV1 and MDA-MB-436luc cell lines 
All lentivirus used are described in the Lentiviral vector generation paragraph. Lentiviral 
infection was conducted at a Multiplicity of infection (MOI)=10 on 6-well plates containing 1x105 
cells/well. Viral dilution was prepared in pre-warmed Opti-MEM™ (Gibco, Cat. No 11058021) 
containing 4 ng/ml of protamine sulfate. After removal of cell growth medium, 1 ml of the viral 
dilution was added per well. Primary breast Cancer-Associated Fibroblasts (CAFs), obtained 
as described in the previous section, were incubated for 4h and then 2ml of complete medium 
was added on top. After incubation for 24h post-infection, previous medium was removed and 
fresh pre-warmed medium was added. Luciferase-expressing MDA-MB-436 cells (MDA-MB-
436luc) were generated by infection with pLVX-CMV-ChFP2A-RE8luc. The expression of 
Cherry fluorescent protein in the infected cells allowed Fluorescence Activated Cell Sorting 
(FACS) of positive cells. Afterward, functional luciferase expression was assayed using a 
luminometer. Non-targeting control (CAFscr) and CAV1 silenced (CAFshCAV1) fibroblasts 
were obtained by infection with pLVX-CMV-ChFP2A-PuroR-miR30.scr and four different CAV1 
targeting pLVX-CMV-ChFP2A-PuroR-miR30.shCAV1 lentivirus respectively. The expression of 
puromycin resistance gene allowed for the selection of positively infected cells using 2 µg/ml 
puromycin (Sigma, Cat. No P8833). Another set of CAFs used in the mitochondrial content 
and ROS determination assays, negative for CherryFP fluorescent protein, was generated by 
infection with pLVX-CMV-PuroR-miR30.scr/shCAV1 virus. 
2.5 Cell culture mediums 
Human breast cancer cell lines were cultured in DMEM/F-12 (Lonza, Cat.No 12-719Q). 
Primary human breast Cancer-Associated Fibroblasts (CAFs), HeLa, and PC-3 cells were 
passaged in Dulbecco’s Modified Eagle Medium, 25mM Glucose (Lonza, Cat. No BE12-604F). 
For experiments using different glucose concentrations, Dulbecco’s Modified Eagle Medium, 
No Glucose (Gibco, Cat.No 11966-025) was used and glucose content was adjusted 
accordingly: DMEM High Glucose (HG) contains 25mM glucose and DMEM Low Glucose (LG) 
2.5mM glucose. CAF cell lines (CCD-1068/69sk) were grown in IMDM (Lonza, Cat. No 12-
722F) and primary panCAFs in RPMI (Lonza, BE12-702F). All DMEM, DMEM/F-12, and IMDM 
media were supplemented with 10% South American-sourced FBS (Gibco, 10270-106), 100 
units/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine unless stated otherwise. For 
panCAFs supplementation also included 10 mM HEPES, 1 mM pyruvate and 20%FBS. 
HUVEC cells were grown in Endothelial Cell Growth Medium (PromoCell, Cat.No C-22010) + 
ECGM SupplementMix (Promocell, Cat.No C-39215). Endothelial Cell Growth Medium 2, 
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PromoCell (Cat.No C-22011) + ECGM-2 SupplementMix (PromoCell, Cat.No C-39216) was 
used for the sprouting assays. 
2.6 In vitro drug treatments of CAFs 
150,000 fibroblasts per well were seeded in 6-well plates using complete HG DMEM. 18h post-
seeding, different treatments, glucose concentrations and vehicle controls were applied. After 
removal of seeding medium: (1) 48h treatments of 5mM 2-Deoxyglucose (2-DG, Sigma, Cat. 
No D6134) and 25mM Sodium dichloroacetate (DCA, Sigma Cat. No 347795) treatments were 
performed in complete DMEM 5mM glucose, vehicle used was dH2O. (2) Glutathione 
treatments, 5mM GSH (Sigma Cat. No G4251) and 5mM GSH-EE (Sigma Cat. No G1404), 
were applied for 24h in complete LG DMEM, vehicle used was PBS pH 6.5 + 1mM EDTA. (3) 
48h treatment of 25µM Lovastatin (Tocris, Cat. No 1530) in DMSO was carried out in complete 
LG DMEM, (4) 24h treatments of 1µM Thapsigargin (Tocris, Cat. No 1138) in DMSO were 
done in both HG DMEM and LG DMEM, (5) 2µM 24h mitoQ (kindly provided by Dr. José 
Antonio Enríquez) treatments dissolved in PBS were performed in HG and LG DMEM. A series 
of treatments were applied for 24h to fibroblasts without post-seeding medium change and 
using DMSO as vehicle: either (1) 10µM PERK inhibitor GSK2606414 (PERKi, Cayman, Cat. 
No 17376), (2) 1µg/ml Tunicamycin (Sigma, Cat. No T7765) or (3) 10µM 4μ8C (Sigma, Cat. 
No SML0949). 
2.7 Orthotopic injection of cancer cells 
Cells for mammary fat pad injection were cultured in the absence of antibiotics. Each flask was 
washed with PBS prior to trypsinization. After detachment cells were centrifuged for 5 min at 
300rcf, the resulting pellet was washed and centrifuged twice in PBS to remove traces of FBS. 
Cells were finally resuspended in PBS before assessing cell concentration with a Z1 Cell 
Coulter (Beckman), >95% cell viability was checked by Trypan Blue exclusion. A total volume 
of 20μl was injected into the fat pads of 8-10-week-old female NSG mice using a 50μl Hamilton 
syringe (Hamilton, Cat. No 80400). Hair in the injection area was removed the day before. 
Each individual injection was composed of 7µl of Matrigel (Corning, Cat. No 354230, Lot. No 
5173009) + 13µl PBS cell suspension containing: either 1x106 breast cancer cells or 1x106 
breast cancer cells + 1x106 CAFs. Mammary glands were harvested 4-5 weeks post-
transplantation, fat adhered to the tumor was eliminated before fixation to avoid problems 
during vibratome cutting. Tumor volume was assessed using a precision caliper to measure 
the width (W) and length (L). Volume was then calculated using the spherical assumption 
formula (W2 x L)/2. 
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2.9 In vivo bioluminescence imaging 
A dose of 150mg/kg mice body weight of D-luciferin dissolved in 100µl of PBS (Promega, Cat. 
No E1605) was injected intraperitoneally in the lower left abdominal quadrant in groups of 4-5 
mice. 3 min after injection mice were sedated using 2% isoflurane and placed in the imaging 
chamber of an IVIS Lumina III Imaging system (PerkinElmer, Massachusetts, USA). 5 min 
post-injection a series of pictures with different exposures (0.1 to 2 seconds, Binning Small, 
F/Stop 1) were taken every minute for 30 min in order to obtain data from the plateau of 
luciferase light emission and avoid signal saturation. Average luciferase emission was 
quantified as Relative Luminescent Units (RLUs, proportional to photons/second) across 
experimental groups in comparable exposure and light production kinetics using Living Image 
software 4.4 (PerkinElmer).  
2.10 HypoxyprobeTM, blood vessel perfusion and permeability in vivo assays 
The following sterile saline solutions were injected into the tail vein before performing primary 
tumor resection (mastectomy): (1) For the hypoxia assays, 100µl of 2 mg/ml Pimonidazole-
HCl (Hypoxyprobe, Cat. No HP10-200kit), 60 min before resection, (2) For the perfusion 
assays, 100µl of 0.5 mg/ml biotin labeled Isolectin GS-IB4 from Griffonia simplicifolia 
(Invitrogen, Cat. No I21414), 20 min prior resection, (3) For the permeability assays, 100µl of 
5mg/ml 70,000MW biotynilated dextran (Invitrogen, Cat. No D1957), 30 min ahead of 
resection. After mastectomy, the fat adhered to the tumor was removed as its prone to cause 
problems during vibratome cutting, extracted tumors were cut in half and placed in cold 4% 
PFA for later inclusion in agarose and vibratome processing. 
2.11 Tumor inclusion and vibratome cutting 
Tumor fixation after mastectomy was performed in 4% PFA at 4ºC for 2h on a rocking platform. 
Before inclusion in agarose, three washes with cold PBS were carried out. A solution of 3% 
UltraPure™ Low Melting Point agarose (Invitrogen, Cat. No 16520050) was prepared in PBS 
and kept at 45ºC. Tumors were placed with the middle cut facing the bottom of a 24-well plate 
and melted agarose was poured on top. Plates were placed afterward at 4ºC to facilitate 
agarose polymerization and PBS was added to maintain sample hydration. After plate removal, 
agarose blocks containing the fixated sample were cut into 200µm thickness sections using a 
Vibratome® 1500. Obtained tissue slices were placed in cold PBS for further processing. 
2.12 Vibratome immunofluorescence (IF) staining and imaging  
Tissue slices placed in individual wells from a 24-well plate were permeabilized using PTT 
Buffer (PBS + 0.3% Triton X-100 + 0.1% Tween20) for 1h at 4ºC, blocked with PBT Buffer 
(PBS + 0.3% Triton X-100 + 4% Goat Serum (Jackson Immunoresearch, Cat. No 005-000-
121)) for 2h at 4ºC and incubated overnight at 4ºC with the corresponding primary antibodies 
48 
 
in PBT buffer: (1) for CD31 stainings, 1:250 of Anti-PECAM 1 Armenian Hamster antibody, 
clone 2H8 (Merck Millipore, Cat. No MAB1398Z), (2) for hypoxic regions detection using 
Pimonidazole, 1:100 of biotinylated Hypoxyprobe™-1 mAb (Hypoxyprobe, Cat. No HP10-
200kit), (3) for HIF1A nuclear localization, 1:250 of Anti-HIF-1-alpha Rabbit antibody (Abcam 
Cat. No ab51608), (4) for pericyte coverage, 1:250 of Anti-PDGFRB Rabbit antibody, clone 
G.290.3 (Invitrogen Antibodies, MA5-15143) or (5) for lymphatic vessel detection, 1:250 of 
Anti-LYVE1 Rabbit pAb (Abcam, ab14917). After incubation, six 15 min washes in cold PT2 
buffer (PBS + 0.15% Tween) and a final cold PBS wash were carried out. Secondary antibody 
or labelled streptavidin incubations in PBT Buffer were performed at 4ºC for 6 h: (1) for CD31 
stainings, 1:500 of Alexa Fluor® 647 AffiniPure Goat Anti-Armenian Hamster IgG (H+L) 
(Jackson Immunoresearch, Cat. No 127-605-160), (2) for pimonidazole, dextran and isolectin 
detection, 1:500 of BV421 Streptavidin (BD Biosciences, Cat. No 563259), (3) for HIF1A and 
LYVE1 stainings, 1:500 of Goat anti-Rabbit IgG (H+L) Secondary Antibody, Alexa Fluor® 647 
conjugate (Thermo Fisher Scientific, A-21245), or (4) for PDGFRB detection, 1:500 of BV421 
Goat Anti-Rabbit IgG (BD Biosciences Cat. No 565014). Post-secondary incubation, three 15 
min washes in PT1 buffer at 25ºC (PBS + 0.3% Tween), a 4ºC overnight wash in PT2 Buffer, 
two 15 min washes in PT2 Buffer and a final cold PBS wash were applied. Sample staining 
was finished including all tissue slices in slides using Fluoromount™ (SIGMA, Cat. No F4680). 
Images were acquired with Zeiss LSM 700 confocal microscope at 21-23 ºC, in series of stacks 
separated by 10µm using a Plan-Apochromat 10x/0.45 M27 Objective. Dextran extravasation 
details were acquired using an LD LCI Plan-Apochromat 25x/0.8 Imm Korr DIC M27 Objective. 
Individual tile-scanned stacks were exported into .tiff files using ZEN 2012 Software, and 
maximal intensity projections were generated using ImageJ (https://imagej.nih.gov/). 
2.13 Image analysis and registration of tumor xenograft vasculature 
In-depth unbiased characterization of tumor xenograft vascular networks was based on a 3D 
automated image analysis pipeline336. Here, modules of the pipeline that permit the extraction 
of parameters regarding the morphology and physiologically meaningful features 
(angioarchitecture) of the tumor vasculature were used (see Table S1).  
In brief, CD31 z-stacks were preprocessed by means of non-local means filtering337 to enhance 
their quality. Subsequently, a rough segmentation of the tumor tissue was produced by 
thresholding. The tissue volume was used to assign voxels of the denoised image volumes 
outside of the tumoral areas to the background (i.e. with zero value). The intensity of the 
images was subsequently automatically adjusted. 
After preprocessing, the vascular network labeled by CD31 was segmented. To achieve this, 
3D Frangi filtering338 was applied to the pre-processed image volumes to identify tubular 
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structures with a diameter within the range 2.5 – 10 µm. The segmentation of the vascular 
network was afterward used to quantify its morphological features, such as complexity (fractal 
dimension) and geometric/topological properties (vascular volume/surface area/breadth/Euler 
characteristic density and surface area per vascular volume ratio).  
In order to study the angioarchitecture of the network, the skeleton of the vasculature was 
extracted along with the branching and ending points of the network. Furthermore, 
morphological characteristics of the individual vessels that comprise the vasculature were 
calculated. It should be noted that spur segments of CD31 that were not branching were 
considered as artifacts and not part of the main skeleton. Moreover, for the normalization of 
some of the metrics to mm3 of tissue, a more accurate definition of the tumor tissue was 
required. Towards this aim, multi-level thresholding339 was applied to all denoised images 
volumes following adjustment of their intensity. Only voxels of the highest intensity classes 
were considered as part of the tumor tissue. 
Statistical analysis of the parameters was performed by means of One-way ANOVA and 
Bonferroni’s correction for multiple comparisons. Lastly, Paraview340 was used for the 3D 
visualization of the segmented volumes and skeletons. The code was written in MATLAB 
(Mathworks). 
For image analysis of tumor-derived vibratome tissue slices obtained from in vivo perfusion 
assays, JACoP plugin (https://imagej.nih.gov/ij/plugins/track/jacop2.html), a colocalization tool 
for ImageJ, was used. Manders' coefficients (fraction of CD31 channel overlapping Isolectin 
channel, as markers of total and perfused vessels) from thresholded tumor images were 
represented. Higher coefficient values are indicative of an increased number of properly 
perfused tumor capillaries. 
2.14 Second Harmonic Generation (SHG) imaging 
Imaging of fibrillary collagen in vibratome sections was performed using a Zeiss LSM 780 
microscope equipped with a short pulse laser (Spectra-Physics Mai Tai DS [pulse<70 ps] 
Laser) capable of performing two-photon microscopy. Images were acquired in series of stacks 
separated by 10µm using a W Plan-Apochromat 20x/1.0 DIC D=0.17 M27 75mm Objective. 
Individual tile-scanned stacks were exported into .tiff files using ZEN 2012 Software, and 
maximal intensity projections were generated using ImageJ (https://imagej.nih.gov/). 
2.15 Micro-PET-CT Imaging and Processing  
All PET-CT studies were performed in the Advanced Imaging Unit at CNIC, with a nanoScan 
PET-CT device (Mediso, Hungary). Animals were fasted overnight, and full body CT scanning 
was performed 1h after 18F-fluorodeoxyglucose (18F-FDG) injections (12MBq dose), followed 
by metabolic PET static acquisition for 15 min. Image analysis was performed in pre-fused and 
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pre-reconstructed images with Osirix (Aycam Medical Systems, LLC); recurrent tumors were 
selected and maximum standardized 18F-FDG uptake value (SUVmax) was calculated for 
each animal. Amide software341 was used for image visualization and 3D rendering of tumors.  
2.16 Collagen 3D in vitro cell culture 
A solution of rat tail Collagen I High Concentration (Corning®, Cat.No 354249) was prepared 
at a concentration of 1.6 mg/ml according to manufacturer’s protocol (NaOH neutralization) 
and kept on ice to avoid polymerization. Taking care of not forming bubbles, 5ml of this 
collagen solution was mixed with 1.2ml of supplemented DMEM containing 5x105 fibroblasts. 
500µl of the resulting cell suspension was plated in Ultra-Low attachment 24-well plates 
(Corning® Costar®, Cat.No CLS3473-24EA). Plate was placed in a cell incubator for 30 min to 
facilitate matrix polymerization. After gel polymerization, culture medium was added on top. 
Gels were cultured at 37 °C, 5% CO2 for 7 days. Fibroblasts were then extracted from the 
matrix using a solution of 5mg/ml of Collagenase Type 2 (Worthington, Cat.No LS004176) 
prepared in PBS. Collagen digestion process was carried out at 37ºC in 15 min, cells were 
then spun down for 2 min at 350rcf and washed once in cold PBS. The resulting cell pellet was 
either processed for protein or RNA extraction. 
2.17 Protein extraction and Western Blot (WB) analysis 
All cell cultures were approximately 80% confluent at the time of lysis. For p62 and LC3 WBs 
cells were lysed in a buffer containing 8 M Urea, 0.5% (v/v) Triton X-100, 100 mM DTT, 
1xComplete® protease inhibitor (PI), and 8% phosphatase inhibitor cocktail I and III, 
respectively (Sigma). The rest of lysates were performed in RIPA Buffer containing the same 
protease and phosphatase inhibitors as the Urea buffer. Protein concentration was determined 
by Bradford protein assay (BioRad, Cat. No 5000006). Equal amounts of proteins were 
separated using NuPAGE® Novex® 12% or 4–12% Bis-Tris Gels (Invitrogen, Cat. No 
WG1402BOX). iBlot® 2 NitroCellulose Membranes (Invitrogen, Cat. No IB23001) were blocked 
and antibodies diluted in a 1:1 mixture of Odyssey blocking buffer (Li-Cor) and TBST (20 mM 
Tris, pH 7.6, 137 mM NaCl with 0.1% Tween 20). Bound antibodies were imaged by near-
infrared fluorescence using fluorescent dye-labeled secondary antibodies and Odyssey NIR 
scanner (Li-Cor Biosciences). Images were processed using the Li-Cor Odyssey software 
image studio 3.1. Antibodies used for WB are listed in Table S3. All immunoblots displayed in 
main figures are cropped.  
2.18 RNA purification and qPCR analysis 
RNA was isolated from either primary tumor tissue or cultured cells with the Rneasy® Plus 
Mini Kit (Qiagen, Cat. No 74136). Representative portions of tumor tissue were first placed in 
lysis buffer and disrupted with sterile ceramic beads using a MagNA Lyser (Roche), with two 
51 
 
rounds of 6500rpm for 30 seconds each, with care taken to maintain the sample cold. RNA 
was quantified by spectrophotometry (ND1000 Spectrophotometer, NanoDrop, (Thermo 
Scientific, Wilmington, USA) and RNA integrity in samples used for RNASeq analysis was 
monitored by RNA 6000 Nano Kit (Agilent Cat.No 5067-1151). cDNA was synthesized from 1 
µg of total RNA using the High-Capacity RNA-to-cDNA™ Kit (Applied Biosystems, Cat.No 
4387406). qPCR was performed using Fast SYBR Green Master Mix (Applied Biosystems, 
Cat. No 4385616) in either a StepOnePlus™ Real-Time PCR System (Applied Biosystems) or 
a CFX384 Touch™ Real-Time PCR Detection System (BioRad). All samples were analyzed 
in triplicate, and RNA levels were obtained either with StepOnePlus™ Software v2.3 (Applied 
Biosystems) or CFX Manager™ Software (Biorad). For fold-change expression normalization 
hGAPDH, hHPRT and hACTIN housekeeping genes were used. See Table S2 for a list of 
primers used in this study. 
2.19 RNASeq data processing and differential expression analysis  
Next-generation sequencing experiments were performed at CNIC Genomics Unit using an 
Illumina HiSeq 2500 System (Illumina, USA) configured for single read (SR) sequencing. 
Resulting sequences were processed by the Bioinformatics Unit at CNIC. RNASeq sequencing 
reads were pre-processed by means of a pipeline that used FastQC342, to assess read quality, 
and Cutadapt v1.3343 to trim sequencing reads, eliminating Illumina adaptor remains, and to 
discard reads that were shorter than 30 bp. The resulting reads were mapped against a 
reference transcriptome and quantified using RSEM v1.2.25344. Around 80-90% of the reads 
participated in at least one reported alignment. Expected expression counts calculated with 
RSEM were then processed with an analysis pipeline that used Bioconductor package 
EdgeR345 for normalization (using TMM method) and differential expression testing. Changes 
in gene expression were considered significant if associated to Benjamini and Hochberg 
adjusted p-value < 0.05. For reads derived from human cell line samples, the reference 
transcriptome was GRCh38.76. For reads derived from xenografts, the reference was a 
human/mouse combined transcriptome generated by putting together 194,353 human and 
99,934 mouse transcripts associated to primary assemblies in GRCh38.76 and GRCm38.76, 
respectively. RSEM parameters were adjusted to minimize the number of alignment 
mismatches (--bowtie-e 30), to increase the number of allowed valid alignments for 
multimapper reads (--bowtie-m 60) and to disable sampling of alignments during bam file 
generation. To estimate the degree of cross-species mapping, bam files were processed with 
an “ad hoc” script written in Perl: about 80%, 18% and 2% aligned reads were mapped 
specifically to human, mouse or both types of transcripts, respectively. Differential expression 
testing was performed separately for human and mouse genes and a blocking variable was 
used to define sample pairs coming from the same animal. To estimate the effect of cross-
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species mapping on differential expression analysis, an alternative test was performed after 
eliminating the contribution of reads that mapped to both human and mouse transcripts: 98% 
of the genes detected as differentially expressed in contrast xenograft transcriptome were 
shared. RNASeq-derived gene expression heatmaps represent normalized transcript counts 
for each replicate using a three-colour scale (green, black and red). For each individually 
represented gene, brighter green corresponds to the lowest transcript count, red to the highest 
and black to the median. Enrichment analysis was performed using Ingenuity Pathway 
Analysis (IPA, QIAGEN), Enrichr web tool346 (http://amp.pharm.mssm.edu/Enrichr/) and 
STRING (https://string-db.org/).   
2.20 Sprouting angiogenesis assay 
Protocol was performed as previously described347 with the following modifications: Assays 
were performed in a µ-Slide Angiogenesis well (Ibidi, Cat. No 81506) using 10µl of 
fibrinogen/bead solution, EGM-2 medium was changed by complete ECGM-2 medium (see 
Cell culture medium section) and CAFs were layered on top of the cloth at a concentration of 
5000 cells/well. Fresh ECGM-2 was added 18h post CAFs seeding, and sprouting was allowed 
for 48h. Samples were fixed with 8% PFA for 30 min and stained with a solution containing 
5µM Hoechst 33342 and 0.5µM Alexa Fluor™ 647 Phalloidin (Invitrogen, Cat. No A22287). 
Images were acquired with Zeiss LSM 700 confocal microscope at 21-23 ºC, in series of stacks 
separated by 4µm using a Plan-Apochromat 10x/0.45 M27 Objective. 
2.21 IL-6 and IL-8 concentration determination by ELISA 
Supernatants from CAFs cultured in 3D Collagen I matrices were recovered and centrifuged 
at 4ºC, 300rcf for 5 min prior to the assay. Human IL-6 and Human IL-8/CXCL8 Quantikine 
ELISA Kits (R&D Systems, Cat. No D6050 and D8000C respectively) were used to measure 
cytokine concentration present in 50µl of medium using four technical replicates per condition. 
2.22 HUVECs and CAFs conditioned medium assays 
Conditioned DMEM medium was collected from CAFs cultured in Collagen I 3D matrices. 
Medium was centrifuged at 4ºC, 300rcf for 5 min to remove floating debris prior to the assays. 
18h post-seeding half of the ECGM was removed and substituted by conditioned DMEM. RNA 
extraction was performed 24h after adding the conditioned DMEM. For total cell number count 
and proliferation assays, 2500 HUVEC cells/well were seeded in a in a 0.2% gelatin-coated 
96-well optical plate using complete ECGM medium. Once cells were attached, seeding 
medium was removed and 50µl ECGM + 1/10 of ECGM SupplementMix was added in each 
well for a period of 14h of starvation. After starvation, 50µl of conditioned DMEM was added, 
and HUVEC cells were allowed to grow for 32h. Afterwards, cells were fixed with 4%PFA and 
stained with either a 5µM solution of Hoechst 33342 for automated confocal Opera imaging or 
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with 1:1000 DRAQ5 for Odyssey plate imaging. For EdU incorporation assays, Click-iT™ EdU 
Alexa Fluor™ 647 Imaging Kit (Invitrogen, Cat. No C10340) was used according to the 
commercial protocol. Incorporation was allowed for 3h prior to fixating the 96-well samples, 
EdU was added at 6X concentration using 20µl of HBSS per well. 
2.23 In vitro co-culture assay, image acquisition, and analysis 
Cell seeding and staining were performed with an automated liquid handling Freedom EVO® 
series platform (Tecan). Seven 384-well optical plates were seeded in parallel, with 12 wells 
per cell combination and using starving DMEM/F12 without serum. Each well contained either 
500 CAFs, 500 cancer cells or a combination of both. After 24h of starving, complete 
DMEM/F12 was added in a 1:1 proportion and the first plate of the assay was fixed with PFA 
3% for 30 min after two consecutive warm (37 ºC) PBS washes. This fixation process was 
repeated every 24h until all seven plates were ready for staining with a 5µM solution of Hoechst 
33342 (Thermo Scientific, Cat. No 62249). Plates were read using an automated Opera 
confocal microscope (Perkin Elmer) with a 20X High NA Air objective. Images were analyzed 
using Acapella platform (Perkin Elmer) in order to classify cells in the co-culture as CAFs 
(GFP+) or cancer cells (GFP-) and obtain cell numbers from each class. 
2.24 SeaHorse: Oxygen consumption rate and glycolytic flux evaluation 
Real-time oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) in CAFs 
were determined with an XF-96 Extracellular Flux Analyzer (Seahorse Bioscience). 96-well 
SeaHorse plates were coated with 1µg/ml of fibronectin prior to cell seeding. 6 wells containing 
5000 cells/well in 2.5mM glucose DMEM were used for each condition. Cells were treated were 
indicated with 5 mM 2-DG, 25mM DCA, 25µM Lovastatin or 5mM GSH for 18h prior to 
OCR/ECAR measurement. The assay was performed in Seahorse XF Assay Minimal Media 
supplemented with 2mM glutamine, 1mM pyruvate and 25 mM glucose. Drug treatments were 
also added during the assay maintaining the same concentrations. The pH was adjusted to 7.4 
with KOH (herein called seahorse medium). Three consecutive measurements were 
performed under basal conditions and after the sequential addition of the following ETC 
inhibitors: 1μM oligomycin, 1 μM FCCP, 1 μM rotenone and 1 μM antimycin. Basal respiration 
rate (BRR) was defined as OCR in the absence of any inhibitor. Maximal respiration rate (MRR) 
was defined as the OCR after addition of oligomycin and FCCP. Spare respiration capacity 
(SRC) was defined as the difference between MRR and BRR. ECAR was measured in the 
absence of drug. To normalize respiration rates per well, cell counts were assayed by CyQuant 
Cell Proliferation Assay (Thermo Fisher) and values from respiration were referred to values 
of cell number for representation. 
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2.25 Determination of levels of angiogenesis-related proteins using Proteome Profiler 
Representative frozen portions of the tumor were lysed in cold PBS + cOmplete™, Mini, EDTA-
free Protease Inhibitor Cocktail (Roche, Cat.No 04693159001) with sterile ceramic beads 
using a MagNA Lyser (Roche), with two rounds of 6500rpm for 30 seconds each, with care 
taken to maintain the sample cold. After homogenization, Triton X-100 was added to a final 
concentration of 1%, samples were frozen at -80ºC, thawed and centrifuged at 4ºC/10,000g 
for 5 min. Resulting supernatants were recovered and assayed for protein concentration. Pools 
of supernatants from 4 biological replicate tumors representing the same experimental 
conditions were prepared. 200µg of protein from the tumor lysate pool was assayed using a 
membrane-based antibody detection Proteome ProfilerTM Human Angiogenesis Array Kit (R&D 
Systems, Cat. No ARY007) according to the kit protocol. In order to adapt the protocol for Near 
Infrared (NIR) fluorescence detection using an Odyssey NIR scanner (Li-Cor Biosciences), 
HRP-conjugated Streptavidin provided in the kit was replaced with DyLight 800 Streptavidin 
(Invitrogen, Cat. No 10668484). 
2.26 Mitochondrial content and ROS production analysis by flow cytometry and 
immunofluorescence (IF) 
For flow cytometry assays 150,000 CAFs per well were seeded in a 6-well plate using DMEM 
HG. 18h later medium was changed to either 2ml DMEM 25 mM glucose or DMEM 2.5mM 
glucose, and the corresponding treatments (5mM 2-DG or 25Mm DCA). 48h post-treatments, 
half of the medium was removed and a 1:2000 dilution of 1mM MitoTracker DeepRed FM 
(Invitrogen, Cat. No M22426) and 1mM Mitotracker Orange CM-H2TMRos (Invitrogen, Cat. 
No M7511) in HBSS was added per well, along with single staining and negative controls. Cells 
were placed in the incubator for 30 min and then washed with warm PBS before trypsinization. 
Three subsequent wash and centrifugation, at 4ºC/300g for 5 min, steps were carried out in 
cytometer tubes a solution of PBS + 2%FBS. Final pellet was resuspended in 300µl of PBS + 
2%FBS and analyzed in a BDTM LSR II Flow Cytometer (BD Biosciences). Data analysis was 
performed using FlowJo V10 software. For immunofluorescence 5000 CAFs per well were 
seeded in a 96-well optical plate using DMEM HG. Treatments and staining were carried out 
in the same way as for flow cytometry. Instead of trypsinized, these cells were fixed in PFA 4% 
at the end of the protocol and imaged in a Zeiss LSM 700 confocal microscope at 21-23 ºC 
using an EC Plan-Neofluar 40x/0.75 Objective. Samples stained for CAV1 and mitochondrial 
content were permeabilized and blocked for 1h/25ºC in PBS + BSA 1% + 0.2% Triton X-100 
(PB Buffer), stained with a 1:1000 dilution of anti-Caveolin-1 (D46G3) XP® Rabbit mAb (Cell 
Signalling, Cat. No 3267) in 1:1 mix of PB buffer:PBS (SB Buffer) for 1hr/25ºC and a secondary 
staining mix of 1:1000 GARAB Alexa 561 and 1:2000 Hoechst 33342 in SB Buffer. Three 
washes of PBS + Tween 0.05% were carried after primary and secondary incubation.  
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2.27 High Content Screening (HCS) of potential CAV1 drug modulators in pancreatic 
CAFs (panCAFs) 
Prior to panCAF cell seeding, designed 384-well plates were coated with corresponding 
siRNAs (non-targeting siCTRL, siRNA CAV1 and siRNA INCENP) according to the referenced 
reverse transfection protocol348. Afterwards, 1500 cells/well of panCAF1790 fibroblasts were 
seeded in 50µl of RPMI (+ supplements; see Cell culture mediums) using a Thermo Multidrop 
automated cell seeder. Cells were then left untreated inside the incubator for 20h to allow for 
its attachment.  Following drug treatment, cell fixation and staining procedures were performed 
in an automated Tecan platform. Drug treatment was performed by adding an extra 50µl per 
well of a RPMI 20%FBS solution containing a 2X concentrated stock of each drug. 48h post-
treatment assay was stopped with a 37ºC PBS wash and a posterior fixation step with 3% 
PFA. Samples stained for CAV1 were permeabilized and blocked for 1hr/25ºC in PBS + BSA 
1% + 0.2% Triton X-100 (PB Buffer), stained with a 1:1000 dilution of anti-Caveolin-1 (D46G3) 
XP® Rabbit mAb (Cell Signalling, Cat. No 3267) in 1:1 mix of PB buffer:PBS (SB Buffer) for 
1hr/25ºC and a secondary staining mix of 1:1000 GARAB Alexa 488, 1:200 of Wheat Germ 
Agglutinin-Alexa 647 (Invitrogen, Cat. No W32466) and 1:2000 Hoechst 33342 in SB Buffer. 
Three washes of PBS + Tween 0.05% were carried after primary and secondary incubation. 
Image acquisition was performed in an Opera confocal microscope (Perkin Elmer) with a 20X 
High NA Water objective. Image analysis for nuclei number and CAV1 intensity evaluation was 
performed in Acapella suite (Perkin Elmer), briefly CAV1 signal intensity was quantified in the 
cytoplasmic area marked by Wheat Germ Agglutinin. For a list of compounds used in this 
screening and a detailed toxicity analysis see the following reference349. 
2.28 NFκB nuclear/cytoplasmic localization analysis by immunofluorescence (IF) 
Analyses for NFκB localization were performed by immunostaining of primary breast CAFs 
treated for 24h at the concentrations indicated in the section In vitro drug treatments of CAFs 
and processed for immunofluorescence as described in the HCS section above, using an anti-
NFκB polyclonal antibody (Abcam, Cat. No ab16502) and counterstaining for DNA (Hoechst 
33342). Image acquisition was performed in an Opera confocal microscope (Perkin Elmer) 
with a 20X High NA Water objective. Image analysis for NFκB localization was performed in 
Acapella suite (Perkin Elmer), shortly NFκB signal intensity was quantified in the cytoplasmic 
area marked by the CAF-derived GFP and in the nucleus stained by Hoechst, afterwards a 
ratio was established among the two obtained measurements.    
2.29 ATF4 localization analysis by immunofluorescence (IF) 
Analyses for ATF4 localization in were performed by immunostaining of primary breast CAFs 
treated for 24h at the concentrations indicated in the section In vitro drug treatments of CAFs 
and processed for immunofluorescence as described in the HCS section above, using an anti-
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ATF4 monoclonal antibody (Santa Cruz, Cat. No sc-390063) and counterstaining for DNA 
(Hoechst 33342) and calreticulin (Abcam, Cat. No ab2907). Images were acquired on an SP8 
Leica laser confocal microscope through a 63X/1.25NA and 40X/0.85NA objective, equipped 
with a DRM camera. 
2.30 Histological and immunohistochemical studies 
Primary tumors were collected during mastectomy and lungs were harvested after necropsy 
as previously described350  and fixed with 4% PFA. After tissue processing, paraffin organ 
embedding was carried out using a paraffin embedding module (Leica, Cat. No EG1150) and 
4µm tissue sections for study were obtained using a microtome (Leica RM2245). For 
metastasis determination, 10 consecutive sections of lung sections were stained with routine 
hematoxylin and eosin (H&E) using an automated multistainer (Leica ST5020). 
Immunohistochemistry detection of Ki67 for cell proliferation checking was performed using a 
kit (Master Diagnostica, Cat.No MAD-000310QD), for secondary staining peroxidase-
conjugated EnVision Flex DAKO reagent was used (Agilent, Cat.K4003), coloration was done 
with 3,3′-Diaminobenzidine (DAB) substrate chromogen (Agilent, Cat. No K3468), finally nuclei 
were counterstained with hematoxylin. Slide preparations were produced with an automated 
glass coversliper (Leica CV5030). Preparations were scanned with Hamamatsu Nanozoomer 
2.0 RS (Hamamatsu, Japan), with the digitalization software NDP.scan 2.5. Images were 
visualized using NDP.view2 software (Hamamatsu, Japan). 
Registration of lung histology images for quantification of metastasis was carried out in Fiji 
(ImageJ 1.50e_x64) from stacks conformed by consecutive slices correspondent to the same 
sample. Linear stack alignment with scale-invariant feature transformation (SIFT) algorithm351 
was applied to find a rigid transformation for each slice using default parameters. Registered 
images, obtained by interpolation of transformed images, were later analyzed manually in Fiji 
to quantify metastasis-affected area. 
Image processing and quantification of Ki67-based proliferation were developed as a macro in 
Fiji. After homogenization and background subtraction using rolling ball algorithm352 
(radius=10), color deconvolution353 was used to separate Hematoxylin, DAB, and a third 
component that did not perfectly matched the stains. Foreground and background pixels were 
detected in each component after normalization and edge-preserving smoothing using bilateral 
filter 354 (radius=3, range=50), by applying a robust automatic threshold selection355 (noise=5, 
lambda=3) and a posterior watershed algorithm356. Segmentation of cells was obtained from 
the iterative union of foreground pixels, hole-filling and object-split using watershed. Detection 
of proliferative/non-proliferative cells was carried out by geodesic reconstruction of cell 
segmentations from DAB/Hematoxylin foreground pixels. Noisy structures and under-
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segmentations were discarded by size filtering. Proliferation readout measured the ratio of 
proliferative cells with respect to the total. 
2.31 Electron microscopy 
CAF cells were grown on 100-mm dishes, treated as indicated, and fixed with 4% 
paraformaldehyde and 2% glutaraldehyde for 120 min at room temperature. Upon gentle 
scrapping, postfixation was carried out with 1% OsO4 and 1.0% K3Fe(CN)6 in H2O at 4 °C for 
60 min. Samples were subsequently dehydrated with ethanol and embedded in Epoxy 812 
Resin (TAAB Laboratories) according to standard procedures. Ultrathin (80 nm) sections were 
stained with saturated uranyl acetate and lead citrate and visualized with a JEOL JEM 1010 
(Tokyo, Japan) electron microscope at 80 kV. 16-bit images were recorded with a 4 k × 4 k 
CMOS F416 camera from TVIPS (Gauting, Germany), typically at 12000X magnification. 
Average intermembrane space from the smaller dimension across ER sections, mitochondria 
width/length and mitochondria cristae width were computed upon manual segmentation using 
ImageJ plugin.  
2.32 Lentiviral vector generation 
See Table S4 for a list of primers used for cloning and resulting lentiviral vectors. A common 
backbone for all lentiviral constructs, except where mentioned otherwise, was generated by 
cloning a PCR amplified cassette (with primers A1&A2) containing a constitutive CMV 
promoter driving the expression of Cherry fluorescent protein and a P2A linker peptide357 
between ClaI and MluI sites of pLVX-shRNA2 vector (Clontech, Cat. No 632179), replacing 
both original CMV and U6 promoters, the shRNA MCS and ZsGreen1 protein. Template 
plasmid for cassette amplification, pRRL-CMV-ChFP2A, was donated by the Viral Vectors unit 
at CNIC. The resulting plasmid was called pLVX-CMV-ChFP2A. Lentiviral construct driving the 
expression of PpyRE8 Far Red luciferase (pLVX-CMV-ChFP2A-RE8luc) was generated by 
cloning a PCR amplified cassette (with primers L1&L2) between the PacI and PmeI sites 
located downstream of P2A self-cleaving peptide357 present in pLVX-CMV-ChFP2A backbone. 
Template plasmid, pGEX-6P-2 PpyRE8 HCO, contained a modified version of Photinus pyralis 
capable of generating light in the far red light spectrum358, was generated and donated by 
Professor Bruce Branchini lab (Connecticut College, USA). Lentiviral constructs for silencing 
CAV1 were created by cloning a PCR amplified cassette (with primers M1&M2) containing the 
Puromycin resistance (pac) gene and non- targeting miR30.shRNA between PacI and MluI 
present in pLVX-CMV-ChFP2A plasmid. pGIPZ non-silencing shRNAmir lentiviral control 
vector (Dharmacon), was used as the PCR template. The resulting plasmid, pLVX-CMV-
ChFP2A-PuroR-miR30.scr, was used to clone in four different sequences targeting human 
CAV1 transcript. Chemically synthesized and PAGE purified oligos (Sigma), were aligned to 
form a dsDNA structure with flanking XhoI and EcoRI ready available sites and cloned into 
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pLVX-CMV-ChFP2A-PuroR-miR30.scr substituting the non-targeting sequence. Three of the 
sequences targeting CAV1 derived from http://cancan.cshl.edu/cgi-bin/Codex/Codex.cgi  and 
a fourth one101 was adapted to fit the miR30.shRNA format. See non-targeting and CAV1 
targeting sequences in Table S4B. A second version of the plasmid, pLVX-CMV-PuroR-
miR30.scr, was created by cloning a PCR amplified cassette (with primers M1.1&M2) between 
AgeI and MluI sites present in pLVX-CMV-ChFP2A plasmid, resulting in the removal of Cherry 
fluorescent protein. pGIPZ non-silencing shRNAmir lentiviral control vector (Dharmacon), was 
used as the PCR template.  
An alternative backbone, where the CMV promoter was substituted for a MCS for the insertion 
of tissue-specific promoters (Table S4C) was generated by cloning a PCR amplified cassette 
(with primers B1&B2) containing a Cherry fluorescent protein and a P2A linker peptide between 
ClaI and XbaI sites of pLVX-shRNA2 vector (Clontech, Cat. No 632179), replacing both original 
CMV and U6 promoters, the shRNA MCS and ZsGreen1 protein. Template plasmid for 
cassette amplification, pRRL-CMV-ChFP2A, was donated by the Viral Vectors unit at CNIC. 
Subsequent Far Red luciferase cloning was performed as stated above and a MCS was 
included (SpeI-AscI-AgeI-NdeI) by hybridizing two 5’ phosphorylated oligos (MCS1+MCS2) 
synthesized by Sigma and cloned upstream of CherryFP in the ClaI RE site of the pLVX 
backbone. The resulting plasmid was called pLVX-MCS-ChFP2A-RE8luc. Silencing miRNA 
backbone and non-targeting miR30.scr were amplified from pGIPZ (with primers MB1 & MB2) 
and cloned downstream of RE8luc in between PmeI and MluI sites. Resulting plasmid was 
termed pLVX-MCS-ChFP2A-RE8luc-miR30.scr Subsequent cloning of CAV1 targeting 
sequences was performed as described above. A region of the ITGA11 promoter134,359 (-2123 
TSS +25) was amplified (with primers I1 & I2) and cloned in between the AgeI and NdeI RE 
sites present in the MCS of the different non-targeting and CAV1 targeting versions of pLVX-
MCS-ChFP2A-RE8luc-miR30; resulting plasmids were named pLVX-MCS-ChFP2A-RE8luc-
miR30.scr/shCAV1 respectively. 
Selection of infected cells was achieved either through FACS (Sinergy 4L system, SONY) or 
puromycin selection through two consecutive passages at 2 µg/ml. 
2.33 Statistical analysis  
All the statistical tests were performed using GraphPad PRISM6 software unless mentioned 
otherwise. Statistical significance was evaluated by the appropriate methods stated in the 
figure legends or in the methodology section. Means were represented as ±SEM unless stated 
otherwise. Differences were considered as statistically significant at *P<0.05, **P<0.01, 
***P<0.001, and ****P<0.0001 
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3. RESULTS 
3.1 Modification of CAV1 stromal levels: approaches and tool generation 
One of the main research aims of this thesis was to establish effective loss-of-function 
experimental systems allowing for the specific dissection of stromal CAV1 contribution to tumor 
progression in vivo. In order to tackle these requirements, two different complementary 
approaches were devised.  
3.1.1 Engineering promoter-based fibroblast selectivity in dual-reporter miRNA-based lentiviral 
vectors 
In a first model, breast cancer biopsy fragments would have been orthotopically transplanted 
into immunodeficient NSG mice and transduced intratumorally with lentiviral vectors targeting 
the CAV1 mRNA, selectively in fibroblasts (Fig. 11A). In this strategy, human breast tumor 
biopsies, containing both patient stroma and cancer cells, would have been engrafted onto 
immunodeficient NSG mice as a means to expand the small biopsies into tumor masses. 
Subsequently, the resulting tumors would have been subdivided and frozen to set up a small 
tumor biobank that would have later been used to transplant and perform in vivo intratumoral 
lentiviral injections. 
In order to selectively target stromal fibroblasts, present in the tumor biopsy, a lentiviral vector 
expressing a CAV1-targeting microRNA-like (miRNA) under the control of a fibroblast-specific 
promoter, was developed (Fig. 11B and Table S4). This lentiviral vector also contained a 
bicistronic cassette, linked by a self-cleaving P2A peptide357, composed of a CherryFP 
fluorescent protein, for in vitro studies, and a far-red light emitting luciferase (RE8luc)358 
optimized for in vivo tracking. Downstream of the expression cassette, either a non-targeting 
scramble miRNA or four different human CAV1 targeting miRNAs were cloned.  
The inclusion of the CAV1 targeting sequences into a miRNA frame, as opposed to 
RNApol III-based silencing systems (shRNA), allows for the simultaneous transcription of the 
expression cassette (CherryFP - P2A - RE8luc, aka ChFP2A-RE8luc) and the silencing 
element (miRNA) under the control of a unique upstream RNApol II-driven promoter360. Thus, 
the detection of in vitro fluorescence or in vivo bioluminescence would be indicative of ongoing 
miRNA transcription.  
A first vector version was constructed to bear a constitutive cytomegalovirus promoter (PCMV) 
to check the downregulation efficiency of all four different miRNA sequences targeting CAV1. 
The miR30.CAV1.2 sequence showed the highest silencing efficiency as compared with the 
others in a variety of model systems (Fig. 11E and 13B). 
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Standard lentiviral vector packaging systems do not confer cell type-level selectivity for 
infection. Thus, adapting a fibroblast-specific promoter that would actively drive the expression 
of the integrated provirus selectively in stromal fibroblasts was paramount. In order to screen 
for fibroblast-specific transcripts and promoters, the expression of a number of published 
fibroblast-specific markers (FAP, FSP1, and ITGA11) was assessed both in cancer-associated 
and normal fibroblasts and in different breast cancer cell lines (Fig. 11C).  
 
Figure 11. Engineering promoter-based fibroblast selectivity in dual-reporter miRNA-based 
lentiviral vectors. (A) In vivo targeting of breast tumor stromal fibroblasts. Depiction of immunodeficient 
NSG mice implanted with tumors derived from human biopsies (xenografts) and intratumorally injected 
with lentivirus in which fluorescent protein/luciferase and microRNA expression are controlled by a 
fibroblast-specific promoter.  (B) Third generation lentivirus expressing a bicistronic cassette, containing 
a: (i) fluorescent protein (CherryFP, in red) and a light-emitting luciferase (RE8luc, in dark red) linked 
via a P2A self-cleaving peptide (in white), and (ii) a miR30-based shRNA silencing element. Expression 
of both elements (i and ii) is controlled either by a tissue-specific promoter (PITGA11, lower scheme) 
inserted into a multicloning site (MCS, in green, upper scheme) or a ubiquitous PCMV promoter. Unique 
restriction enzyme sites are depicted below the schemes and the rest of lentiviral vector elements (LTRs, 
Ψ, RRE, cPPT, and WPRE) are shown in grey. (C) Expression levels of CAV1, ITGA11, FAP and FSP1 
in different CAFs cell lines, normal (NFs) skin fibroblasts (SkinFib) and breast cancer cell lines (brCAN). 
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Heatmap shows high (in red) and low (in blue) expression levels of mRNA expression assayed by qPCR 
(ITGA11 was assayed using 5 different primers, PB2-6). Western blot depicts protein levels of ITGA11 
in the aforementioned cells; GAPDH was used as loading control. (D) Representative fluorescence 
microscopy images of brCAN (MCF7) and CAFs (1068sk) co-cultures infected with a CherryFP (in red) 
containing lentivirus (ChFP2A-RE8luc) expressed under the control of PCMV (left panel) or ITGA11 
promoter (right panel). Pan-cytokeratin, an epithelial marker of brCAN is shown in green. Scale bar: 
20µm. (E) Western blot showing CAV1 expression levels in HeLa and PC-3 cells after infection with 
either non-targeting (miR30.scr) or CAV1-targeting (miR30.CAV1) PCMV ChFP2A-RE8luc lentivirus. 
While Fibroblast Specific Protein 1 (FSP1) is a widely used fibroblast marker361, not all isolated 
fibroblasts exhibited significant expression. Moreover, “mesenchymal-like” breast cancer cell 
lines such as MDA-MB-231 did express detectable levels (Fig. 11C). Finally, ITGA11 promoter 
was chosen over FAP promoter given the overall higher expression of its mRNA in CAFs (Fig. 
11C). 
The specificity of ChFP2A-RE8luc lentivirus containing the ITGA11 promoter was tested in an 
in vitro co-culture system of MCF7 breast cancer and CCD1068SK CAF cell lines, showing a 
lack of CherryFP expression in cancer cells and CherryFP production in fibroblasts (Fig.11D). 
 
Figure 12. CAFs – CAV1 targeting in CAFs-brCAN co-culture assay. (A) Fluorescence microscopy 
tilescan reconstruction of brCAN/CAFs co-culture assays. CCD 1068SK CAFs show expression of 
CAV1 (in green) while MCF7 brCAN cells do not. MCF7 are marked with an antibody against Pan-
Cytokeratin, an epithelial cell marker (in magenta). Infected cells are expressing CherryFP (in red) and 
nuclei are stained with DAPI (in blue). (B) Representative images of brCAN/CAFs co-culture assays. 
CAV1 levels in cells infected with non-targeting CMV miR30.scr (left panel, white arrow marked, in red) 
remain unaffected.  CAFs expressing CAV1 targeting miRNAs under the control of a PCMV promoter 
(central panel, white arrow, in red) downregulate CAV1 levels. Co-cultures infected with ITGA11 
promoter controlled lentivirus (right panel, in red), while maintaining CAF expression specificity, showed 
poor CAV1 silencing efficiency.  
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As the objective of this lentiviral system was to achieve CAV1 silencing specifically in CAFs, 
while leaving brCAN cells unaffected, miRNA-expressing ChFP-P2A-RE8luc lentiviral vectors, 
either under the control of the ubiquitous PCMV or the fibroblast-specific ITGA11 promoter were 
tested in the same CAF/brCAN co-culture scenario (Fig. 12A). CAFs proved difficult to 
transduce, as seen in the infections with the PCMV version of the lentivirus, and while ITGA11 
remained a good promoter choice for fibroblast-specific expression, CAV1 silencing efficiency 
was unsatisfactory in these systems as most infected CAFs (CherryFP positive) displayed 
detectable residual CAV1 expression (Fig. 12B). 
Given the technical challenges posed by the first approach, a second strategy that overcame 
the hurdles of a potential suboptimal in vivo CAF infection and CAV1 downregulation was 
finally chosen.  
3.1.2 Efficient CAV1 silencing ex vivo (pre-grafting) in CAFs for comparative xenograft studies 
In this second strategy, primary breast stromal CAFs and TNBC breast cancer cell lines (TCs) 
were modified ex vivo prior to their injection into the mammary fat pad of NSG mice (Fig. 13A). 
Two stable CAF cell lines derived from human primary breast CAFs expressing high levels of 
CAV1 were generated: (i) CAFscr, infected with a non-targeting lentivirus, and (ii) 
CAFshCAV1, where CAV1 was silenced using a lentiviral construct (Fig. 13C).  
 
Figure 13. Efficient CAV1 silencing ex vivo (pre-grafting) in CAFs for comparative xenograft 
studies. (A) Experimental approach to generate mouse xenograft models of human breast cancer with 
high and low stromal levels of CAV1. Three different cell combinations were injected into the mammary 
fat pads of NSG mice: (i) isolated luciferase-labeled breast cancer cells (TCsluc) without a stromal 
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component (CAFs), (ii) TCsluc with CAFscr, constituting the high stromal CAV1 xenografts (sCAV1high), 
and (iii) TCsluc  with CAFshCAV1, as low stromal CAV1 tumors (sCAV1low).  (B) Western blot showing 
CAV1, ITGA11 and ACTA2 expression levels in brCAFs cells after infection with either non-targeting 
(miR30.scr) or CAV1-targeting (miR30.CAV1.2-4) PCMV ChFP2A-PuroR lentivirus. ITGA11 (Integrin α11) 
and ACTA2 (Smooth muscle actin) are considered normal- and cancer-associated fibroblast markers 
respectively.  (C) Lentiviral vector pLVX-CMV-ChFP2A-RE8luc, aimed at miRNA expression (non-
targeting or CAV1 targeting) from Fig. 11B where the luciferase gene has been swapped with a 
puromycin resistance gene (PuroR) allowing antibiotic-mediated selection of transduced cells.  (D) 
Lentiviral vector used to generate fluorescent protein/luciferase-labeled TCs (TCsluc). Its bicistronic 
expression cassette contains a: (i) fluorescent protein (CherryFP, in red), for FACS sorting, and a 
luciferase (RE8luc, in dark red) for in vivo tracking, linked via a P2A self-cleaving peptide (in white); all 
under the control of an ubiquituos PCMV promoter. 
Then, three different combinations of human cells were injected into the mammary fat pad of 
immunodeficient NSG mice: (i) either luciferase-labeled human breast cancer cell lines (TCsluc: 
MDA-MB-436 or MDA-MB-468), (ii) breast cancer cells (TCs) plus CAFscr fibroblasts or (iii) 
breast cancer cells (TCs) together with CAFshCAV1 fibroblasts. Tumor xenografts containing 
CAFscr or CAFshCAV1 fibroblasts were considered as high (sCAV1high) or low stromal CAV1 
(sCAV1low) tumors respectively (Fig. 13A). 
For the generation of CAFscr and CAFshCAV1 cells, a modified version of the lentivirus 
designed in the first approach was used (Fig. 11B). In this lentivirus the luciferase cassette 
was substituted by a puromycin resistance gene (PuroR) allowing an antibiotic-mediated 
selection of infected cells. In this case, as expression specificity was no longer needed 
(infection was performed in vitro in non-mixed cell populations), both the expression cassette 
(ChFP2A-PuroR) and the miRNA-based silencing elements were under the control of an 
ubiquitous PCMV promoter (Fig. 13C).  
Lentivirus-mediated CAV1 silencing in CAFs was performed using 3 different miRNA 
sequences (miR30.CAV1.2-4), again showing the highest CAV1 silencing levels in the case of 
miR30.CAV1.2 (Fig. 13B). Primary human breast CAFs infected with miR30.scr were labeled 
CAFscr, while the ones infected with miR30.CAV1.2 were used for the rest of the study as 
CAFshCAV1 given they had the highest level of CAV1 silencing. 
In order to track cancer cell growth in vivo, luciferase-labeled breast cancer cell lines were 
generated (TCsluc) from established TNBC cell lines (MDA-MB-436 and MDA-MB-468) via 
lentiviral infection. The lentiviral vector used in the infection of TCs (pLVX-CMV-ChFP2A-
RE8luc) expressed a CherryFP fluorescent protein, that allowed for FACS sorting of infected 
cells, and a far-red light emitting luciferase (RE8luc) optimized for in vivo tracking of labeled 
TCs via bioluminescence detection358 (Fig. 13D). 
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3.2 Stromal CAV1 levels modulate primary tumor growth  
Using the aforementioned second strategy (Fig. 13A), a first set of experiments with non-
luciferase-labeled TNBC cells (TCs) was performed. In this set of experiments, tumor resection 
was carried out 30 days after cell injection (engraftment) into the mammary fat pad. 
Examination of primary tumor size after mastectomy revealed that sCAV1high tumors (TCs + 
CAFscr) were significantly bigger (Fig. 14B and 14D) and showed a clear reddish pigmentation 
(Fig. 14A and 14C), as compared with either the sCAV1low group (TCs + CAFshCAV1) or 
tumors generated by the injection of only cancer cells (TCs). While MDA-MB-436 cells were 
able to generate a visible tumor when injected alone, MDA-MB-468 cells were less penetrant, 
giving rise to tumor masses only in some mice (Fig. 14C).  
Figure 14. Stromal CAV1 
levels modulate primary 
tumor growth. (A) 
Orthotopic xenograft 
tumors were generated by 
injecting MDA-MB-436 TCs 
alone or in combination with 
CAFs (expressing high or 
low CAV1 levels, CAFscr 
and CAFshCAV1 
respectively). Tumors were 
isolated at 30 days post-cell 
injection. Representative 
tumors are shown. Scale 
bar: 10mm (B) Tumor size 
was calculated at 30 days 
post-injection of TC and 
CAF cells. Data are 
presented as boxplots (Min 
to Max values); n=4 mice/group, **P<0.01, ***P<0.001 (One-way ANOVA, Bonferroni’s multiple 
comparison test). (C) Orthotopic xenograft tumors from isolated MDA-MB-468 breast tumor cells (TCs) 
or in combination with CAFs. Mice were mastectomized and tumors isolated at 30 days following 
injection into mammary glands. Representative tumors are shown. Of note, at this time point, no tumor 
was developed from MDA-MB-468 TCs when injected alone (image depicts mammary fat pads). Scale 
bar: 10mm. (D) Tumor size was calculated at 30 days post-injection of TC and CAF cells. Data are 
presented as boxplots (Min to Max values); n=6 mice/group, **P<0.01, (Two-tailed unpaired t-test). (E 
and F) Tumor size was calculated at 40 days post-injection of breast tumor cells (MDA-MB-436 or MDA-
MB-468, respectively) and CAF cells. Difference in volume between CAFscr and CAFshCAV1 derived 
tumor xenografts is no longer significant although tendency remains. Data are presented as boxplots 
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(Min to Max values) and are representative of 2 independent experiments; n=4 mice/group, ***P<0.001 
(One-way ANOVA, Bonferroni’s multiple comparison test). (G) RNASeq heatmap of tumor xenograft 
lysates showing significant changes in expression levels of glycolytic enzymes. Mastectomy was 
performed 30 days post-cell injection. In gene expression heatmap, red denotes increased gene 
expression while green corresponds to downregulation. LogFC (Fold Change) of gene expression 
compared to the MDA-MB-436 + CAFscr control. n=3 tumor/group. 
By extending the period of primary tumor growth before resection from the usual 30 to 40 days 
MDA-MB-468 cells generated small tumors on their own (Fig. 14F). Upon extension of primary 
tumor growth experiments, statistical significance for the difference in size among high and low 
stromal CAV1 tumors was lost, although trends agreed with the previous significant differences 
(Fig. 14E and 14F). 
Low stromal CAV1 (sCAV1low) MDA-MB-436 xenografts resected 30 days post-cell injection 
also showed a significant upregulation of glycolysis-related genes upon RNASeq transcription 
analysis of whole tumor xenograft lysates (Fig. 14G and Table S6A).  
Analogous experiments were performed using a luciferase-expressing MDA-MB-436 cell line 
(MDA-MB-436luc) to track cancer cell growth non-invasively at different time points (Fig. 15A). 
Again, the presence of CAFs encouraged primary cancer cell growth (Fig. 15B). 
Figure 15. Tracking in 
vivo tumor cell 
growth. (A) 
Bioluminescent 
imaging of mice 
transplanted with a 
luciferase-expressing 
breast cancer cell line 
(MDA-MB-436luc) either 
isolated or in 
combination with 
CAFs. Images 
correspond to 23 days 
post-cell injection time 
point. Color scale 
shows luminescence 
count production. (B) Quantification of tumor cell-derived bioluminescence during primary tumor 
xenograft growth. Last two data points are not shown as they are not representative of tumor size due 
to necrosis and tumor tissue opacity. Data are presented as mean ± SEM and are representative of 3 
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independent experiments; n=4 mice/group, *P<0.05 compared to MDA-MB-436 luc, (Individual time point 
analysis: One-way ANOVA, Tukey’s multiple comparison test). 
An intriguing observation was that sCAV1low tumors showed a two-stage growth curve. During 
the first stage of tumor growth, TCsluc from sCAV1low tumors grew faster (Fig. 15B). However, 
around day 10 post-cell injection in the mammary fat pad, this behavior was reversed and 
TCsluc growth in sCAV1low tumors (red hue data) was stalled compared to sCAV1high tumors 
(blue hue data), which continued growing exponentially beyond that time threshold (Fig. 15B). 
Supporting an underlying differential proliferation rate for such differences in the later phase, 
sCAV1high tumors exhibited increased nuclear Ki67-positive cell counts (a standard marker 
of cell proliferation) upon immunostaining of histological tumor sections (Fig. 16A and 16B). 
 
Figure 16. Proliferation assessment by Ki67 IHC. (A) Ki67 (proliferation marker, in brown) IHC of 
MDA-MB-436 derived primary breast xenografts removed 30 days post-cell injection. Total cell nuclei 
are shown upon hematoxylin staining (light blue). Automated image analysis (lower panels) allowed for 
classification of Ki67+ proliferating cell nuclei (red) and Ki67 – non-proliferating cell nuclei (blue). Scale 
bar: 1mm. (B) Proliferating (Ki67+) cell quantification in tumor xenograft IHC sections (see Figure S1I).  
Data are presented as boxplots (Min to Max values); n=4 tumor/group, *P<0.05, ****P<0.0001, (One-
way ANOVA, Bonferroni’s multiple comparison test).   
In order to isolate these effects, a series of in vitro experiments, where TCs co-cultured 
together with CAFs of either genotype and then profiled using automated high-content image 
analysis were performed (Fig. 17A). In accordance with the first stage of the biphasic tumor 
growth observed in vivo, these studies showed that cancer cells co-cultured with CAFshCAV1 
fibroblasts multiplied faster than cancer cells cultured alone or in combination with CAFscr 
fibroblasts (Fig. 17B and 17C). Quantification of CAFs present in the co-culture assay showed 
no differences in cell number for the duration of the experiment (Fig. 17D and 17E). 
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Figure 17. In vitro co-
culture assay of breast 
CAFs and TNBC cell 
lines (TCs) (A) Co-culture 
assay of CAFs and TCs, 
showing an input image of 
GFP positive CAFs 
(green), total nuclei (blue) 
and Ki67 staining (red). 
Presence or absence of 
GFP allowed for 
classification of cells into 
class CAFs (green nuclei) 
or class TCs (red nuclei), 
respectively, for later 
quantification. Scale bar: 
20µm. (B and C) Breast 
tumor cell (TCs) class 
quantification in MDA-MB-
436 + CAFs and MDA-
MB-468 + CAFs co-
cultures, respectively, 
along 7 days. Presence of 
CAFshCAV1 encourages 
increased TCs numbers. 
Note the stalled cell growth in the case of isolated MDA-MB-468 cell line grown in absence of CAFs. 
Data are presented as mean ± SEM and are representative of 3 independent experiments; n=12 
well/group, *P<0.05, ***P<0.001, ****P<0.0001, compared to TCs + CAFscr at Day 6 (Two-way ANOVA, 
Bonferroni’s multiple comparison test). (D and E) Fibroblast (CAFs) class quantification in MDA-MB-436 
and MDA-MB-468 co-cultures, respectively, along 7 days. Cell growth shows no difference among 
CAFscr and CAFshCAV1 fibroblasts. Note the absence of false positive classifications of fibroblasts in 
images derived from cancer cell-only (TCs) conditions (in grey). Data are presented as mean ± SEM 
and are representative of 3 independent experiments; n=12 well/group (Bonferroni’s and Tukey’s 
multiple comparison test). 
Cancer-Associated Fibroblasts (CAFs) had already been described as cancer cell growth 
promoters45,75–77. With these results, it could be observed how CAV1 levels in stromal 
fibroblasts dynamically affect the different stages of tumor growth. While CAFshCAV1 
fibroblasts promote a quick initial cancer cell proliferation in vitro and in vivo, long-term growth 
is better supported by CAFscr-containing sCAV1high tumors.  
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3.3 Aberrant proangiogenic signaling generates a dysfunctional tumor vasculature in 
sCAV1low tumors  
The extent and functionality of tumor vasculature play a key role in blood perfusion (and thus, 
oxygen and nutrient delivery) determining tumor metabolism and growth kinetics46,145,259,362. 
Given the observed differences in color and growth rate among high and low stromal CAV1 
tumor xenografts, the vasculature structure and functionality of these tumors was assessed as 
a potential factor influencing the aforementioned phenomena. 
Blood vessel density was significantly increased in tumors containing CAFs compared to 
tumors composed of only MDA-MB-436 cancer cells, in accordance with the proposed role 
these CAFs have in enhancing angiogenesis45,75–77. Among CAF-containing xenografts, 
sCAV1low tumors showed a significantly higher vascular density compared to sCAV1high 
tumors (Fig. 18A).  
 
Figure 18. (A) sCAV1low tumor xenografts show the highest blood vessel density.  Representative 
tumor xenograft sections (and insets) depicting distinctive blood vessel densities. Blood vessels are 
stained using CD31, an endothelial cell marker. Scale bar: 1mm.  (B) Automated image segmentation 
of tumor xenograft vasculature. Vessel volume is defined by CD31 denoised Z-stack images (grey). 
Skeleton (cyan) and branching points (yellow) are built within the vessel volume to calculate structural 
properties (see Table S1). Scale bar: Original 1mm, Zoom 15X 0.25mm. 
As a consequence of an excessive and sustained proangiogenic signaling145–147, tumor 
vasculature acquires an aberrant morphology, characterized by: (i) disproportionate blood 
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vessel density, (ii) abundant branching and (iii) an increased number of blind ends. As revealed 
by automated image segmentation and analysis (Fig. 18B), these hallmarks/signatures of 
vascular network aberrancy148,149, were increased in sCAV1low tumor xenografts as compared 
to sCAV1high tumors (Fig. 18B, 19A and Table S1). 
 
Figure 19. Increased vascular density and proangiogenic signaling in sCAV1low tumors. (A) 
Vascular volume density of tumor xenograft quantification. Data are presented as mean ± SD in a scatter 
plot; n = 11 whole tumor images/MDA-MB-436 group and n = 31 whole tumor images/MDA-MB-436 + 
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CAF groups, *P<0.05, **P<0.01, ***P<0.001, (One-way ANOVA, Bonferroni’s multiple comparison test). 
(B) RNASeq heatmap of tumor xenograft lysates showing expression levels of angiogenesis-related 
factors. Mastectomy was performed 30 days post-cell injection. Significant upregulation of 
proangiogenic factors is noted as * P<0.05, ** P<0.01, *** P<0.001, **** P<0.0001 (Benjamini-Hochberg 
adjusted P-values). In gene expression heatmap red denotes increased gene expression while green 
corresponds to downregulation. LogFC (Fold Change) of gene expression compared to the MDA-MB-
436 + CAFscr control. n=3 tumor/group. (C) Representative human angiogenesis proteome profiler 
arrays of pooled tumor xenograft lysates. Dot signal intensity correlates with protein amount captured 
by the membrane-immobilized antibodies. Highlighted pairs of dots (1-6) correspond to upregulated 
proangiogenic factors in MDA-MB-436 + CAFshCAV1 xenografts (see Figure 19D). Results are 
representative of 3 independent experiments. (D) Expression levels of angiogenesis-related proteins 
captured in the proteome profiler (see Fig. 19C) were measured by densitometry and expressed as 
mean pixel density after subtracting background. 
In accordance with the structural features observed in sCAV1low tumors (increased vascular 
density, branching, and blind end numbers), RNASeq analysis of these tumors showed an 
upregulation of cytokines associated with a proangiogenic phenotype (Fig. 19B). Using 
membranes spotted with capture antibodies, the presence of these proangiogenic factors in 
tumor lysates was also tested. Results showed a similar upregulation at the protein level of the 
following proangiogenic factors: IL-8, IL-1β, VEGF-A, PDGF-AB/BB, DPP4 and PTX3 (Fig. 
19C and 19D). Among these proangiogenic factors, Interleukin-8 (IL-8), a cytokine with potent 
proangiogenic effects194–196,363,364, also involved in neutrophil recruitment365,366 and recently 
linked with breast cancer stem cell (CSCs) maintenance367,368, ranked as highest among these 
genes differentially upregulated in sCAV1low tumors, both at the transcript (CXCL8) and 
protein (IL-8) levels (Fig. 19C and 19D).  
The aforementioned morphological features, associated with impaired vascular maturation, are 
all indicative of poor vessel functionality, both in terms of low perfusion and increased 
permeability148,150.  
In order to analyze blood vessel functionality, perfusion capacity and permeability of the tumor 
capillaries were checked by injecting either biotin-labeled isolectin or a defined size dextran, 
in the tail vein of mice prior to performing mastectomy. Blood vessels in sCAV1low tumors 
showed not only a poorer perfusion, marked by the very limited isolectin staining (Fig. 20A), 
but also increased leakiness as pointed by dextran extravasation (Fig. 21). Conversely, 
sCAV1high tumors showed ~60% of isolectin-stained CD31-positive structures, indicating an 
estimated >3-fold higher perfusion as compared to sCAV1low tumors (Fig. 20B). 
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Figure 20. Perfusion of tumor vasculature is impaired in sCAV1low tumors. (A) Representative 
details of xenograft tumor sections showing inadequate perfusion in sCAV1low tumors. Blood vessels 
are revealed by CD31 (red) and isolectin staining demarks properly perfused capillaries (green). n=4 
tumor/group. Scale bar: 0.5mm. (B) Quantification of isolectin positive tumor blood vessels (CD31+) for 
proper perfusion determination (see Fig. 20A). Data are presented as mean ± SEM; n=14 images/group, 
****P<0.0001, (Two-tailed unpaired t-test). 
Capillary leakiness was also 
qualitatively assessed by relative 
interstitial signal of labeled dextran 
as compared to that retained within 
vascular structures. sCAV1low 
tumors exhibited substantial 
dextran signal in the interstitial 
space (Fig. 21), suggesting 
altered permeability barrier in the 
vasculature of these tumor 
xenografts.  
A balance of proangiogenic and 
antiangiogenic molecules 
maintains an organized and 
efficient blood supply in tissues. In 
the case of tumors, the exacerbated production of proangiogenic factors results in the growth 
of abnormal and inefficient vascular networks145–147. These networks show high vascular 
permeability and poor perfusion levels, features that the present work show to be exacerbated 
in sCAV1low TNBC tumor xenografts. 
Figure 21. Permeability assessment of tumor xenograft 
vasculature. Blood vessels are defined by CD31 staining (red) 
and dextran is shown in green. Note the dextran leakage 
outside of the capillaries in the low sCAV1low tumors. n=4 
tumor/group. Scale bar: 200µm 
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3.4 Inadequate blood supply in sCAV1low tumors results in increased hypoxia and 
fibrosis  
Tumors can grow to a size of approximately 1–2 mm3 before their metabolic demands are 
restricted due to a limited diffusion of oxygen and nutrients138,259. From that point onwards, 
blood vessels are required to sustain a supply of oxygen and nutrients to the tumor. The 
observed differences in vascular network functionality of tumors as dictated by their stromal 
CAV1 levels prompted to evaluate the differences in oxygen supply when comparing these 
conditions.  
In order to study the levels of hypoxia (deprivation of an adequate oxygen supply) within the 
tumor, pimonidazole staining was used. Pimonidazole is a vital probe which becomes 
specifically activated in hypoxic cells in which its binding to protein thiol groups is greatly 
enhanced369. The resulting protein adducts can subsequently be detected through 
immunostaining. Upon pimonidazole immunostaining, an increased area of the tumor affected 
by hypoxia was observed in the case of sCAV1low tumors, even in vascularized regions 
(Fig. 22A). The formation of lymphatic vessels, a key route for metastatic dissemination of 
breast cancer13–15, was also observed both around hypoxic areas370,371 and the outer border of 
tumor xenografts, although no significant differences were observed in the extent of the tumor 
area covered by lymphatic vasculature (Fig. 22B).  
 
Figure 22. Hypoxia and lymphatic vessel detection in breast tumor xenografts. (A) Representative 
tissue sections obtained from primary breast tumor xenografts showing blood vessels stained with 
endothelial marker CD31 (red) and pimonidazole adducts, a marker of hypoxia (blue). Note the 
differential size of the necrotic core (in black, negatively stained) at inner regions of the tumors. Scale 
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bar: 1mm.  (B) Breast primary tumor xenograft tissue sections showing intra- and peritumoral lymphatic 
blood vessels (marked by LYVE-1 staining) around the hypoxic necrotic core. Scale bar: 1mm. 
In addition, Hypoxia-Inducible Factor 1 Alpha (HIF1A) nuclear localization, as a marker of 
hypoxia155, correlated with pimonidazole positive areas (Fig. 23A) and comparative RNASeq 
transcriptional analysis of tumors confirmed an increased expression of hypoxia response 
transcript signatures in sCAV1low tumors (Fig. 23B). Importantly, extending the time of 
primary tumor growth, from 30 to 40 days, led to an enrichment in the response to hypoxia 
expression profile in sCAV1low xenografts as compared to their sCAV1high counterparts 
(Figure S1). 
 
Figure 23. sCAV1low tumors suffer increased hypoxia. (A) Co-staining of pimonidazole adducts 
(blue) and HIF1A (red) showing hypoxic regions in primary breast tumor sections. Scale bar: 0.5mm. 
(B) Heatmaps derived from RNASeq expression profiles of primary tumor lysates showing a significant 
upregulation of genes related to hypoxia in sCAV1low tumors resected 30 days post-cell engraftment. 
n=3 tumors/group. In gene expression heatmap, red denotes increased gene expression while green 
corresponds to downregulation. n=3 tumor/group. See also Fig. S1. 
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As sustained hypoxic conditions are related to increased ECM deposition and tissue 
fibrosis73,372, collagen fiber formation in tumor xenografts was evaluated by Second Harmonic 
Generation (SHG) imaging. In this regard, a clear increase in ECM deposition and fiber 
formation, aka fibrosis, a condition associated with poor prognosis and increased malignancy 
in breast cancer103,373, was observed in sCAV1low tumors upon SHG microscopic examination 
(Fig. 24A). Moreover, unbiased gene expression analysis of tumor lysates by RNASeq 
confirmed an increase in the expression of genes associated with ECM deposition and 
remodeling (Fig. 24B). 
Given that the amount of pimonidazole that is detected is directly proportional to the level of 
hypoxia within tumors369, the co-localization of pimonidazole positive regions with nuclear 
HIF1A staining and the transcriptional profile of these tumors, it could be concluded that tumors 
with low stromal CAV1 (sCAV1low) were suffering increased hypoxia when compared to the 
ones with a higher stromal CAV1 expression (sCAV1high). 
 
Figure 24. sCAV1low tumors show increased fibrosis. (A) Second Harmonic Generation (SHG) 
imaging (green) of primary breast tumors showing the increased fibrosis of tumors with low stromal 
CAV1 even in highly vascularized areas marked by CD31 staining (red). Scale bar: 200µm.  (B) 
Heatmaps derived from RNASeq expression profiles of primary tumor lysates showing a significant 
upregulation of genes related to ECM organization in sCAV1low tumors resected 30 days post-cell 
engraftment. n=3 tumors/group. See also Fig. S1. 
3.5 CAFshCAV1 proangiogenic expression profile increases endothelial cell 
proliferation and sprout formation  
Given the changes in vascular network morphology and functionality observed in the previous 
tumor xenografts, where the most salient differential element was CAV1 stromal expression 
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levels, a decision was made to study the role that these stromal CAFs could be playing in 
angiogenesis induction and regulation. 
First, the recapitulation of these gene signatures was corroborated in vitro. To do so, CAFscr 
and CAFshCAV1 cells were 3D-cultured in collagen I gels, and their transcriptome profiles 
were analyzed by RNASeq. Gene set enrichment analysis revealed that CAFshCAV1 showed 
an increased expression of CXCL8 (IL-8), IL6, CCL2, VEGFA and IL1B, encoding for those 
cytokines associated with proangiogenic and proinflammatory processes177,192–198 which were 
previously identified as relatively increased in vivo in sCAV1low tumors. Furthermore, the 
expression of negative regulators of angiogenesis, such as EDN1, THBS1, THBS2, and 
VASH1, was attenuated in CAFshCAV1 fibroblasts (Fig. 25A). Confirmation of this RNA 
expression profiles was obtained by qPCR, except for THBS1/2 downregulation, which using 
this approach fell below the significance threshold (Fig. 25B).  
In order to check if this increased expression of cytokines also correlated with a rise in 
secretion, conditioned medium of these 3D-cultured CAFs was assayed by ELISA. Results 
showed a correlation between expression of CXCL8 and IL6 genes and secretion levels of IL-8 
and IL-6 cytokines (Fig. 25C and 25D). 
 
Figure 25. CAFshCAV1 fibroblasts show a proangiogenic expression profile.  (A) Gene expression 
profile heatmaps (RNASeq-derived) from CAFs cultured for 7 days in a 3D Collagen I matrix. 
Upregulation of proangiogenic and downregulation of antiangiogenic factors is shown. In gene 
expression heatmap red denotes increased gene expression while green corresponds to 
downregulation. LogFC (Fold Change) of gene expression compared to the CAFscr control. n=2 group. 
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(B) RNASeq gene expression validation by qPCR (see Fig. 25A). Significant upregulation of 
proangiogenic CXCL8, IL1B, IL6, CCL2 and VEGFA genes and downregulation of antiangiogenic EDN1 
gene can be observed. n=5, ****P<0.0001, (Two-way ANOVA, Bonferroni’s multiple comparison test). 
(C and D) IL-6 and IL-8, respectively, concentration determination by ELISA in supernatants derived 
from 3D-cultured CAFs. n=4, ***P<0.001, ****P<0.0001. All quantification data are presented as mean 
± SEM. Statistical significance was calculated by Two-tailed unpaired t-test when two experimental 
conditions were compared. 
As an in vitro approach for testing the influence these CAFs could exert over the endothelial 
cells (that are part of the tumor blood vessels), Human Umbilical Vein Endothelial Cells 
(HUVECs) were exposed to CAF-conditioned medium as well as grown in the presence of 
CAFs in in vitro co-culture assays (Fig. 26).  
When culturing endothelial HUVEC cells under the exposure of CAFshCAV1-conditioned 
medium (CM), an increase in total endothelial cell number (Fig. 26A and 26B), as well as an 
increase in proliferation, measured by EdU incorporation (Fig. 26A and 26C), was observed 
when compared to HUVECs grown under the influence of CAFscr-conditioned medium.  
 
Figure 26. CAFshCAV1 display a proangiogenic effect in in vitro assays. (A) Representative 
HUVEC cell immunofluorescence depicting Edu incorporation into proliferating cells (red) and total cell 
nuclei number (blue, H33342 staining). HUVEC cells were grown in the presence of CAFscr or 
80 
 
CAFshCAV1 conditioned medium (CM). Scale bar: 200 µm. (B) HUVEC cell count after 32h exposure 
to CAF-conditioned medium. Cell count is increased when cultured under CAFshCAV1-derived medium 
influence. n=5, ***P<0.001. (C) HUVEC proliferation, measured by EdU incorporation, shows a boost 
when endothelial cells are cultured in CAFshCAV1 conditioned medium. n=3, ***P<0.001. (D) HUVEC 
sprouting assay shows an increase in endothelial sprout formation and length when co-cultured with 
CAFshCAV1 fibroblasts. Absence of fibroblasts results in sprout formation failure and disorganized 
growth. HUVEC cell nuclei appear in blue (H33342) and actin cytoskeleton in red (phalloidin).  n=3. 
Scale bar: 100 µm. (E, F, and G) Quantification of sprout number/sphere, sprout length and nuclei 
number sprout, respectively. Co-culture with CAFshCAV1 fibroblasts shows an increase in all three 
parameters correlating with the production of proangiogenic factors. n=3, **P<0.01, ***P<0.001.  All 
quantification data are presented as mean ± SEM. Statistical significance was calculated by Two-tailed 
unpaired t-test. 
In order to mimic the formation of new blood vessels, an in vitro angiogenesis HUVEC 
sprouting assay in co-culture with CAFs was performed. This assay confirmed that HUVEC 
sprouting is only observed in the presence of a supporting layer of fibroblasts (CAFs in this 
case), as previously reported347,374,375 (Fig. 26D).   When co-culturing these HUVEC cells with 
CAFshCAV1 fibroblasts an increase in the length and number of these sprouts, characteristics 
of an enhanced proangiogenic response347,375, was noted when compared to the CAFscr co-
culture. (Fig. 26E and 26F). Increased sprout length was a result of increased cell number per 
sprout, rather than by endothelial cell elongation or hypertrophy (Fig. 26G), in accordance with 
the higher proliferation rates quantified for HUVEC cells exposed to CAFshCAV1 conditioned 
medium (Fig. 26C). 
Taken together these experiments support a positive regulatory role of CAFs in the angiogenic 
process, which is dysregulated when CAV1 is downregulated and results in an exacerbated 
proangiogenic signaling that is capable of boosting endothelial cell proliferation and the 
disordered formation of new blood vessels. 
3.6 CAV1 downregulation in CAFs leads to metabolic inflexibility and loss of organelle 
homeostasis resulting in increased proangiogenic cytokine production  
CAV1 downregulation posed CAFs to exert an in vivo and in vitro proangiogenic effect. Still, 
the molecular mechanisms by which CAV1 downregulation leads to increased production of 
proangiogenic factors remained elusive. In order to unveil the signaling networks responsible 
for the production of these factors, the same RNASeq of 3D-cultured CAFscr and CAFshCAV1 
cells was analyzed in a search for pathway upregulation/enrichment. 
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Figure 27. Transcriptional profile analysis reveals signatures compatible with the activation of 
an Integrated Stress Response (ISR). (A) Canonical pathway analysis using IPA (IPA; Qiagen, 
www.ingenuity.com) of transcriptomics data from 3D-cultured CAFs (RNASeq). Blue denotes 
downregulated genes in the pathway, while red upregulated. (Pathway overlap significance represented 
as –log Benjamini-Hochberg adjusted P-value). (B and C) Gene expression profile heatmaps (RNASeq-
derived) from CAFs cultured for 7 days in a 3D Collagen I matrix. Significant (B) downregulation of 
ribosomal proteins (RPS/RPL) and (C) upregulation of mitochondrial genome-encoded (MT) OXPHOS 
genes and SOD2 (superoxide dismutase 2) is shown. In gene expression heatmap red denotes 
increased gene expression while green corresponds to downregulation. n=2 group. 
This transcriptome analysis revealed signatures compatible with a robust activation of an 
integrated stress response (ISR)376,377 in CAFshCAV1 fibroblasts (Fig. 27A), including: (i) 
repression of the initiation phase of protein synthesis (eIF2α signaling downregulation) and (ii) 
decreased expression of ribosomal protein family genes (RPL & RPS) (Fig. 27B); in addition 
to mitochondrial dysfunction-related traits378, such as imbalanced upregulation of mitochondrial 
genome-encoded (MT) oxidative phosphorylation (OXPHOS) and superoxide response genes 
(SOD2) (Fig. 27C and 28B). 
Further ultrastructural electron microscopy analyses of CAFshCAV1 cells revealed an altered 
mitochondrial architecture, especially when cells were exposed to low glucose levels (2.5mM) 
akin those found in vivo. Mitochondria from CAFshCAV1 fibroblasts showed reduced length, 
and aberrant cristae architecture (i.e. broader necks and reduced extension) (Fig. 28A, 2SA, 
and 2SB), as previously reported in CAV1-knockout cells379. A deeper characterization of 
CAFshCAV1 cells also showed: (i) Increased mRNA levels of mitochondrially encoded (MT) 
oxidative phosphorylation (OXPHOS) system genes (Fig. 27C and 28B) and (ii) increased net 
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mitochondrial mass and enhanced reactive oxygen species (ROS) production as shown by 
fluorescence microscopy and cytometry assays (Fig. 28C, 28D and 28E), pointing to a 
potentially compensatory behavior for mitochondrial dysfunction. These findings harmonize 
with previous studies reporting a lower efficiency of the OXPHOS system in mitochondria 
derived from Cav1-knockout mice317,380,381. 
 
Figure 28. CAFshCAV1 fibroblasts show dilated ER structures and increased mitochondrial 
mass and ROS production. (A) False-colored electron microscopy section of CAFs cultured in high 
and low glucose DMEM. CAFshCAV1 fibroblasts show aberrant mitochondrial architecture (light red) 
and dilated ER (light blue). (B) RNASeq gene expression validation by qPCR (see Fig. 27C). Significant 
upregulation of mitochondrial genome-encoded (MT) OXPHOS genes and SOD2, a mitochondrial-
derived ROS processing enzyme, are shown. Expression levels of NDUFS1, NDUFS2, SDHA and 
SDHB, genes part of the mitochondrial OXPHOS machinery, but codified by the nuclear genome, remain 
unchanged. Data are presented as mean ± SEM relative to CAFscr CTRL; n=6, *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001, (Two-way ANOVA, Bonferroni’s multiple comparison test). (C) 
Representative fluorescence microscopy images of GFP+ CAFs (in green), stained for nuclei (H33342, 
in blue), mitochondria (MitoTracker 647, in red) and mitochondria-derived ROS production (MitoTracker 
CM-H2TM ROS, in magenta). Scale bar: 20µm. (D and E) Quantification of mitochondrial content and 
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mitochondria-derived ROS production in CAFs, respectively, by flow cytometry. Data are presented as 
representative histograms normalized to mode; n=5. 
Intriguingly, the endoplasmic reticulum (ER) was also sensitive to CAV1 downregulation. CAV1 
mRNA silencing in CAFs led to apparent dilated ER structures (Fig. 2SC), a higher degree of 
ER discontinuity, and relative loss of ER-mitochondria communication (Fig. 28A). In 
agreement with challenged ER homeostasis upon CAV1 knockdown in CAFs, the 
transcriptome analyses revealed activation of integrated stress response (ISR) signatures, 
such as the already mentioned eIF2α signaling downregulation (Fig. 27A) and the decreased 
expression of ribosomal protein family genes (RPL & RPS) (Fig. 27B). Accordingly, 
CAFshCAV1 fibroblasts revealed an increased staining for the transcription factor ATF4, which 
induces transcription of genes directed by the PERK arm of the UPR382 (Fig. 2SD), and an 
upregulation of bona fide UPR transcriptional targets such as CHOP and XBP1 (Fig. 31A). 
Because these conditions of dysregulated mitochondrial metabolism and altered ER organelle 
homeostasis have been reported to increase proangiogenic and proinflammatory 
signaling244,251–255,383–385, the causative relationship between these functional imbalances and 
the enhanced secretion of proangiogenic factors and inflammatory cytokines in CAFshCAV1 
fibroblasts was explored.  
3.7 Mitochondrial dysfunction is not the cause of proangiogenic cytokine upregulation 
A first approach was to intervene the functional alterations observed for mitochondria upon 
CAV1 downregulation. Metabolically, loss of CAV1 reduces the efficiency of the mitochondrial 
respiratory chain, and thus aerobic glycolysis predominates over oxidative phosphorylation 
(OXPHOS) as a means for energy production307,317,380.  
Taking advantage of this preference for energy production, CAFshCAV1 fibroblasts were 
forced to use OXPHOS, and thus their dysfunctional mitochondria, by drug treatments with 
2-deoxyglucose (2-DG), a glycolysis inhibitor, and dichloroacetic acid (DCA), which shifts 
glucose catabolism from glycolysis to OXPHOS. Besides manifesting CAFshCAV1 
mitochondrial dysfunction characterized by impaired OXPHOS (Fig. 29A), these treatments 
resulted in the upregulation of CXCL8, IL1B, IL6, and VEGFA, especially in the case of 2-DG 
treatments (Fig. 29B and 29C). CAFs cultured in low glucose medium (2.5mM) showed similar 
results (Fig. 29D).  
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Figure 29. 2-DG and DCA treatments manifest CAFshCAV1 mitochondrial poor OXPHOS 
performance and increased cytokine production. (A) Seahorse CAF mitochondrial functionality 
assessment by Oxygen Consumption Rate (OCR, a proxy of mitochondrial oxidative phosphorylation, 
OXPHOS) and Extracellular Acidification Rate (ECAR, a proxy of glycolytic efficiency) ratio 
determination. CAFs were treated overnight and during OCR/ECAR determination with either 5mM 
2-DG or 25mM DCA, aimed at forcing mitochondrial use for energy production, which showed the poor 
efficiency of OXPHOS (low OCR/ECAR ratio) in CAFshCAV1 fibroblasts. OCR/ECAR ratios are 
presented as boxplots (Min to Max values) and are representative of 3 independent experiments; n=6 
wells/condition, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, (Two-way ANOVA, Tukey’s multiple 
comparison test). (B,C, and D) qPCR expression analysis of CAV1, cytokines (IL1B, IL6, CXCL8, CCL2 
and VEGFA) and ER stress markers (CHOP and XBP1) from CAFs cultured in either (D) high (25mM) 
or low (2.5mM) glucose DMEM or treated with (C) 25mM DCA or (B) 5mM 2-DG. For qPCR gene 
expression analysis data are presented as mean ± SEM relative to CAFscr CTRL; n=5, *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001, Significance for comparisons against CAFscr CTRL (vehicle) is 
depicted in blue, and for CAFshCAV1 CTRL (vehicle) in red (Multiple t-test comparisons, with 
Holm-Sidak multiple comparison correction). 
CAV1 deficiency is associated with reduced cholesterol transport316 and cholesterol 
accumulation in mitochondrial membranes, driving mitochondrial dysfunction and aerobic 
glycolysis307,317. This cholesterol accumulation has been reported to prevent the activity of 
mitochondrial glutathione/2-oxoglutarate antiporters, thus lowering the pool of this ROS-
quenching agent (glutathione) in the mitochondria386,387.  
This CAFshCAV1 cellular model also exhibited increased intracellular cholesterol levels (data 
not shown), as well as elevated ROS (Fig. 28C and 28E). CAF cells were thus exposed to 
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(i) an inhibitor of endogenous cholesterol synthesis (lovastatin), to curb intracellular free 
cholesterol accumulation; and (ii) the antioxidant glutathione (GSH), in an attempt to revert 
mitochondrial dysfunctionality (Fig. 30).  
 
Figure 30. Partial mitochondrial function restoration does not reverse cytokine production. (A 
and B) Seahorse CAF mitochondrial functionality assessment by OCR/ECAR ratio determination. CAFs 
were treated overnight and during OCR/ECAR determination with: (A) 25µM Lovastatin and (B) 5mM 
GSH, aimed at restoring mitochondrial functionality, which resulted in an increased OCR/ECAR ratio for 
CAFshCAV1 versus CAFscr fibroblasts, both as a result of increased OXPHOS efficiency and the higher 
mitochondrial content found in CAFshCAV1. OCR/ECAR ratios are presented as boxplots (Min to Max 
values) and are representative of 3 independent experiments; n=6 wells/condition, *P<0.05, **P<0.01, 
***P<0.001, ****P<0.0001, (Two-way ANOVA, Tukey’s multiple comparison test). (C and D) qPCR 
expression analysis of CAV1 and cytokines (IL1B, IL6, CXCL8, CCL2 and VEGFA) from CAFs treated 
with (C) 25µM Lovastatin or (D) 5mM Glutathione (GSH). For qPCR gene expression analysis data are 
presented as mean ± SEM relative to CAFscr CTRL; n=5, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, 
Significance for comparisons against CAFscr CTRL (vehicle) is depicted in blue, and for CAFshCAV1 
CTRL (vehicle) in red (Multiple t-test comparisons, with Holm-Sidak multiple comparison correction). 
None of these treatments, despite being capable of alleviating intrinsic mitochondrial 
dysfunction, as assessed by OXPHOS efficiency (Fig. 30A and 30B), were capable of curbing 
the expression of proangiogenic and proinflammatory cytokines, in fact, a moderate increase 
in their expression was observed for CAV1-deficient cells (Fig. 30C and 30D). Treatment with 
an exogenous, fully cell permeant ethyl-ester GSH derivative (GSH-EE), showed similar 
results in terms of cytokine upregulation (data not shown).  Thus, it was interpreted that the 
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proangiogenic secretory profile displayed by CAFshCAV1 fibroblasts was unlikely to directly 
derive from a compromised mitochondrial performance. 
3.8 Endoplasmic reticulum (ER) stress induction links CAV1 downregulation and 
proangiogenic cytokine production 
Next, the impact on proangiogenic paracrine signaling of CAFs of either inducing ER stress 
(and the consequent UPR response), using ER stressors such as Thapsigargin or 
Tunicamycin, or specifically disrupting acting branches of the adaptive UPR response (PERK 
and IRE1) was tested.  
First, CAFs were exposed to either Thapsigargin or Tunicamycin, which, either by inhibiting 
the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase (SERCA) and autophagosome-
lysosome fusion, or by blocking protein glycosylation, respectively, lead to the accumulation of 
unfolded proteins and activation of ER stress/UPR388. Importantly, exposure to ER stressors 
not only upregulated the expression of proangiogenic factors such as IL6, CXCL8, and VEGFA 
(along with bona fide ER stress markers such as XBP1 and CHOP), but also downregulated 
CAV1 expression, both at the transcriptional and protein levels (Fig. 31A and 31B). A slight 
downregulation of IL1B and CCL2 upon Thapsigargin treatment was also observed (Fig. 31A). 
Figure 31. Endoplasmic reticulum (ER) stress induction links CAV1 downregulation and 
proangiogenic cytokine production (A, C, and D) qPCR expression analysis of CAV1, cytokines 
(IL1B, IL6, CXCL8, CCL2 and VEGFA) and ER stress markers (CHOP and XBP1) from CAFs treated 
for 24h with: (A) 1µM Thapsigargin, an ER stress inducer, (C) 10µM GSK2606414, a PERK inhibitor, or 
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(D) 5 µM 4µ8C, an IRE1α inhibitor. (I) CAV1 Western Blot analysis of CAFs treated for 24h with 
Thapsigargin. Note the decreased CAV1 protein levels upon treatment. ERK1/2 is used as loading 
control. For qPCR gene expression analysis data are presented as mean ± SEM relative to CAFscr 
CTRL; n=5, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, Significance for comparisons against CAFscr 
CTRL (vehicle) is depicted in blue, and for CAFshCAV1 CTRL (vehicle) in red (Multiple t-test 
comparisons, with Holm-Sidak multiple comparison correction). 
Then these analyses were extended to treatments specifically abrogating not ER functional 
impairment, but its downstream adaptive UPR signaling. Thus, the impact of shutting down 
two of the key UPR signaling branches, PERK and IRE1α, on cytokine production was 
evaluated (Fig. 31C and 31D).  
While exposure of CAFs to GSK2606414, a PERK inhibitor (PERKi)256, led to a significant 
downregulation of the proangiogenic/proinflammatory CXCL8 cytokine transcript (Fig. 31C), 
treatment with 4µ8C, an IRE1α inhibitor, markedly upregulated the expression of this gene 
(Fig. 31D).  These complementary results point to a PERK driven axis as an inducer of the 
expression of IL-8 cytokine upon CAV1 downregulation and ER stress activation; a role that is 
further enhanced, as a compensatory effect, upon IRE1α UPR axis inhibition. Although CCL2 
and IL1B expression follow the same pattern, the same conclusion could not be reached given 
that ER stress induction with Thapsigargin also results in their downregulation (Fig. 31A). 
Even though VEGFA and IL6 are markedly upregulated upon ER stress induction with 
Thapsigargin (Fig. 31A) neither PERK nor IRE1α UPR axis inhibition resulted in the 
downregulation of any of the two genes (Fig. 31C and 31D). Interestingly, CAV1 
downregulation and XBP1/CHOP (ER stress markers) upregulation were also apparent upon 
drug-mediated inhibition of both PERK and IRE1α UPR axes (Fig. 31C and 31D).  
Taken together these results, regarding the expression of the aforementioned genes under ER 
induction and PERK or IRE1α inhibition, showcase the redundant and compensatory roles that 
alternative UPR signaling axes activate when one of them is inhibited. Still, the PERK UPR 
axis, upon CAV1 downregulation (and subsequent ER stress activation), poses as a plausible 
responsible for IL-8 upregulation; a proangiogenic cytokine that is key for the observed 
phenotype of dysfunctional vasculature and increased aggressiveness phenotype observed in 
sCAV1low tumors (see below). 
In addition, a relationship between CAV1 levels an ER stress was established, since CAV1 
downregulation activates ER stress (and the subsequent UPR response) and vice versa, ER 
stress induction promotes CAV1 downregulation both at the transcriptional and protein level. 
Supporting this data, a small pilot screening where different drugs were tested in an attempt 
to regulate CAV1 levels in pancreatic CAFs offered proteasome inhibitors (bortezomib and 
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MG-262), considered indirect activators of ER stress389, as positive hits for downregulation of 
CAV1 (Fig. S3). 
3.9 Low stromal CAV1 levels in breast tumor xenografts are associated with poor 
prognosis and aggressive metastatic cancer  
Besides angiogenesis, hypoxic conditions can also promote tumor aggressiveness46,73,280–284 
and lymphangiogenesis370,371, the formation of new lymphatic vessels. Not only these vessels 
constitute efficient conduits for breast cancer cell dissemination13–15 but lymphangiogenesis is 
also considered a plausible promoter of breast cancer metastasis15,390.  
Given that low CAV1 stromal levels result in increased tumor hypoxia, a metastasis-promoting 
factor, and new lymphatic vessel formation was observed in hypoxic areas (Fig. 22B), the 
survival, relative rate of metastatic dissemination and subsequent thriving of cancer cells were 
analyzed in mice bearing low or high stromal CAV1 tumors. 
To assess metastatic potential, disease progression was followed up after surgical resection 
of the primary tumor. A first intriguing observation was that mice bearing sCAV1low tumors 
exhibited significantly lower survival rates, as 50% of this mice group died 2.5 months post-
mastectomy, while survival of mice that had been injected only breast cancer cells 
(MDA-MB-436) or a combination of cancer cells and CAFscr fibroblasts remained unaffected 
for the duration of the experiment (Fig. 32A). These observations strongly suggested that in 
this experimental system, low stromal CAV1 expression was associated with worse 
progression of the disease after removal of primary tumors, presumably because of differential 
metastatic potential. 
 
Figure 32. Low stromal Cav1 levels in breast primary tumor are associated with poor prognosis 
and aggressive metastatic cancer (A) Kaplan-Meier survival curve illustrating post-mastectomy 
progression-free survival in mice inoculated pre-mastectomy either with tumor cells only (MDA-MB-436), 
tumor cells plus control fibroblasts (436 + CAFscr, sCAV1high) or tumor cells plus fibroblasts with low 
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levels of CAV1 (436 + CAFshCAV1, sCAV1low). **P<0.01, log-rank (Mantel-Cox) test; n=8 mice/group 
from 2 independent experiments. (B) Representative 3-D tumor renderings (in red) from mice PET-CT 
studies performed 2 months post-mastectomy. Recurrent tumors after mastectomy can be observed in 
the mammary fat pad on both groups, while axillary lymph node and lung metastasis are only detectable 
in the group with low stromal CAV1 (sCAV1low, MDA-MB-436 + CAFshCAV1). 
In order to study breast cancer cell dissemination in a non-invasive manner, 60 days 
post-mastectomy PET-CT studies of mice using radiolabeled glucose were carried out. As a 
consequence of cancer cell metastatic dissemination, secondary tumors, also apparent by 
visual inspection, formed in the lymph nodes located below the upper limbs of mice, a typical 
site for early metastasis in breast cancer13–15,390 (Fig. 32B). During necropsy, and posterior 
histological analysis, the presence of metastases at axillary lymph nodes was evaluated and 
showed a significantly higher occurrence in the case of mice that bore a sCAV1low primary 
tumor (Fig. 33C). 
Importantly, mice that carried a sCAV1low primary tumor before mastectomy showed a higher 
maximum glucose uptake in recurrent tumors (Fig. 33E), as well as PET-CT detectable lung 
metastatic foci (Fig. 32B), both indicative of increased tumor aggressiveness.  
 
Figure 33. (A) Mouse diagram showing areas analyzed post-mastectomy to evaluate metastatic burden 
and aggressiveness. (B) Representative images of H&E-stained lung sections harvested 2.5 months 
post-mastectomy. Metastatic lesions appear as dark purple regions, in contrast to the rest of the lung 
tissue, due to an accumulation of cancer hematoxylin-stained cell nuclei (black arrows). Mice bearing 
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only tumor cells show no lung metastasis while the presence of both tumor cells and Cancer-Associated 
fibroblasts give rise to lung metastasis, with greater extent (~ 15-fold) in the case of sCAV1low tumors. 
Scale bar: 1mm. (C) Axillary lymph node tumor metastasis incidence evaluated (by PET-CT and 
necropsy analysis) 60 days post-mastectomy. *P<0.05; n=7 mice from 2 independent experiments. 
(Contingency analysis: Two-sided Fisher’s exact test). (D) Lung area affected by metastatic tumor cells 
at 2.5 months post-mastectomy (see Fig. 6D). ****P<0.0001. Data are presented as mean ± SEM; 
n=8/CAFscr group and n=4/CAFshCAV1 group (rest of individuals could not be quantified due to mice 
death as shown in Fig. 6A). (E) Maximum levels of glucose absorption in recurrent tumors obtained from 
PET-CT studies performed 2 months post-mastectomy (see Figure 33B). Analysis shows an increased 
absorption in the recurrent tumors derived from more aggressive TCs + CAFshCAV1 xenografts. Data 
are presented as mean ± SEM; n=4, *P<0.05. Statistical significance was calculated by Two-tailed 
unpaired t-test when two experimental conditions were compared unless stated otherwise. 
Since PET-CT studies are not able to detect lung micro metastases unless these lesions reach 
a certain size, H&E staining of the lungs of these mice was performed in order to determine 
the post-mastectomy metastatic burden. A significant increase in lung areas affected by 
metastatic lesions in mice that pre-mastectomy bore low CAV1 stromal tumors was detected. 
Metastasis in lungs of mice bearing tumor xenografts composed exclusively of cancer cells 
was not observed (Fig. 33B and 33D). 
In summary, sCAV1low tumors showed an enhanced growth and dissemination of lung and 
lymph node metastasis that translated into lower survival. Taken as a whole, these results 
pointed to an increased aggressiveness of sCAV1low tumors. 
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4. DISCUSSION 
Efforts in breast cancer research have recently shifted from the understanding of cancer cell 
transformation to the study of the complex cross-talk between cancer cells and the 
stroma/tumor microenvironment (TME)45–48, of which Cancer-Associated Fibroblasts (CAFs) 
constitute a major share73,75,128. Furthermore, breast cancer clinical outcome is strongly related 
to stromal characteristics and markers58,59,108–111. Among these markers, downregulation of 
CAV1 in CAFs has been associated with changes in tumor growth and prognosis with varied 
results303,308,323, thus further work is needed to justify the potential prognostic use of stromal 
CAV1. 
Here it is shown how selectively downregulating CAV1 in stromal CAFs generates a defective 
tumor vasculature in TNBC mouse xenografts. According to the presented results, this work 
proposes that such dysfunctional network in sCAV1low tumors, and the subsequent increased 
tumor hypoxia therein: (i) favors malignancy and increased metastasis via the lymphatic 
system and (ii) sustains the imbalance among pro- and anti-angiogenic cues, further 
aggravating the aberrant angiogenic process.  
In addition, this work establishes a positive feedback loop relationship between CAV1 
downregulation and induction of endoplasmic reticulum (ER) stress, which results in the 
exacerbated proangiogenic signaling deemed responsible for the formation of the non-
functional tumor vasculature in the first place. Among these proangiogenic cues, upregulated 
both in CAFshCAV1 fibroblasts and corresponding sCAV1low tumors, IL-8 poses as a pivotal 
factor in inducing the observed aberrant tumor vasculature and enhanced metastasis 
phenotype. 
These results, however, do not exclude the implication of CAFs-derived metabolites in the 
proangiogenic phenotype, or the influence of IL-8 secretion in neutrophil recruitment and later 
promotion of angiogenesis. 
Nevertheless, the reported observations provide an alternate mechanism for the increased 
aggressiveness previously reported in low stromal CAV1 breast tumors89,90,331–334,391,392, a 
phenotype that has been explained thus far by changes in the metabolism of the cancer 
microenvironment87,88, and a new model for the loss of CAV1 expression in CAFs, a question 
that remained a puzzle128,323. 
4.1 Decreased functionality of tumor vasculature in the context of low stromal CAV1: 
effects in tumor growth and hypoxia 
Here, it is shown how breast tumor xenografts expressing low stromal levels of CAV1 
(sCAV1low) display a two-step growth curve. Initially, these tumors grow faster than their high 
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stromal CAV1 counterparts, a behavior fitting previous studies that associate a loss of stromal 
CAV1 with a metabolic shift favoring cancer cell growth and viability87,88. These metabolic 
changes associated with CAV1 downregulation in CAFs include: (i) an increased production 
of lactate and pyruvate due to mitochondrial dysfunction, termed Reverse Warburg effect87, 
and (ii) an increased generation of recycled free amino acids, fatty acids and nucleotides, a 
product of autophagy promotion393. In this previously referenced model, adjacent cancer cells 
would directly utilize these energy metabolites and recycled building blocks generated by 
stromal CAFs to sustain growth. Moreover, the same growth encouraging behavior by 
CAFshCAV1 fibroblasts on TNBC cell lines is recapitulated in vitro as supported by the here 
presented co-cultures assays. 
While these changes in CAF metabolism explain the in vitro behavior of tumor cells and the 
initial stages of tumor onset, where short distance diffusion of these metabolites is possible, it 
does not take into account changes in angiogenesis, the formation of new blood vessels, a 
process that shapes tumor behavior in terms of growth, metabolic reprogramming and 
aggressiveness46,74,138,145,259. Besides, cancer cell growth in sCAV1low xenografts is stalled at  
later stages and does not reach the exponential growth phase characteristic of 
neovascularization, a process known as the angiogenic switch140. As a consequence, 
sCAV1low tumors are significantly smaller than their sCAV1high stromal counterparts.  
Even though a trend for smaller size in sCAV1low tumor remains, further growth of these 
xenografts abolishes significant size differences. This is a plausible consequence of an 
adaptive response of cancer cells to the increased hypoxic conditions394 present in sCAV1low 
tumors, mediated by a metabolic reprogramming where glycolytic enzymes are 
upregulated73,74, or a possible overgrowth of the tumor stromal compartment in response to 
hypoxia73,372.   
Surprisingly, blood vessel density was higher in sCAV1low tumors. In line with this observation, 
unbiased RNASeq and proteome profiler analysis of xenograft lysates showed an enhanced 
and dysregulated proangiogenic signaling in these tumors. Consistent with these findings, the 
mammary stromal compartment in Cav1-knockout mice shows dramatically increased 
vascularization395.  
Functionality assessment of tumor vasculature, in terms of perfusion and permeability, shed 
light on the apparent contradiction between the profuse vascularization of sCAV1low tumors 
and their lack of thriving at later tumor growth stages. sCAV1low tumor blood vessels were not 
properly perfused and showed signs of increased permeability, characteristics of an inefficient 
vascular network. In accordance with this data, a previous study showed that Lewis lung 
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carcinoma (LLC) tumors implanted in  Cav1 −/− mice display increased angiogenesis and 
tumor vascular permeability396. 
These abnormal tumor vascular networks arise as a consequence of the imbalance between 
proangiogenic and antiangiogenic molecules145–147, a condition that the present study shows 
to be aggravated in both sCAV1low TNBC xenografts and CAFshCAV1 fibroblasts. The 
resulting structurally aberrant and dysfunctional tumor vascular networks, in turn, promote 
tumor hypoxia152, which further aggravates the imbalance in the production of pro- and anti-
angiogenic factors. This translates into the generation of a hypoxic/faulty angiogenesis self-
sustained positive feedback loop, where dysfunctional tumor vascularization and consequent 
hypoxia feed on one another152. 
4.2 Role of CAFshCAV1 fibroblasts in aggravating dysfunctional tumor angiogenesis 
In line with the increased density of blood vessels present in sCAV1low tumors, transcriptional 
profiling of CAFshCAV1 fibroblasts also showed a marked upregulated proangiogenic 
signature. Among other upregulated proangiogenic factors such as VEGFA, this profile 
showed upregulated (both at the transcript and protein levels) IL6 and CXCL8, cytokines that 
have been demonstrated to stimulate defective angiogenesis via VEGFA upregulation195,397, 
the increment of endothelial permeability194 and promotion of faulty pericyte coverage193.  
Since angiogenesis is governed by the interaction of many cues, further study will be required 
to characterize the contribution of each CAFshCAV1-produced factor in the observed 
phenotype. Still, a key role of the proangiogenic cytokine CXCL8/IL-8194–196 in the observed 
vascular dysfunction phenotype present in sCAV1low tumors can be proposed based on: (i) 
the levels of expression of CXCL8, being the highest upregulated cytokine among 
proangiogenic factors in both CAFshCAV1 fibroblasts and sCAV1low tumors, (ii) the role IL-8 
plays in dysfunctional tumor angiogenesis, and (iii) the association of high expression levels 
of CXCL8/IL-8 (both stromal and in circulation) with poor prognosis in breast cancer patients 
(see below). 
CAFshCAV1 fibroblasts do not only display a proangiogenic expression profile, but they are 
also capable of inducing enhanced sprout formation and increased endothelial cell proliferation 
in in vitro co-culture and conditioned medium experiments, respectively. Altogether these 
results point to a regulatory role of CAFshCAV1 fibroblasts in increased angiogenesis 
mediated by secreted factors.  
In addition, CAFs are major biosynthetic sources of ECM structural and remodelling proteins, 
which can modulate the relative availability of angiogenic growth factors by sequestration. By 
producing ECM-degrading enzymes (i.e. MMPs), CAFs influence in the release of such latent 
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angiogenic factors (bFGF, VEGF-A, TGF-β), rendering them bioavailable to their receptors on 
endothelial cells47,72,86.  
Differential protease expression in sCAV1low tumors, as compared to sCAV1hogh tumors, 
would thus constitute a factor influencing the capillary network formation, however 
transcriptional profiling by RNASeq and later qPCR validation (of both in vivo tumor xenografts 
and in vitro CAFs) showed no differences in expression levels of MMPs associated with 
regulation of the angiogenic process, such as MMP-2, 9, and 14202,232. Besides differential 
protease expression, modification of ECM mechanical properties by CAFs have also been 
linked with angiogenesis242. In this scenario, the observed increased collagen deposition and 
fibrosis in sCAV1low tumors could offer a stiffer environment linked to enhanced angiogenesis.  
Apart from the balance between pro- and anti-angiogenic cues, endothelial cell metabolism 
has recently been put forward as a key regulator of angiogenesis222,223. In this regard, another 
conceivable CAFshCAV1-derived factor influencing the observed proangiogenic phenotype 
would be the distinctive metabolite secretion profile these fibroblasts resulting from a rewiring 
of their mitochondrial metabolism87,307,317,380; downregulation of CAV1 has been shown to result 
in increased lactate production and secretion, a metabolite that in turn promotes 
angiogenesis363,398.  
Still, the following question arises: is this imbalance between pro- and anti-angiogenic factors 
secreted by CAFshCAV1 fibroblasts continuously controlling the tumor angiogenesis process? 
Looking at the here presented evidence we can envision a situation in which loss or 
downregulation of CAV1 in the tumor stroma, through the promotion of CAFshCAV1-derived 
exacerbated proangiogenic signaling, primes and triggers the formation of an inefficient 
vascular network, which in turn results in increased hypoxia and thus gives rise to a positive 
feedback loop. In this loop, low intratumoral oxygen concentration would further aggravate the 
proangiogenic factor imbalance responsible for the generation of the non-functional 
vasculature in the first place, by sustaining the proangiogenic signaling characteristically 
activated upon hypoxia151–155. Thus, temporal modulation of stromal CAV1 expression at 
different stages may have a differential impact on tumor progression. 
4.3 Interleukin-8 in tumor angiogenesis and metastasis: a direct cause-effect 
relationship?  
The in vitro endothelial sprouting and proliferation assays presented in this work point to a 
direct regulatory role of CAF-derived secreted factors in angiogenesis. Among the upregulated 
proangiogenic factors expressed by CAFshCAV1, IL-8 has been characterized as a potent 
proangiogenic effector and inducer of vascular permeability194–196,399,400, including in the context 
of breast cancer, where its downregulation results in reduced blood vessel density401.  
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Even though the NSG mouse model system used in this work is severely immunodeficient, 
lacking mature B, T and NK cells62; defective monocytes and fully-functional neutrophils 
constitute most of the remaining mouse immune cells detectable in peripheral blood402,403. On 
this subject, IL-8 constitutes a potent chemotactic effector over neutrophil recruitment365,366, an 
immune cell type that is linked with the induction of angiogenesis when recruited into the 
tumor230,234,404. With this information in mind, one could argue that besides the direct effect IL-8 
has over endothelial cells during angiogenesis, neutrophil recruitment, caused by IL-8 
upregulation in CAFshCAV1 fibroblasts and derived sCAV1low tumors, could also play a role 
in the observed exacerbated proangiogenic phenotype, a possibility unexplored in this work.  
Concerning tumor metastasis, IL-8 has also been shown to be key in the maintenance of breast 
cancer stem cells (CSCs)367,368,399, an important tumor subpopulation that has recently been 
linked with tumor initiation, metastasis, and disease recurrence.  
In this regard, future IL-8 inhibition in vivo experiments in sCAV1low/sCAV1high xenografts, 
either using IL-8-blocking monoclonal antibodies or CXCR1/2 (IL-8 receptors) antagonists, 
would help to find if the upregulation of this cytokine in sCAV1low tumor xenografts is linked 
with the observed increased aggressiveness in this particular tumor xenografts. The proposed 
inhibition studies would also help to rule out which of the above-mentioned phenomena 
(dysfunctional angiogenesis, neutrophil recruitment and/or CSCs maintenance), caused by 
IL-8 upregulation, is behind the aggressive phenotype of sCAV1low tumor xenografts. 
Given its reported potent proangiogenic effect and its upregulation in the more aggressive and 
aberrantly vascularized sCAV1low tumors, IL-8 constitutes a potential inhibition target for 
vascular normalization.  
On one hand, one could anticipate that treatment of sCAV1low tumors, which express high 
levels of IL-8, with IL-8 inhibitors could result in vascular normalization, increased tumor 
oxygenation, and thus lower metastasis incidence. Supporting the association of increased 
IL-8 levels and the more aggressive phenotype observed in the here reported sCAV1low tumor 
xenografts, (i) increased levels of circulating IL-8 have been linked with poor prognosis and 
enhanced tumor cell dissemination in human patients392,405 and (ii) elevated stromal IL-8 
expression is part of a gene signature predicting poor prognosis in breast cancer patients58. 
On the other hand, IL-8 inhibitor treatment of the less-aggressive sCAV1high tumors (where 
IL-8 is not upregulated) could cause an impairment of tumor blood vessel functionality, which 
would promote increased rates of metastases as a consequence of the raised hypoxic 
conditions. This relationship between hypoxia and increased tumor aggressiveness is 
discussed in the next section.  
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4.4 Hypoxia, fibrosis and poor prognosis in sCAV1low tumors 
Concomitant with hypoxia, an increased modification and deposition of extracellular matrix 
(ECM), in accordance with altered transcriptome signatures, could also be observed in 
sCAV1low tumors. This could be a consequence of hypoxic conditions372 or an independent, 
intrinsic secondary effect caused by downregulation of CAV1, given its antifibrotic role406.  
Hypoxia and aggressive tumor phenotype73,269,280–283 are not only linked by fibrosis, a condition 
associated with therapy-resistant and metastatic breast tumors121,407, but also by the role 
hypoxic conditions play in:  (i) maintenance of the cancer stem cell (CSC) phenotype required 
to generate secondary tumors408, (ii) premetastatic niche formation409, (iii) cancer cell 
motility410, (iv) local tissue invasion, and (v) the generation of lymphatic vessels153,371,411, which 
constitute a common conduit for breast cancer cell dissemination and metastasis13–15. As a 
general process, hypoxia contributes to cancer cell escape by providing an aggressive 
selection pressure for resilient stem-like tumor cells that subsequently migrate away from the 
primary tumor46. 
In the here described in vivo experiments it is shown that stromal downregulation of CAV1 in 
TNBC xenografts results in lower survival rates, higher incidence of axillary lymph node 
metastasis and increased lung area affected by metastasis, suggesting that, in line with 
previous studies331,334, low stromal CAV1 TNBC tumors are more aggressive. Previous studies 
support a link between loss of Caveolin-1 (CAV1) in CAFs with poor clinical outcomes in breast 
cancer in terms of decreased survival, early tumor recurrence, lymph node metastasis and 
resistance to tamoxifen89,90,331–334. Similar clinical values of decreased stromal CAV1 levels 
have also been found in gastric cancer412,413, prostate cancer414,415 ,and malignant 
melanoma416. Conversely, it has been suggested that stromal CAV1 expression is a negative 
prognostic indicator in breast cancer correlating with increased cancer dissemination101; 
however, this study was focused in local tissue invasiveness via remodeling of the stromal 
ECM rather than the usual lymphatic metastasis of breast cancer.  
Such is the importance of lymphatic dissemination of breast cancer in the clinical setting that 
one of the most critical steps in staging a newly diagnosed patient with breast cancer is 
determining if cancer has spread to the regional lymph nodes15,417. On this subject, since 
cancer cell presence in regional mammary “sentinel” lymph nodes is considered to be a strong 
predictor of recurrence and survival13,15, specific techniques for detecting nodal involvement 
and the extension of lymphatic dissemination have been developed (Sentinel lymph node 
mapping)418.   
In this regard, lymphatic propagation has been described as the preferred way for breast 
cancer metastatic dissemination13–15. First, cancer cells derived from the primary tumor site 
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would invade the regional “sentinel” lymph nodes followed by spreading to distal nodes. At this 
point, nodal metastatic cells can use either lymphatic or blood vessels for subsequent 
lymphogenous or hematogenous dissemination, respectively14,15,390. 
The results presented in this work suggest that initial cancer dissemination in our xenograft 
mouse model occurs preferentially via lymphatic vasculature, given that the first structures 
found affected after mastectomy, in the luciferase (data not shown) and PET-CT metastases 
studies, were the axillary lymph nodes. Supporting this hypothesis, further progression of the 
disease resulted in the invasion of the mediastinal ganglia and the lung, whose apex is right 
next to the subclavian vein where the lymphatic thoracic duct and the venous system 
communicate419, as observed during histological analysis.  
This lymphatic network would constitute the escape route of cancer cells from a harsh hypoxic 
environment that keeps aggravating as a consequence of a dysfunctional vasculature - 
hypoxia - proangiogenic signaling imbalance loop. In addition, the increased interstitial fluid 
pressure present in solid tumors, caused by vascular dysfunction and worsened by fibrosis, all 
of them features aggravated in sCAV1low tumors, could also be a factor facilitating tumor cell 
escape from the primary tumor, as in an attempt to achieve homeostasis that interstitial fluid 
would be released through the lymphatic system15. 
Effective transport of cancer cells through the lymphatic system ends up entering the thoracic 
duct,  from where these cells have access to venous blood15. In addition, recent studies report 
an alternative hybrid route for breast cancer cell dissemination in mice via invasion of local 
blood vessels within a node14,420.Once breast cancer cells enter the blood circulation they elicit 
the establishment of metastatic lesions in the lungs, liver, brain and bones. In the case of basal-
like breast cancers (BLBCs), a classification under which most TNBCs are included40,41, the 
preferred metastatic sites are brain, lung and distant lymph nodes, and to a significantly lesser 
degree liver and bone16. Thus, our experimental xenograft model, using genetically modified 
CAFs to dissect stromal CAV1 function, recapitulated such natural metastatic tropism, as 
preferred target organs for metastasis were lung and distal lymph nodes, and with rare 
exceptions, the liver. 
Direct hematogenous and gradual lymphogenous dissemination routes are not mutually 
excluding, in this regard the enhanced permeability of low stromal CAV1 tumor vasculature 
could also constitute a facilitating factor for tumor cell intravasation and subsequent 
metastasis205,229,313. 
As already mentioned, cytokines secreted by CAFs present in the tumor stroma, such as 
CCL2421 and IL-8368,399, have also been shown to increase breast cancer stem cells (CSCs) 
which promotes metastasis. While hypoxia remains as a major candidate driving force, the 
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upregulation of these cytokines in CAFshCAV1 fibroblasts could also exert an intrinsic 
influence on the observed phenotype of increased aggressiveness in sCAV1low tumors.  
Different studies have attempted to explain the increased aggressiveness of sCAV1low tumors 
by virtue of two non-mutually-excluding models: a “Reverse Warburg effect”87 and the 
“autophagic tumor stroma”422 models, whereby loss of CAV1 in CAFs results in the production 
of metabolites and recycled products used by cancer cells. While these models explain the 
impact on cancer cell growth and survival, the connection to increased aggressiveness and 
metastasis is not so clear. Furthermore, although CAFshCAV1 fibroblasts displayed 
upregulation of autophagy markers, (DRAM1, CTSB and BNIP3) (Fig. S4A), as already 
described elsewhere393, conclusive proof of an active autophagy flux423 in our CAF cellular 
model was not found as both p62/SQSTM1 accumulation and LC3-II/LC3-I ratio, common 
active autophagy flux monitoring methods, showed no differences between CAFscr and 
CAFshCAV1 fibroblasts (Fig. S4B). 
Complementary to the “Reverse Warburg effect” model, the current work suggests increased 
hypoxic conditions in low stromal CAV1 breast tumors as: (i) a factor governing the increased 
aggressiveness and metastasis in these cancers and (ii) the link sustaining the positive 
feedback loop among dysfunctional vasculature and imbalanced proangiogenic signaling. 
4.5 Endoplasmic reticulum (ER) stress: A missing link between CAV1 downregulation 
and increased proangiogenic/proinflammatory cytokine production 
Previous studies have reported a transcriptional upregulation of IL1B, IL6, CXCL8, VEGFA 
and TGF-β in Cav1-knockout mouse mammary stromal fibroblasts395,424. Bioinformatic analysis 
predicted these and other target genes to be regulated by HIF1A (Hypoxia Inducible Factor 1 
Alpha) and NFκB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) transcription 
factors378, predicted hits that have also been observed in our RNASeq data analysis derived 
from CAFscr and CAFshCAV1 fibroblasts. 
4.5.1 Mitochondrial dysfunction, NFκB and HIF1A activation are not responsible for 
increased cytokine production in CAFshCAV1 fibroblasts 
A potential underlying molecular link between the transcriptional upregulation of 
proinflammatory/proangiogenic cytokines and mitochondrial dysfunction observed in 
CAFshCAV1 fibroblasts was explored on the basis of the previously described causative role 
of damaged mitochondria as sources for inflammation and oxidative stress383–385. 
Oxidative stress and the induction of autophagy can act as pro-activation cues for NFκB 
signalling425,426, a transcription factor already predicted to drive the production of those 
cytokines. This hypothesis was further supported by our initial observations: (i) mitochondria 
in CAFshCAV1 fibroblasts show both an increased ROS production and a dysfunctional 
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phenotype, and (ii) forced induction of mitochondrial OXPHOS usage by CAFs, (via 2-DG, 
DCA and low glucose treatments) leads to further upregulation of cytokine expression, 
especially in the case of dysfunctional mitochondria-bearing CAFshCAV1 fibroblasts. These 
findings harmonized with previous studies reporting a lower efficiency of the OXPHOS system 
in mitochondria derived from Cav1-knockout animals317,380,381. 
However, partially restoring mitochondrial functionality, either by limiting endogenous 
cholesterol accumulation (lovastatin) or administering exogenous ROS quenchers (GSH and 
GSH-EE), resulted in a modest increase in cytokine production, ruling out compromised 
mitochondrial performance as a direct cause for increased cytokine production in CAFshCAV1 
cells.  
Active autophagic flux in CAFscr and CAFshCAV1 fibroblasts, as another pro-activation cue 
for NFκB, was evaluated and, as already mentioned, there were no significant differences in 
this cellular model (Fig. S4A and S4B). Moreover, although activation of NFκB and HIF1A 
have been demonstrated to induce CAV1 downregulation393,427, neither NFκB nuclear 
localization (Fig. S4C, S4D and S4E) nor HI1FA expression (Fig. S4F) were significantly 
increased in CAFshCAV1 cells in the present study. Our negative results regarding 2-DG 
treatment of CAFs as a differential cause for NFκB activation allowed to rule out a potential 
connection between the observed upregulation of cytokine production and NFκB activation; 
while 2-DG treatment causes a surge in the studied cytokines expression, NFκB nuclear 
localization remained unaffected (Fig. S4D and S4E).  
Taken together these observations support the interpretation that both mitochondrial 
dysfunction and NFκB/HIF1A activation can be discarded as major driving causes for cytokine 
upregulation observed in CAFshCAV1 fibroblasts. Still, given the documented links between 
these processes and CAV1-dependent cell homeostasis, it will be interesting in the future to 
assess their contribution under specific conditions, such as concomitant abrogation of UPR 
signaling (see below). 
4.5.2 ER stress activation in CAFshCAV1 fibroblast: pledging guilty for increased 
proangiogenic/proinflammatory cytokine production 
Besides mitochondria, another critical organelle that is emerging as a major determinant in the 
field of angiogenesis is the endoplasmic reticulum (ER)244. Under stress conditions (such as 
during hypoxia or nutrient deprivation), the endoplasmic reticulum, as a cellular sensor of 
metabolic imbalance, is able to modulate the formation of new blood vessels to alleviate these 
stressors244. Moreover, CAV1 downregulation and induction of ER stress have been recently 
linked428–430. 
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Originally described as a consequence of misfolded protein accumulation, “ER stress” refers 
to any disequilibrium between ER performance of functional capacity, and the functional 
demand imposed by a given cell state. Eukaryotes have evolved complex signaling networks, 
collectively termed UPR, to monitor parameters affecting ER integrity and function and elicit 
adaptive functional programs244,376,377,431,432.  
Lipid imbalances and physical properties of the ER membrane are conditions inherently 
capable of triggering robust UPR signaling, too433. However, these specialized signaling 
systems are also sensitive to cues such as nutrient deprivation and hypoxia244,250,251, because 
the ER is an organelle onto which key limiting steps for lipid metabolism, red/ox regulation, 
calcium and energy homeostasis converge. For this same reason, the UPR does not only 
regulate “ER-specific” functions but also feeds into broad cell homeostatic programs, including 
metabolic regulation, inflammation, and proangiogenic signaling244,376,377,431,432. Thus, UPR 
signaling contributes to an ever-growing number of physiological and physiopathological 
processes, including tumor biology431,432 and angiogenesis244. 
Interestingly, both 2-DG and low glucose, treatments aimed at inducing OXPHOS usage and 
under which cytokine production was upregulated in CAFs, are also documented used 
inducers of ER stress388.  
In order to further investigate if ER stress could be responsible for the increased cytokine 
production in CAFshCAV1 fibroblasts, commonly used markers of ER stress activation434 were 
evaluated in these cells. Among these markers: (i) Ultrastructural examination of the ER by 
electron microscopy, (ii) CHOP and XBP1 transcript upregulation, (iii) increased XBP1 splicing 
and ATF4 staining; in conjunction with unbiased transcriptome profiling assays (RNASeq) 
pointed to the activation of ER stress and subsequent UPR upon downregulation of CAV1 in 
CAFs. 
Importantly, treatment of CAFs with direct ER stress inducers (Thapsigargin and Tunicamycin) 
resulted in a marked increase in the production of IL6, CXCL8 and VEGFA. Similarly, using 
genome-wide microarrays247, other groups have reported upregulation of CXCL8 and VEGFA, 
as well as other proangiogenic mediators, following experimental in vitro induction of ER stress 
with Thapsigargin. Moreover, human breast carcinoma cell lines respond to nutrient 
deprivation and ER stress also by upregulating CXCL8 and VEGFA435. Furthermore, induction 
of many of these proangiogenic factors was of similar magnitude or even greater following ER 
stress than in hypoxic or in aglycemic conditions. 
Treatments aimed at specifically abrogating UPR axes downstream of ER stress offered an 
insight into the pathways responsible for the upregulation of IL-8/CXCL8, a potential key 
cytokine for the observed aberrant tumor vasculature phenotype, in CAFshCAV1 fibroblasts. 
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Given the increased ATF4 staining (Fig. S2D), CHOP upregulation and downregulation of cap-
dependent translation (eIF2α-dependent) observed in CAFshCAV1 fibroblasts, the PERK axis 
of the UPR is clearly activated. In this regard, PERK inhibition resulted in the downregulation 
of CXCL8, pointing to a scenario in which ER stress induction, as a consequence of CAV1 
downregulation, and via the PERK-eIF2α-ATF4 axis, would control the expression of this 
cytokine.  Supporting this finding, ATF4 has been described to modulate CXCL8 expression249 
and the PERK-eIF2α-ATF4 axis activation has been reported to confer a survival advantage 
to hypoxic tumors251, probably via angiogenesis induction. On the other hand, IRE1α inhibition, 
markedly upregulated the expression of CXCL8, probably via a compensatory effect of the 
PERK pathway. 
Even though VEGFA and IL6 are markedly upregulated upon ER stress induction, neither 
PERK nor IRE1α UPR axis inhibition resulted in the downregulation of any of these two genes. 
In the same way as IRE1α inhibition elicits a compensatory response for CXCL8 expression 
via alternative UPR axes activation, this could be the case for VEGFA and IL6, since these 
genes are upregulated in response to both PERK and IRE1α axes248,254,255,436. Lack of CHOP 
inhibition upon PERKi treatment could be explained by the shutdown of PERK-driven negative 
feedback loops (required to reverse CHOP expression), or by parallel ISR pathways437 (feeding 
on CHOP upregulation) that could be engaged by the inhibition of PERK. 
Although IL1B and CCL2 follow the same expression patterns that CXCL8 upon IRE1α and 
PERK inhibition, exogenous ER induction favors their downregulation, thus further studies will 
be required to unveil the regulatory pathways of these two cytokines upregulated in 
CAFshCAV1 fibroblasts. 
The sum of these results regarding the expression of the aforementioned genes under ER 
induction and PERK or IRE1α inhibition, showcase the high redundancy and reciprocal 
compensation regulating UPR signaling. Nonetheless, the PERK-eIF2α-ATF4 pathway is 
proposed as a predominant, essential branch of the UPR driving IL-8 upregulation upon CAV1 
downregulation. 
4.5.3 ER stress and CAV1 downregulation: a self-sustaining loop 
Previous hypothesis for the source of CAV1 downregulation in stromal CAFs include128,323: 
(i) activation of oncogenes (HRas, V-Abl and Bcr-Abl) or inactivation of tumor suppress genes 
(p53)438, (ii) activation of the TGF-β signaling pathway, similar to the activation of fibroblasts in 
wound healing439, and (iii) oxidative stress generated by tumor cells, which may downregulate 
CAV1 in the surrounding stroma via HIF1A and NFκB activation422,427.  
The current work offers an alternative explanation for decreased stromal levels of CAV1 
observed in patients with aggressive breast cancer; it shows how ER stress induction derives 
107 
 
in a notable downregulation of CAV1 mRNA, which translates into a decrease of CAV1 protein 
levels, although not as immediate given the high stability of this membrane protein440. Data 
supporting this claim is not limited to the CAV1 downregulation observed in CAFs when using 
canonical inducers of ER stress (Thapsigargin, Tunicamycin, 2-Deoxyglucose and low glucose 
treatments)388, it is also based on the decreased CAV1 levels detected upon proteasome 
inhibitor treatments (indirect ER stress inducers)389 performed in an unbiased drug screening 
(Fig. S3).  
In line with this hypothesis, CAV1 has previously been reported to be reduced in an ER-stress 
dependent manner in endothelial cells429,430 and its overexpression has been also shown to 
rescue Thapsigargin-induced ER stress428. In addition, CAV1 is synthesized in the rough 
endoplasmic reticulum (RER) as an integral membrane protein303, so perturbations in this 
organelle could directly affect CAV1 production. 
As a side note, tamoxifen, an estrogen receptor modulator used in breast cancer treatment23,24, 
also constituted a positive hit for downregulation of CAV1 in CAFs. This phenomenon could 
be behind the tamoxifen-resistance associated with low stromal CAV1 breast cancers333. 
On the other hand, this work also shows how CAV1 silencing results in ER stress activation. 
Supporting this data, CAV1 downregulation, via Sirtuin1 deletion and miR-204 upregulation, 
has also been recently reported to induce ER stress441. Moreover, CAV1 is key in the formation 
of junctional complexes coupling the plasma membrane with ER for correct calcium (Ca2+) 
signalling315, thus perturbations in Ca2+ levels upon CAV1 downregulation could constitute an 
inducer of ER stress, given the importance of Ca2+ homeostasis for ER functionality.  
Furthermore, since CAV1 and caveolae are also involved in cholesterol transport316,317, and 
their downregulation or elimination results in altered cholesterol homeostasis, this could 
generate lipid composition changes in the ER membrane inducing a stress response. Still 
linking both aberrant calcium signaling and altered ER membrane lipid composition to ER 
stress induction would require further experimental work. 
Since drug-induced ER stress results in CAV1 downregulation, and this work also shows how 
CAV1 silencing results in ER stress activation, a positive feedback loop between CAV1 loss 
and ER stress activation can be proposed. Also, this loop could be a major component of the 
altered behavior of nutrient-deprived tumors (and thus TME), driving an aggressive phenotype 
and higher propensity to metastasize. As such, CAV1 levels would constitute a useful marker 
to consider intervention of these pathways to modulate tumor progression. 
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4.6 Proposed model and future perspectives 
Cancer and stromal cells face hypoxic and nutrient deficiency conditions during tumor growth. 
The ER, as a cellular sensor of metabolic imbalance, activates a stress response as an initial 
adaptation to these conditions244–247,376,431,432. Based on our evidence, ER stress activation 
could provide a new explanation for a self-sustained circuit leading to CAV1 downregulation in 
CAFs, a question that remained unsolved128,323. 
In this model, ER stress activation in CAFs, as a result of CAV1 downregulation promotes an 
exacerbated proangiogenic signaling that results in the formation of an impaired vascular 
network accompanied by the consequent hypoxia (Fig. 34A). These increased hypoxic 
conditions do not only further aggravate the proangiogenic and ER stress imbalances, they 
are proposed as the reason behind increased aggressiveness observed in sCAV1low tumors 
(Fig. 34B). 
The imbalance between pro- and anti-angiogenic cues found in tumors, a condition that the 
present study shows to be aggravated in sCAV1low TNBC xenografts (Fig. 19), is responsible 
for the formation of structurally aberrant and dysfunctional tumor vascular networks155 (Fig. 18, 
20 and 21). This situation, in turn, aggravates tumor hypoxia152 and promotes a general 
increase in aggressiveness46,73,282–284, traits also displayed by the described sCAV1low tumors 
(Fig. 22, 23, 32 and 33). 
A recent concept in antiangiogenic therapy is that of vascular normalization146,285, where 
instead of aiming at a complete elimination of the tumor vasculature (vascular regression), 
treatments intent to restore the balance among pro- and anti-angiogenic signals in an attempt 
to recover blood vessel functionality266,286. Although this approach of improving tumor irrigation 
might sounds counterintuitive, it has been shown to reduce aggressiveness and improve drug 
delivery.  
In the scenario presented in this work, the balance in low stromal CAV1 tumors is tilted to the 
side of proangiogenic factor production. Among this pool of proangiogenic factors, IL-8 was 
shown to be highly enriched, both in low stromal CAV1 xenograft lysates (Fig. 19B and 19D) 
and CAFshCAV1 fibroblasts (Fig. 25A, B, and D).  In an attempt to normalize and restore 
vascular functionality in low stromal CAV1 tumors, and thus observe a potential decrease in 
the aggressive tumor phenotype showed by these tumors, this work proposes administration 
of IL-8 inhibitors to mice during primary tumor growth. As already mentioned, one could 
anticipate that IL-8 inhibition in sCAV1high xenografts, where IL-8 expression levels are not 
upregulated, could provoke a reduction in tumor blood vessel functionality leading to an 
increased metastatic behavior. 
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Figure 34. Proposed model for increased aggressiveness in low stromal CAV1 (sCAV1low) 
xenografts (A) Upon CAV1 downregulation in CAFshCAV1 fibroblasts, an aberrant proangiogenic 
signaling ensues derived from the activated ER stress. The imbalance in the production of pro- and anti- 
angiogenic cues, derived from these CAFshCAV1 fibroblasts present in xenografts (low stromal CAV1 
xenografts), leads to the formation of an aberrantly dense and dysfunctional tumor vasculature. This 
blood vessel dysfunctionality results in increased intratumoral hypoxia, which promotes fibrosis and 
tumor aggressiveness. Insets of CAFs depict CAV1 in the membrane, mitochondria and the ER in blue. 
Red/green spheres represent pro- and anti-angiogenic cues (respectively). Darkest red spheres 
represent IL-8. (B) CAV1 downregulation and induction of ER stress in CAFs constitutes a positive 
feedback loop that is responsible for activating an exacerbated production of proangiogenic factors. This 
imbalance, in turn, primes the formation of an impaired tumor vasculature that promotes intratumoral 
hypoxia and derives in increased tumor aggressiveness. Hypoxia then constitutes a self-sustaining 
factor via further unbalancing pro- and anti-angiogenic cues and maintaining the ER stress induction – 
CAV1 downregulation loop. 
These anticipated results concerning IL-8 inhibition lead to two important observations: A first 
one concerning the concept of vascular regression versus vascular normalization in 
antiangiogenic therapy, whereby either too strong an inhibition, or the inhibition (and thus 
dysregulation) of an otherwise normal (non-upregulated) proangiogenic factor, results in 
decreased tumor vasculature functionality and a more aggressive tumor phenotype264–268, as 
proposed for sCAV1high tumors.  This study advocates for the latter, where a restoration of 
the imbalance presented by the cues governing angiogenesis in low stromal CAV1 xenografts 
could result in vascular normalization and a less belligerent tumor.  
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Such differential effects of IL-8 inhibition in high or low stromal CAV1 tumors leads to a second 
observation, bringing to the spotlight the importance of correctly stratifying patients in 
accordance to well-defined predictive markers for treatment response. The present study 
propones low CAV1 stromal and high IL-8 tumor expression levels as: (i) markers for poor 
prognosis of breast cancer (TNBC in this case), as a growing body of evidence has already 
reported89,90,331–334,391,392, and (ii) possible predictive markers for treatment response to IL-8 
inhibition. Still, standardized techniques for stromal CAV1 detection in patient biopsies and 
further animal studies will be needed to validate the proposed theoretical predictive value 
before translating it into a clinical setting. 
From a therapeutic point of view, normalizing aberrant angiogenesis in cancer needs new 
avenues of exploration given the relative inefficacy of present anti-angiogenic therapies which 
largely depend on ligand neutralization and perturbation of classic angiogenic signaling 
pathways182,266,267. In this regard, this newly proposed ER stress - IL-8 axis in low stromal CAV1 
TNBC tumors presents itself as a potential target for ameliorating the delivery of 
chemotherapeutic drugs and immune cells to tumor masses through vessel normalization, and 
for curbing stress-induced aggressive behavior leading to metastasis. Moreover, ER stress 
signaling itself is amenable for pharmacological intervention- combinatorial approaches may 
be devised additionally including this novel opportunity for fine-tuning tumor biology and 
architecture. 
Finally, and in a more general sense, this study, in line with a recent tendency45,46,183, suggests 
that modulating the extracellular environment that surrounds and infiltrates tumors may provide 
an additional opportunity for therapeutic intervention in hard to treat cancers such as TNBC. 
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5. CONCLUSIONS / CONCLUSIONES 
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5.1 CONCLUSIONS 
• Presence of Cancer-Associated Fibroblasts (CAFs) in Triple Negative Breast Cancer 
(TNBC) cell line-derived xenografts promotes angiogenesis. 
 
• sCAV1low tumors, derived from co-injection of TNBC cancer cells with CAFshCAV1 
fibroblasts, where Caveolin-1 (CAV1) has been depleted, display an aberrantly high 
blood vessel density when compared to their sCAV1high counterparts. 
 
• Despite the increased vascular network density, tumor blood vessel functionality in low 
stromal CAV1 xenografts is impaired, showing poor perfusion and increased leakiness. 
 
• The dysfunctional vasculature present in sCAV1low tumors results in increased tumor 
hypoxia, which correlates with poor survival and enhanced axillary lymph node and 
lung metastasis.  
 
• Downregulation of CAV1 activates endoplasmic reticulum (ER) stress, and vice versa 
ER stress induction promotes CAV1 downregulation, thus forming a positive feedback 
loop. 
 
• Increased ER stress in CAFs, in this case, provoked by CAV1 downregulation, causes 
an exacerbated proangiogenic phenotype. In particular, upregulation of the 
proangiogenic Interleukin-8 (IL-8) derives from the activation of the PERK axis of the 
Unfolded Protein Response (UPR) activated upon ER stress. 
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5.2 CONCLUSIONES 
• La inclusión de fibroblastos estromales asociados al tumor (CAFs, Cancer-Associated 
Fibroblasts, por sus siglas en inglés) en xenoinjertos de células tumorales de cáncer 
de mama triple negativo (TN) resulta en el incremento de la formación de nuevos vasos 
sanguíneos en los tumores resultantes (angiogénesis). 
 
• Los tumores con bajos niveles de Caveolina-1 (CAV1) estromal que surgen fruto de la 
co-inyección de líneas tumorales TN y CAFs dónde CAV1 ha sido silenciada, 
presentan una mayor densidad de vasos sanguíneos en comparación con aquellos 
tumores con niveles estromales altos de CAV1. 
 
• A pesar de poseer una red vascular más densa, los tumores con bajos niveles 
estromales de CAV1 sufren problemas de irrigación ya que sus capilares presentan 
bajos niveles de perfusión y un incremento de la permeabilidad, lo que se traduce en 
una funcionalidad reducida.  
 
• Estos problemas de irrigación presentes en los tumores con bajos niveles de CAV1 en 
el estroma provocan un aumento de la hipoxia intratumoral, un fenómeno que 
correlaciona con un incremento en la agresividad de dichos tumores (baja 
supervivencia, incremento de metástasis en nodo linfático axilar y pulmones).  
 
• El silenciamiento de CAV1 activa una respuesta de estrés en el retículo 
endoplasmático (ER, Endoplasmic Reticulum, por sus siglas en inglés), y viceversa, la 
inducción de estrés reticular promueve una bajada en los niveles de CAV1, 
estableciéndose un círculo vicioso de retroalimentación positiva. 
 
• El incremento del estrés reticular en CAFs, en este caso provocado por el 
silenciamiento de CAV1, genera un incremento en la producción de factores 
proangiogénicos en dichos fibroblastos. En particular, el aumento de la expresión y 
secreción de la citoquina proangiogénica Interleucina-8 (IL-8) se deriva de la 
estimulación de la vía PERK (vía de la UPR, Unfolded Protein Response, activada en 
respuesta a estrés reticular).   
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Figure S1. Prolonging tumor primary growth results in enriched hypoxia and fibrosis gene 
expression signatures in low stromal CAV1 (sCAV1low) tumors. (A) RNASeq-derived gene 
expression profile heatmaps of primary tumor xenograft lysates showing a significant upregulation of 
genes related to extracellular matrix organization and hypoxia in sCAV1low tumors resected 40 days 
post cell injection in the mammary fat pad. n=3/group. In gene expression heatmap red denotes 
increased gene expression while green corresponds to downregulation. (B) Gene enrichment analysis 
of differentially expressed genes in sCAV1low tumors resected 40 days post cell injection in the 
mammary fat pad. Analysis was performed with with Enrichr web tool, it shows top hits in Gene Ontology 
(GO) of Biological Process and MGI Mammalian Phenotype scored by P-value. Note the enrichment in 
biological processes related to response of low oxygen levels (hypoxia). Significance is represented as 
–log (P-value). 
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Figure S2. ER stress-related organelle morphological traits and UPR-derived transcription factor 
nuclear localization are enriched in CAFshCAV1 fibroblasts. (A, B, and D) Quantification of  (A and 
B) mitochondrial, and (C) endoplasmic reticulum structural features associated with disfunctionality and 
ISR activation. Features, such as ER and mitochondrial cristae engrossment become more apparent 
under ER stress inducing low glucose (LG) cell culture conditions. (D) Representative fluorescence 
microscopy images of CAFs grown in HG or LG DMEM, stained for nuclei (H33342, in cyan), 
endoplasmic reticulum (Calreticulin, in white) and ATF4/CREB2 transcription factor from PERK axis of 
the UPR (MitoTracker CM-H2TM ROS, in red). In basal HG conditions, according with UPR PERK axis 
activation, CAFshCAV1 fibroblasts show increased staining of ATF4, a situation that becomes clearer 
under the ER stress, and thus UPR, inducing LG condition. Scale bar: 20µm. 
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Figure S3. High Content Screening of drugs regulating CAV1 levels in pancreatic CAFs. (A) Whole 
384-well plate fluorescence microscopy image reconstruction. Each grid cell corresponds to 4 merged 
wells (20 images each) treated with the same experimental condition. Pancreatic CAFs were seeded 
and treated for 24h with serial dilutions of different predicted DMSO-dissolved CAV1 regulators. 
Afterwards, cells were fixed and stained for CAV1 (in green) and nuclei (DAPI, in red). As a control for 
the staining process a number of wells were pre-coated before cell-seeding with CAV1 siRNA (dark 
blue), siINCENP (which generates multinucleated cells and serves as a control for the siRNA delivery, 
in orange) and a non-targeting siRNA control. DMSO was the control vehicle (light blue). (B and C) 
Heatmap representation of (B) CAV1 cytoplasmic fluorescence intensity and (C) nuclei number, 
respectively. (D and E) Quantification of (D) CAV1 fluorescence intensity and (E) nuclei numbers. 
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Figure S4. Autophagy, NFκB and HIF1A signalling are not upregulated in CAFshCAV1 
fibroblasts. (A) qPCR expression analysis of CAV1, mitophagy (BNIP3) and autophagy 
(CTSB,DRAM1) markers in primary breast CAFs. (B) Western Blot analysis of CAFs cultured in High 
(25mM) or Low (2.5mM) glucose DMEM for 48h. Bafilomycin A1 is an inhibitor of the late phase of 
autophagy, which allows the study of active autophagy flux by preventing the degradation of LC3 and 
p62, common autophagy markers. Both in basal and BafA1 treated conditions CAFs show no difference 
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in LC3-II/LC3-I ratio or p62 accumulation. Data are representative of 4 independent experiments.  (C) 
Representative CAFs fibroblast immunofluorescence depicting NFκB staining (in green) and total cell 
nuclei number (red, DAPI staining). CAFs cells were grown in the presence of TNF-α (as a positive 
control treatment for NFκB nuclear translocation), and other treatments capable of inducing cytokine 
upregulation (2-DG, DCA) or quenchig mitochondrial ROS (mitoQ) in either high (HG) or low (LG) DMEM 
(HG images are shown). Observe nuclear localization of NFκB upon TNF treatment and the absence of 
differences in the untreated CAFs. See Fig. S4D and S4E. Scale bar: 20 µm (D and E) Quantification 
of NFκB nuclear/cytoplasmic intensity. Data is representative od 3 independent experiments. (Two-way 
ANOVA, Bonferroni’s multiple comparison test). Besides upon TNF treatments no significant differences 
are observed among CAFscr and CAFshCAV1 fibroblasts. (F) Western Blot analysis of CAFs cultured 
in low (2.5mM) glucose DMEM for 7 days. No differences were observed in HIF1A levels. For qPCR 
gene expression analysis data are presented as mean ± SEM relative to CAFscr CTRL; n=5, *P<0.05, 
**P<0.01, ***P<0.001, ****P<0.0001, Significance for comparisons against CAFscr CTRL (vehicle) is 
depicted in blue, and for CAFshCAV1 CTRL (vehicle) in red. (Multiple t-test comparisons, with Holm-
Sidak multiple comparison correction). 
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Figure S5. Signaling pathways upregulated in CAFshCAV1 fibroblasts. (A and B) Gene enrichment 
analysis performed in Panther and KEGG cell signaling pathway databases, respectively, via Enrichr 
web tool. TOP10 hits are shown. 
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Figure S6. Signaling pathways upregulated in low stromal CAV1 (sCAV1low) xenografts. (A and 
B) Gene enrichment analysis performed in Panther and KEGG cell signaling pathway databases, 
respectively, via Enrichr web tool. TOP10 hits are shown. Raw data corresponds to low stromal CAV1 
tumors mastectomized 30 days post-cell injection in the mice fat-mammary pad. 
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Table S1. Morphological parameters of tumor xenograft vasculature obtained upon 
automated image analysis. Related to Figure S2A and S2B. Mean ± SD of all parameters for 
MDA-MB-436 (TCs), MDA-MB-436 + CAFscr (TCs + CAFscr) and MDA-MB-436 + 
CAFshCAV1 (TCs + CAFshCAV1) tumors (columns 2 to 4) along with multiple comparisons 
between the different tumor categories (columns 5 to 7). Up and down-arrows indicate increase 
and decrease respectively of the parameter value for (i) TCs tumors compared with TCs + 
CAFscr tumors (column 5), (ii) TCs tumors compared with TCs + CAFshCAV1 tumors (column 
6), and (iii) TCs + CAFscr tumors compared with TCs + CAFshCAV1 tumors (column 7). Red 
(for increase) and blue (for decrease) colors are used to denote that the difference is 
statistically significant. Data include images from 3 independent experiments; n = 11 whole 
tumor images/MDA-MB-436 group and n = 31 whole tumor images/MDA-MB-436 + CAF 
groups, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001, (One-way ANOVA, Bonferroni’s 
multiple comparison test). 
 
TCs SCR shCAV1 
TCs 
vs 
SCR 
TCs 
vs  
shCAV1 
SCR 
vs 
shCAV1 
Morphology (Structure-level metrics) 
Fractal Dimension 1.76±0.12 1.81±0.15 1.84±0.21 ↓ ↓ ↓ 
Lacunarity (×102) 95.94±1.29 92.12±2.47 90.75±4.84 ↑* ↑*** ↑ 
Vascular Volume Density (%) 7.75±1.78 11.35±3.68 14.37±3.84 ↓* ↓*** ↓** 
Vascular Surface area per vascular 
volume ratio (mm2/mm3) 
204.65±20.72 222.78±50.68 210.14±31.31 ↓ ↓ ↑ 
Vascular surface area density (mm2/mm3) 15.74±3.19 24.56±8.21 30.42±10.59 ↓* ↓*** ↓* 
Breadth Density (mm2/mm3) 126.36±27.46 201.07±70.25 233.94±106.39 ↓* ↓** ↓ 
Euler Characteristic Density (1/mm3) -705.92±667.9 -2947.4±2720.06 -5240.46±7899.6 ↑ ↑ ↑ 
Total network length (mm) 237.56±105.78 846.55±442.83 1026.31±437.93 ↓*** ↓*** ↓ 
 
Angioarchitecture (Skeleton-based metrics) 
Vascular segment radius (µm) 8.58±1.09 7.98±1.46 8.15±1.18 ↑ ↑ ↓ 
Vascular segment length (µm) 41.13±11.86 41.4±7.6 40.55±10.6 ↓ ↑ ↑ 
Vascular segment surface (µm2) 1648.5±634.25 1553.62±495.33 1565.4±553.36 ↑ ↑ ↓ 
Vascular segment volume (µm3) 5780.59±2498.3 5084.82±2080.56 5205.15±2186.38 ↑ ↑ ↓ 
Tortuosity (µm/ µm) 1.58±0.1 1.55±0.08 1.53±0.07 ↑ ↑ ↑ 
Branching nodes (×104)a 13.11±4.95 12.64±2.97 13.97±5.92 ↑ ↓ ↓ 
Blind ends/sprouts (×104)a 0.17±0.18 0.24±0.19 0.38±0.49 ↓ ↓ ↓ 
Branching nodesb 13.11±4.95 12.64±2.97 13.97±5.92 ↓ ↓ ↓ 
Blind ends/sproutsb 4.29±2.48 3.84±1.3 3.96±1.98 ↑ ↑ ↓ 
Number of bifurcationsb 11.17±4.17 10.63±2.56 11.62±5.02 ↑ ↓ ↓ 
Number of trifurcationsb 1.62±0.69 1.64±0.39 1.91±0.79 ↓ ↓ ↓ 
Number of higher order connectionsb 0.32±0.14 0.37±0.12 0.44±0.18 ↓ ↓ ↓ 
 
aNumber per mm3 of tissue 
bNumber per mm vascular length 
 
 
 
 
 
 
150 
 
Table S2. List of primer sequences used for qPCR gene expression analysis. Related to 
materials & methods section: RNA purification and qPCR analysis. List of primers used for 
human gene expression analysis.  
qPCR SYBR-primers used in human gene expression analysis 
Symbol Acc No Fwd primer (5’-3’) Rev primer (5’-3’) 
    
GAPDH NM_002046 ATCACCATCTTCCAGGAGCG CCTGCAAATGAGCCCCAG 
ACTB NM_001101 CACCTTCCAGCAGATGTGGA AGCATTTGCGGTGGACGATGG 
HPRT1 NM_000194 CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA 
CAV1 NM_001172895 GATCAGTGGGCCTCCAAGG GCTCACACAATGGCCTCCAT 
VEGFA  NM_003376 AGGGCAGAATCATCACGAAGT AGGGTCTCGATTGGATGGCA 
IL1B NM_000576 TTCGACACATGGGATAACGAGG TTTTTGCTGTGAGTCCCGGAG 
IL6 NM_000600 CCTGAACCTTCCAAAGATGGC TTCACCAGGCAAGTCTCCTAA 
CXCL8 NM_000584 ACTGAGAGTGATTGAGAGTGGAC AACCCTCTGCACCCAGTTTTC 
SDHA NM_004168 CAGCATGTGTTACCAAGCTG GGTGTCGTAGAAATGCCACC 
SDHB NM_003000 GACACCAACCTCAATAAGGTCTC GGCTCAATGGATTTGTACTGTGC 
NDUFS1 NM_005006 TGGAAGACAAGAACATTGGGC GCAAACCTGATGCAGCGAG 
NDUFS2 NM_004550 ACCCAAGCAAAGAAACAGCC AATGAGCTTCTCAGTGCCTC 
SOD2 NM_000636 CTGATTTGGACAAGCAGCAA CTGGACAAACCTCAGCCCTA 
MT-CO1 GQ369957 GGCCTGACTGGCATTGTATT TGGCGTAGGTTTGGTCTAGG 
MT-CO2 GQ369957 CCATCCCTACGCATCCTTTAC GTTTGCTCCACAGATTTCAGAG 
MT-ND1 GQ369957 TCCTCTTCTTAACAACATACC GGTGAAGAGTTTTATGGC 
MT-ND2 GQ369957 TCCAGCACCACGACCCTACT TTCGATAATGGCCCATTTGG 
MT-ATP6 GQ369957 CCTTATGAGCGGGCACAG CAGGGCTATTGGTTGAATGAG 
MT-ATP8 GQ369957 CTAAATACTACCGTATGGCCC GGGCTTTGGTGAGGGAGG 
CCL2 NM_002982 CAGCCAGATGCAATCAATGCC TGGAATCCTGAACCCACTTCT 
EDN1 NM_001955 AAGGCAACAGACCGTGAAAAT CGACCTGGTTTGTCTTAGGTG 
THBS1 NM_003246 AGACTCCGCATCGCAAAGG TCACCACGTTGTTGTCAAGGG 
THBS2 NM_003247 GACACGCTGGATCTCACCTAC GAAGCTGTCTATGAGGTCGCA 
CTSB NM_001908 ACAACGTGGACATGAGCTACT TCGGTAAACATAACTCTCTGGGG 
DRAM1 NM_018370 TCAAATATCACCATTGATTTCTG GCCACATACGGATGGTCATCTC 
BNIP3 NM_004052 GACGGAGTAGCTCCAAGAGC CTGGTGGAGGTTGTCAGACG 
XBP1 NM_001079539 TTACGAGAGAAAACTCATGGC GGGTCCAAGTTGTCGAATGC 
CHOP NM_001195056 CAGAACCAGCAGAGGTCACA AGCTGTGCCACTTTCCTTTC 
FAP NM_004460 TGAACGAGTATGTTTGCAGTGG GGTCTTTGGACAATCCCATGT 
FSP1 NM_002961 GATGAGCAACTTGGACAGCAA CTGGGCTGCTTATCTTGGGAAG 
ITGA11(2) NM_001004439 ACACAGTTTTGACGGCATTTGG GCAGACAGCAAGCGGTAAA 
ITGA11(3) NM_001004439 GACCTACATGGACATCGTCATTG ATCTTCGCCATACTGCACAAC 
ITGA11(4) NM_001004439 GCAACGCTGTGATTCTGTGG AGATGGGCGTGAAGCAGAGG 
ITGA11(5) NM_001004439 GGGCAGATCCAGGTTGGAGT TCAATGCCAAATGCCGTCCG 
ITGA11(6) NM_001004439 AAGATATGCGGTGGCCGTCC TCGTTCTTGTTGGTGCCTTCC 
MMP2 NM_001127891 CCCACTGCGGTTTTCTCGAAT CAAAGGGGTATCCATCGCCAT 
MMP9 NM_004994 TGTACCGCTATGGTTACACTCG GGCAGGGACAGTTGCTTCT 
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Table S3. List of antibodies used for Western Blot and immunofluorescence assays. 
Related to materials & methods sections: Protein extraction and Western Blot (WB) analysis 
and immunofluorescence analyses (IF). Table includes: (i) Detected protein, (ii) unique 
UniProtKB identifier, (iii) antibody descriptions with clone number in between parenthesis ( ) 
and, for phosphorylated proteins (p-), recognized phosphorylated residues between brackets 
[ ], (iv) species in which the antibody is produced, (v) producer, (vi) catalog number, (vii) 
techniques in which the antibody was used, and (viii) recommended dilutions.  Abbreviations 
stand for: mAb (monoclonal antibody) and pAb (polyclonal antibody). 
Protein UniProtID Antibody Species Producer Cat.No App. Dilution 
        
CAV1 Q03135 Caveolin-1 
(D46G3) XP® 
Rabbit 
mAb 
Cell 
Signalling 
 
3267S 
 
WB, 
IF 
1:5000, 
1:1000 
        
TBA1A Q71U36 Anti-α-Tubulin 
(DM1A) 
Mouse 
mAb 
 
Sigma 
 
T9026 
 
WB 1:5000 
        
LC3B Q9GZQ8 LC3B (D11) 
XP® 
Rabbit 
mAb 
 
Cell 
Signalling 
 
3868S 
 
WB 1:1000 
        
P62 Q13501 Anti-p62 / 
SQSTM1 (C-
term) 
 
Guinea 
Pig pAb 
 
Progen 
 
GP62-C  
 
WB 1:1000 
        
ERK1/2 P27361 / 
P28482 
p44/42 MAPK 
(Erk1/2) 
(L34F12) 
 
Mouse 
mAb 
 
Cell 
Signalling 
 
4696S 
 
WB 1:2000 
        
PERK Q9NZJ5 Anti-PERK Rabbit 
pAb 
 
Abcam ab65142 WB 1:1000 
        
p-PERK Q9NZJ5 Phosp-PERK 
[Thr980] 
(16F8) 
 
Rabbit 
mAb 
Cell 
Signalling 
 
3179S WB 1:1000 
        
ATF4 
 
P18848 CREB-2 
Abody (B-3) 
Mouse 
mAb 
Santa 
Cruz 
sc-390063 IF 1:500 
        
        
Calreticulin 
 
P27797 Anti-
Calreticulin 
Rabbit 
pAb  
Abcam ab2907 IF 1:1000 
        
        
eIF2α Q9BY44 Anti-
EIF2S1/EIF2α 
Mouse 
mAb 
 
Abcam ab5369 WB 1:1000 
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p-eIF2α Q9BY44 Phosp-eIF2α 
[Ser51] 
(119A11) 
 
Rabbit 
mAb 
Cell 
Signalling 
 
3597S WB 1:1000 
        
CHOP P35638 CHOP 
(L63F7) 
 
Mouse 
mAb 
Cell 
Signalling 
2895S WB 1:1000 
        
CHOP P35638 GADD 153 
Antibody (B-3) 
Mouse 
mAb 
Santa 
Cruz  
sc-7351 IF 1:500 
        
        
CD31 P16284 Anti-PECAM-1 
(2H8) 
Armenian 
Hamster 
mAb 
 
Merck MAB1398Z IF 1:250 
        
HIF1A Q16665 Anti-HIF-1 
alpha 
(EP1215Y) 
 
Rabbit 
mAb 
Abcam ab51608 IF 1:250 
        
PDGFRB P09619 PDGFRB 
(G.290.3) 
Mouse 
mAb 
 
Thermo 
Fisher 
MA5-
15143 
IF 1:250 
        
LYVE1 Q9Y5Y7 Anti-LYVE1 Rabbit 
pAb 
Abcam ab14917 IF 1:250 
        
        
NFκB 
(p65) 
Q04206 Anti-NF-kB 
p65 
Rabbit 
pAb 
Abcam ab16502 IF 1:1000 
        
        
ITGA11 Q9UKX5 Human/Mouse 
Integrin alpha 
11 Antibody 
Mouse 
mAb 
 
R&D sys MAB4235 WB 1:500 
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Table S4. CAV1-targeting and luciferase expressing bicistronic lentiviral vectors: 
Cloning primer sequences, synthetic miRNA oligos and lentivirus diagrams. Related to 
materials & methods section: Lentiviral and retroviral vector generation. (A) List of primers 
used for cassette amplification. All primers include the corresponding restriction enzyme sites 
used for cloning on their 5' ends. (B) Chemically synthesized and PAGE purified oligos used 
to generate miR30-based hairpins. Flanking XhoI and EcoRI ready available sites are shown 
in lowercase. Non-targeting and CAV1-targeting sequences are marked in bold. (C) Promoter 
amplification and MCS generation primers (Phos: Phosphorylated 5’). Resulting lentiviral 
vectors: (D) pLVX-CMV-ChFP2A, (E) pLVX-CMV-ChFP2A-RE8luc, (F) pLVX-CMV-ChFP2A-
PuroR-miR30.scr, (G) pLVX-CMV-PuroR-miR30.scr, (H) pLVX-MCS-ChFP2A-RE8luc-
miR30.scr and (I) pLVX-ITGA11-ChFP2A-RE8luc-miR30.scr. Lentiviral backbone elements 
(LTR, RRE, cPPT, WPRE and Ψ) are shown in grey, colored boxes correspond to: CherryFP 
(fluorescent protein), RE8luc (luciferase), PuroR (puromycin resistance) and miR5'-3' 
(microRNA flanking sequences). P2A self-cleaving peptide appears in white. 
 Table S4A. Primers used for lentivirus cassette amplification 
Amplified Cassette Sequence (5' - 3') Designator 
   
CMV-CherryFP-P2A 5'-ACATCGATGGGAGTTCCGCGTTACATAAC-3' Forward (A1) 
 5'-ACGCGTCCAGAGGTTGATTGTCGACG-3' Reverse (A2) 
PpyRE8 luciferase 5'-GCTTAATTAAGGAGGACGCCAAGAACATC-3' Forward (L1) 
 5'-TAGTTTAAACCTCAGATCTTGCCGCCCTTCTT-3' Reverse (L2) 
PuroR-miR30.scr 5'-CCTTTAATTAAGGCCACCGAGTACAAGC-3' Forward (M1) 
 5'-CCAGACGCGTCCTAGGTAATACG-3' Reverse (M2) 
CMV-PuroR-miR30.scr 5'-TACCGGTCATGGCCACCGAGTACAAGC-3' Forward (M1.1) 
 5'-CCAGACGCGTCCTAGGTAATACG-3' Reverse (M2) 
CherryFP-P2A 5'-TAATCGATATGGTGAGCAAGGGCGAGG-3' Forward (B1) 
 5'-TCTAGACCAGAGGTTGATTGTCGACG-3' Reverse (B2) 
miR30.scr backbone 5'-CCCGTTTAAACGTTTGTTTGAATGAGG-3' Forward (MB1) 
 5'-GCCACGCGTAGTGATTTAATTTATACC-3' Reverse (MB2) 
 
Table S4B. Non-targeting and CAV1-targeting synthetic miRNA oligos. 
Target Sequence (5' - 3') 
  
Non-
targeting 
(scr) 
5'-tcgagAAGGTATATTGCTGTTGACAGTGAGCGATCTCGCTTGGGCGAGAGTAAGTAGT 
GAAGCCACAGATGTACTTACTCTCGCCCAAGCGAGAGTGCCTACTGCCTCGg-3' 
 
 5'-aattcCGAGGCAGTAGGCACTCTCGCTTGGGCGAGAGTAAGTACATCTGTGGCTTCAC 
TACTTACTCTCGCCCAAGCGAGATCGCTCACTGTCAACAGCAATATACCTTc-3' 
 
  
shCAV1.2 5'-tcgagAAGGTATATTGCTGTTGACAGTGAGCGCGACGTGGTCAAGATTGACTTTTAGT 
GAAGCCACAGATGTAAAAGTCAATCTTGACCACGTCATGCCTACTGCCTCGg-3' 
 
 5'-aattcCGAGGCAGTAGGCATGACGTGGTCAAGATTGACTTTTACATCTGTGGCTTCACT 
AAAAGTCAATCTTGACCACGTCGCGCTCACTGTCAACAGCAATATACCTTc-3' 
 
  
shCAV1.3 5'-tcgagAAGGTATATTGCTGTTGACAGTGAGCGCCCACCTTCACTGTGACGAAATTAGT 
GAAGCCACAGATGTAATTTCGTCACAGTGAAGGTGGTTGCCTACTGCCTCGg-3' 
 
 5'-aattcCGAGGCAGTAGGCAACCACCTTCACTGTGACGAAATTACATCTGTGGCTTCACT 
AATTTCGTCACAGTGAAGGTGGGCGCTCACTGTCAACAGCAATATACCTTc-3' 
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shCAV1.4 5'-tcgagAAGGTATATTGCTGTTGACAGTGAGCGAGCATCAACTTGCAGAAAGAAATAGT 
GAAGCCACAGATGTATTTCTTTCTGCAAGTTGATGCGTGCCTACTGCCTCGg-3' 
 
 5'-aattcCGAGGCAGTAGGCAGGGCAGTTGTACCATGCATTAATACATCTGTGGCTTCAC 
TATTAATGCATGGTACAACTGCCTCGCTCACTGTCAACAGCAATATACCTTc-3' 
  
shCAV1.5 5'-tcgagAAGGTATATTGCTGTTGACAGTGAGCGAGGCAGTTGTACCATGCATTAATAGT 
GAAGCCACAGATGTATTAATGCATGGTACAACTGCCCTGCCTACTGCCTCGg-3' 
 
 5'-aattcCGAGGCAGTAGGCACGCATCAACTTGCAGAAAGAAATACATCTGTGGCTTCAC
TATTTCTTTCTGCAAGTTGATGCTCGCTCACTGTCAACAGCAATATACCTTc-3' 
 
Table S4C. Primers used for ITGA11 promoter amplification and MCS insertion 
Amplified Cassette Sequence (5' - 3') Designator 
   
-2123 +25 pITGA11 5'-TAACCGGTGGCACCTGTGAGGACGG-3' Forward (I1) 
 5'-TACATATGGCGGCACGGCGGCTG-3' Reverse (I2) 
MCS oligos  
MCS1 5'- [Phos]CGATACTAGTGGCGCGCCACCGGTCATATGAT-3' 
MCS2 5'- [Phos]CGATCATATGACCGGTGGCGCGCCACTAGTAT-3' 
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Table S5. RNASeq gene expression analysis data derived from xenografts removed 30 days post-implantation. Gene expression fold-change (FC) is represented as log2FC and color coded from 
highest (+ values in red, upregulated in low stromal CAV1 xenografts) to lowest (- values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000173432 SAA1 6,45607 9,87E-24 ENSG00000259075 POC1B-GALNT4 3,94572 2,01E-02 ENSG00000101187 SLCO4A1 2,5251 1,11E-50 ENSG00000154639 CXADR 2,0688 1,81E-07 
ENSG00000262526  5,88833 0,0001134 ENSG00000136244 IL6 3,89983 1,29E-15 ENSG00000125618 PAX8 2,51877 7,31E-13 ENSG00000170458 CD14 2,06829 0,0003864 
ENSG00000156510 HKDC1 5,49874 4,09E-28 ENSG00000180543 TSPYL5 3,89127 2,09E-16 ENSG00000177706 FAM20C 2,50785 5,24E-25 ENSG00000214110 LDHAP4 2,04723 6,66E-05 
ENSG00000179046 TRIML2 5,27855 2,61E-32 ENSG00000180190 TDRP 3,88395 4,62E-16 ENSG00000233532 LINC00460 2,50118 3,29E-07 ENSG00000135083 CCNJL 2,03135 1,22E-05 
ENSG00000268902 CSAG2 5,21808 3,93E-11 ENSG00000008517 IL32 3,88117 2,35E-52 ENSG00000154655 L3MBTL4 2,48762 0,0001961 ENSG00000196781 TLE1 2,02634 3,37E-16 
ENSG00000215218 UBE2QL1 5,21187 1,66E-14 ENSG00000169429 CXCL8 3,87617 2,89E-18 ENSG00000189423 USP32P3 2,47984 1,74E-06 ENSG00000163131 CTSS 2,01203 2,73E-11 
ENSG00000164438 TLX3 4,92469 9,69E-24 ENSG00000135116 HRK 3,86492 3,03E-20 ENSG00000182240 BACE2 2,47176 2,46E-18 ENSG00000198093 ZNF649 2,00322 0,0052294 
ENSG00000176887 SOX11 4,90901 1,05E-28 ENSG00000268916  3,86438 2,51E-11 ENSG00000261771 DYX1C1-CCPG1 2,47043 0,0185601 ENSG00000184985 SORCS2 1,99174 7,63E-11 
ENSG00000160233 LRRC3 4,81849 1,07E-19 ENSG00000258498 DIO3OS 3,85396 2,22E-13 ENSG00000160712 IL6R 2,47005 4,90E-12 ENSG00000174990 CA5A 1,99168 5,01E-06 
ENSG00000163995 ABLIM2 4,71884 2,89E-18 ENSG00000099284 H2AFY2 3,84828 2,09E-24 ENSG00000163520 FBLN2 2,46146 1,10E-21 ENSG00000197905 TEAD4 1,98755 1,12E-17 
ENSG00000215612 HMX1 4,67313 7,34E-23 ENSG00000122378 FAM213A 3,8328 4,38E-30 ENSG00000185291 IL3RA 2,45713 0,0010618 ENSG00000105963 ADAP1 1,98246 0,000192 
ENSG00000142185 TRPM2 4,66139 2,19E-19 ENSG00000066735 KIF26A 3,82995 2,94E-14 ENSG00000139910 NOVA1 2,45459 1,82E-09 ENSG00000152977 ZIC1 1,98173 1,31E-06 
ENSG00000147381 MAGEA4 4,64947 1,42E-09 ENSG00000125730 C3 3,82744 4,72E-31 ENSG00000184258 CDR1 2,4513 0,0001209 ENSG00000196967 ZNF585A 1,97959 0,0021731 
ENSG00000147202 DIAPH2 4,64795 4,59E-20 ENSG00000189223 PAX8-AS1 3,79014 2,68E-29 ENSG00000188385 JAKMIP3 2,45061 2,67E-06 ENSG00000135119 RNFT2 1,97841 5,89E-09 
ENSG00000183570 PCBP3 4,63434 2,93E-20 ENSG00000177614 PGBD5 3,765 4,31E-14 ENSG00000011201 KAL1 2,44404 6,66E-05 ENSG00000007516 BAIAP3 1,97298 0,0005208 
ENSG00000165810 BTNL9 4,63172 3,57E-14 ENSG00000185101 ANO9 3,75098 3,09E-23 ENSG00000167972 ABCA3 2,44018 2,19E-17 ENSG00000041353 RAB27B 1,97266 8,27E-06 
ENSG00000189190 ZNF600 4,61218 1,48E-13 ENSG00000160183 TMPRSS3 3,73956 3,85E-08 ENSG00000187479 C11orf96 2,42524 3,17E-05 ENSG00000131127 ZNF141 1,97225 0,0001481 
ENSG00000182195 LDOC1 4,57056 7,69E-12 ENSG00000196387 ZNF140 3,73317 2,67E-09 ENSG00000163347 CLDN1 2,41216 5,45E-11 ENSG00000261971  1,96774 3,88E-08 
ENSG00000170837 GPR27 4,56905 4,50E-18 ENSG00000172247 C1QTNF4 3,73315 2,21E-36 ENSG00000182326 C1S 2,40369 3,14E-39 ENSG00000104177 MYEF2 1,96507 6,18E-13 
ENSG00000198538 ZNF28 4,5632 4,22E-12 ENSG00000080007 DDX43 3,70179 7,51E-16 ENSG00000249751 ECSCR 2,37343 2,28E-09 ENSG00000180573 HIST1H2AC 1,94782 1,01E-15 
ENSG00000148082 SHC3 4,5333 4,28E-14 ENSG00000178445 GLDC 3,69278 1,94E-18 ENSG00000205927 OLIG2 2,36732 0,0005231 ENSG00000205403 CFI 1,92885 0,0006401 
ENSG00000175928 LRRN1 4,51483 2,64E-14 ENSG00000169418 NPR1 3,68105 3,88E-20 ENSG00000101017 CD40 2,35429 8,02E-06 ENSG00000103485 QPRT 1,92682 8,68E-15 
ENSG00000148803 FUOM 4,48079 1,58E-22 ENSG00000204604 ZNF468 3,6788 2,25E-09 ENSG00000236081 ELFN1-AS1 2,35173 0,0002007 ENSG00000185818 NAT8L 1,92228 9,62E-16 
ENSG00000087510 TFAP2C 4,48008 1,18E-11 ENSG00000184160 ADRA2C 3,66878 4,79E-19 ENSG00000245680 ZNF585B 2,35089 2,32E-05 ENSG00000223414 LINC00473 1,92154 5,30E-05 
ENSG00000162493 PDPN 4,43357 5,02E-14 ENSG00000090339 ICAM1 3,65295 1,12E-50 ENSG00000075618 FSCN1 2,32658 1,72E-32 ENSG00000260428 SCXB 1,91711 7,74E-08 
ENSG00000082397 EPB41L3 4,43113 1,42E-47 ENSG00000204179 PTPN20A 3,64801 6,76E-09 ENSG00000103037 SETD6 2,31409 2,28E-06 ENSG00000074181 NOTCH3 1,9138 4,67E-42 
ENSG00000229967  4,429 1,69E-20 ENSG00000185274 WBSCR17 3,64559 9,92E-11 ENSG00000067606 PRKCZ 2,31325 7,65E-11 ENSG00000057294 PKP2 1,91324 0,0004638 
ENSG00000235961 PNMA6C 4,41333 5,19E-16 ENSG00000165300 SLITRK5 3,64371 5,49E-18 ENSG00000135549 PKIB 2,3101 5,62E-08 ENSG00000178726 THBD 1,90624 0,0005497 
ENSG00000163395 IGFN1 4,40006 2,96E-67 ENSG00000077522 ACTN2 3,64004 7,07E-16 ENSG00000272884  2,30707 0,0001068 ENSG00000234284 ZNF879 1,90414 7,29E-06 
ENSG00000197951 ZNF71 4,39976 1,07E-16 ENSG00000101210 EEF1A2 3,61976 1,28E-27 ENSG00000134769 DTNA 2,28899 4,95E-10 ENSG00000129521 EGLN3 1,88955 9,61E-08 
ENSG00000074211 PPP2R2C 4,39297 8,97E-39 ENSG00000126970 ZC4H2 3,59972 7,01E-16 ENSG00000248871 TNFSF12-TNFSF 2,28239 0,0085105 ENSG00000058085 LAMC2 1,87808 0,0001902 
ENSG00000169436 COL22A1 4,3434 5,58E-18 ENSG00000130294 KIF1A 3,59937 1,96E-18 ENSG00000159403 C1R 2,28218 1,58E-43 ENSG00000150782 IL18 1,87653 8,39E-06 
ENSG00000151640 DPYSL4 4,30879 2,62E-22 ENSG00000271503 CCL5 3,59868 1,77E-15 ENSG00000163734 CXCL3 2,27009 2,07E-05 ENSG00000139629 GALNT6 1,86708 2,10E-05 
ENSG00000170430 MGMT 4,30464 7,26E-23 ENSG00000162738 VANGL2 3,5978 6,20E-20 ENSG00000273590  2,24702 1,61E-08 ENSG00000006118 TMEM132A 1,8665 8,43E-39 
ENSG00000170571 EMB 4,29395 6,96E-20 ENSG00000164742 ADCY1 3,59201 5,43E-15 ENSG00000205336 GPR56 2,22789 1,59E-06 ENSG00000092969 TGFB2 1,86084 2,08E-20 
ENSG00000151892 GFRA1 4,29034 3,48E-14 ENSG00000163121 NEURL3 3,58942 6,64E-16 ENSG00000137726 FXYD6 2,21797 3,43E-07 ENSG00000131650 KREMEN2 1,85951 8,02E-06 
ENSG00000197444 OGDHL 4,28886 7,52E-29 ENSG00000165238 WNK2 3,58887 9,30E-12 ENSG00000189337 KAZN 2,21042 7,82E-16 ENSG00000021645 NRXN3 1,84335 0,00261 
ENSG00000182636 NDN 4,27627 1,26E-16 ENSG00000181143 AP1M1 3,58426 3,38E-14 ENSG00000183092 BEGAIN 2,2081 2,15E-12 ENSG00000159167 STC1 1,8242 5,75E-05 
ENSG00000186310 NAP1L3 4,22919 1,54E-14 ENSG00000203326 ZNF525 3,57052 2,71E-10 ENSG00000149582 TMEM25 2,20042 7,16E-06 ENSG00000148655 C10orf11 1,81448 2,11E-06 
ENSG00000102109 PCSK1N 4,2273 2,19E-19 ENSG00000120149 MSX2 3,5535 3,88E-08 ENSG00000118503 TNFAIP3 2,18466 4,31E-29 ENSG00000271781  1,81081 0,002449 
ENSG00000145911 N4BP3 4,21273 1,80E-35 ENSG00000147180 ZNF711 3,54912 2,53E-14 ENSG00000161958 FGF11 2,18416 1,23E-17 ENSG00000272405  1,80968 0,0002899 
ENSG00000224945  4,15583 1,30E-12 ENSG00000276547 PCDHGB5 3,53333 1,30E-09 ENSG00000166432 ZMAT1 2,18303 9,80E-05 ENSG00000103381 CPPED1 1,79918 1,37E-05 
ENSG00000213886 UBD 4,15394 1,69E-10 ENSG00000130540 SULT4A1 3,52892 1,94E-11 ENSG00000104419 NDRG1 2,17977 6,11E-38 ENSG00000136944 LMX1B 1,79561 0,0002691 
ENSG00000180730 SHISA2 4,14703 2,40E-19 ENSG00000180921 FAM83H 3,49797 5,97E-19 ENSG00000174669 SLC29A2 2,17851 3,86E-15 ENSG00000054356 PTPRN 1,79428 1,48E-12 
ENSG00000132182 NUP210 4,13071 4,99E-49 ENSG00000198203 SULT1C2 3,49004 7,39E-21 ENSG00000275216  2,17824 1,19E-11 ENSG00000113645 WWC1 1,78473 1,01E-22 
ENSG00000121413 ZSCAN18 4,12387 2,08E-20 ENSG00000158106 RHPN1 3,48834 4,85E-24 ENSG00000151883 PARP8 2,17801 2,48E-07 ENSG00000235897 TM4SF19-AS1 1,77388 0,0008195 
ENSG00000124260 MAGEA10 4,11305 5,09E-19 ENSG00000196458 ZNF605 3,48556 8,52E-10 ENSG00000134326 CMPK2 2,17512 1,06E-17 ENSG00000111674 ENO2 1,77218 9,09E-45 
ENSG00000163638 ADAMTS9 4,09653 8,20E-14 ENSG00000181218 HIST3H2A 3,45694 6,26E-08 ENSG00000108691 CCL2 2,17391 0,0008947 ENSG00000106070 GRB10 1,77144 3,61E-11 
ENSG00000122133 PAEP 4,06481 7,11E-13 ENSG00000196867 ZFP28 3,44918 9,47E-09 ENSG00000135127 CCDC64 2,1488 1,15E-05 ENSG00000213996 TM6SF2 1,76855 0,005321 
ENSG00000130558 OLFM1 4,0455 5,78E-13 ENSG00000105357 MYH14 3,44476 5,05E-11 ENSG00000250899  2,13849 1,92E-08 ENSG00000152137 HSPB8 1,76411 6,15E-09 
ENSG00000007264 MATK 4,04251 2,92E-15 ENSG00000176595 KBTBD11 3,42226 1,25E-13 ENSG00000172183 ISG20 2,13526 3,28E-15 ENSG00000228203 RNF144A-AS1 1,76171 0,0016197 
ENSG00000196632 WNK3 4,02609 7,92E-12 ENSG00000187957 DNER 3,41543 5,97E-10 ENSG00000102032 RENBP 2,13408 3,47E-21 ENSG00000066248 NGEF 1,76073 0,0002129 
ENSG00000124102 PI3 4,02352 3,20E-16 ENSG00000272620 AFAP1-AS1 3,3905 3,36E-19 ENSG00000198879 SFMBT2 2,13197 0,0002431 ENSG00000160781 PAQR6 1,74684 6,66E-05 
ENSG00000178573 MAF 4,00245 7,00E-11 ENSG00000154118 JPH3 3,38767 1,48E-12 ENSG00000140993 TIGD7 2,13196 0,0001453 ENSG00000105696 TMEM59L 1,73742 1,05E-06 
ENSG00000105717 PBX4 3,99836 1,30E-09 ENSG00000002933 TMEM176A 3,36068 8,12E-09 ENSG00000273259 GAA 2,12397 0,0118809 ENSG00000125538 IL1B 1,73632 0,0087495 
ENSG00000070159 PTPN3 3,9815 1,18E-16 ENSG00000124107 SLPI 3,3442 1,52E-12 ENSG00000134321 RSAD2 2,1142 6,43E-13 ENSG00000077238 IL4R 1,73377 6,09E-13 
ENSG00000173110 HSPA6 3,98013 1,76E-41 ENSG00000129354 AP1M2 3,33094 4,26E-19 ENSG00000225138  2,11221 7,75E-27 ENSG00000007237 GAS7 1,72584 1,91E-08 
ENSG00000166391 MOGAT2 3,97823 2,72E-12 ENSG00000182463 TSHZ2 3,31517 1,22E-07 ENSG00000132470 ITGB4 2,09575 2,04E-22 ENSG00000064042 LIMCH1 1,71832 4,70E-29 
ENSG00000131773 KHDRBS3 3,96972 4,82E-16 ENSG00000121316 PLBD1 3,30886 2,65E-23 ENSG00000226051 ZNF503-AS1 2,09394 1,19E-05 ENSG00000084636 COL16A1 1,7166 2,21E-22 
ENSG00000136856 SLC2A8 3,96295 4,01E-10 ENSG00000102854 MSLN 3,29951 2,17E-14 ENSG00000120784 ZFP30 2,08628 7,67E-05 ENSG00000115457 IGFBP2 1,70963 4,63E-05 
ENSG00000259075 POC1B-GALNT4 3,94572 0,0200657 ENSG00000196730 DAPK1 3,28802 4,45E-09 ENSG00000025708 TYMP 2,06962 1,20E-19 ENSG00000130762 ARHGEF16 1,69384 0,0002014 
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Table S5. RNASeq gene expression analysis data derived from xenografts removed 30 days post-implantation. Gene expression fold-change (FC) is represented as log2FC and color coded from 
highest (+ values in red, upregulated in low stromal CAV1 xenografts) to lowest (- values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000130762 ARHGEF16 1,69384 0,0002014 ENSG00000146054 TRIM7 1,44578 5,14E-06 ENSG00000142303 ADAMTS10 1,27581 0,0042446 ENSG00000171223 JUNB 1,14633 1,13E-16 
ENSG00000197565 COL4A6 1,6927 0,0125043 ENSG00000136048 DRAM1 1,43703 3,94E-11 ENSG00000099812 MISP 1,27049 0,0294167 ENSG00000164171 ITGA2 1,14228 0,002143 
ENSG00000105499 PLA2G4C 1,6876 4,79E-06 ENSG00000261373 VPS9D1-AS1 1,42906 0,0038201 ENSG00000141524 TMC6 1,26933 1,86E-10 ENSG00000205885 C1RL-AS1 1,14154 0,0027376 
ENSG00000074370 ATP2A3 1,68645 0,0052668 ENSG00000173918 C1QTNF1 1,42584 0,0062235 ENSG00000011105 TSPAN9 1,26848 3,54E-13 ENSG00000167785 ZNF558 1,14079 9,61E-06 
ENSG00000188818 ZDHHC11 1,67495 1,99E-05 ENSG00000153233 PTPRR 1,4248 0,0085996 ENSG00000260077  1,26503 0,0423128 ENSG00000184916 JAG2 1,13802 3,86E-05 
ENSG00000162591 MEGF6 1,6742 8,98E-08 ENSG00000197472 ZNF695 1,42106 0,0049257 ENSG00000177989 ODF3B 1,26458 1,04E-05 ENSG00000107201 DDX58 1,13363 1,62E-09 
ENSG00000089820 ARHGAP4 1,67069 2,55E-15 ENSG00000171045  1,42067 1,23E-08 ENSG00000177570 SAMD12 1,26183 0,0303488 ENSG00000171298 GAA 1,1336 6,65E-11 
ENSG00000121753 BAI2 1,66932 4,50E-14 ENSG00000163220 S100A9 1,41975 0,0115374 ENSG00000126602 TRAP1 1,25615 7,28E-13 ENSG00000172059 KLF11 1,13298 2,24E-06 
ENSG00000094963 FMO2 1,65174 0,0006552 ENSG00000120820 GLT8D2 1,41688 0,0023186 ENSG00000111331 OAS3 1,25128 1,80E-20 ENSG00000174672 BRSK2 1,13284 0,013597 
ENSG00000099998 GGT5 1,64671 0,00844 ENSG00000109625 CPZ 1,41686 6,61E-07 ENSG00000138772 ANXA3 1,25017 9,06E-06 ENSG00000146674 IGFBP3 1,13114 5,17E-07 
ENSG00000049249 TNFRSF9 1,64637 1,93E-07 ENSG00000165507 C10orf10 1,41554 3,93E-05 ENSG00000188002  1,25 0,0001792 ENSG00000171388 APLN 1,13007 0,0171553 
ENSG00000161551 ZNF577 1,6445 0,0135396 ENSG00000162849 KIF26B 1,40994 0,0073296 ENSG00000136235 GPNMB 1,24735 1,56E-06 ENSG00000257151 PWAR6 1,12754 0,0426996 
ENSG00000136826 KLF4 1,6419 3,12E-12 ENSG00000136295 TTYH3 1,40716 4,51E-23 ENSG00000181444 ZNF467 1,24626 0,0002993 ENSG00000105699 LSR 1,1272 1,99E-05 
ENSG00000184545 DUSP8 1,64022 2,96E-08 ENSG00000159753 RLTPR 1,40328 0,033833 ENSG00000087253 LPCAT2 1,24615 0,0382874 ENSG00000165124 SVEP1 1,126 0,0204603 
ENSG00000022267 FHL1 1,63878 8,14E-13 ENSG00000119922 IFIT2 1,40135 6,35E-20 ENSG00000077150 NFKB2 1,24591 2,66E-21 ENSG00000137628 DDX60 1,12277 1,58E-08 
ENSG00000162086 ZNF75A 1,6386 0,0013452 ENSG00000240694 PNMA2 1,40101 1,58E-11 ENSG00000169085 C8orf46 1,244 1,15E-05 ENSG00000243649 CFB 1,12228 5,11E-10 
ENSG00000107968 MAP3K8 1,63675 2,42E-05 ENSG00000133424 LARGE 1,40088 0,0258712 ENSG00000072071 LPHN1 1,23772 2,36E-08 ENSG00000143382 ADAMTSL4 1,12046 1,10E-09 
ENSG00000143816 WNT9A 1,62305 0,004985 ENSG00000147852 VLDLR 1,40054 1,73E-06 ENSG00000229644 NAMPTL 1,23614 1,04E-07 ENSG00000188283 ZNF383 1,11806 0,0232879 
ENSG00000145623 OSMR 1,62255 2,76E-21 ENSG00000268083  1,3994 0,0267428 ENSG00000107281 NPDC1 1,23552 5,85E-08 ENSG00000176490 DIRAS1 1,11726 0,0356417 
ENSG00000204682 CASC10 1,62136 0,0039288 ENSG00000223802 CERS1 1,39801 0,0022175 ENSG00000197635 DPP4 1,23529 0,0044652 ENSG00000151025 GPR158 1,10842 0,0083122 
ENSG00000162407 PPAP2B 1,59773 6,12E-08 ENSG00000069431 ABCC9 1,3951 2,52E-07 ENSG00000115461 IGFBP5 1,23516 0,0160575 ENSG00000170365 SMAD1 1,10538 0,0008275 
ENSG00000130600 H19 1,59495 1,20E-23 ENSG00000079215 SLC1A3 1,39503 3,28E-05 ENSG00000198517 MAFK 1,23345 8,83E-22 ENSG00000153885 KCTD15 1,1022 1,12E-06 
ENSG00000198157 HMGN5 1,58704 2,11E-05 ENSG00000164181 ELOVL7 1,39234 0,0247219 ENSG00000147813 NAPRT1 1,22765 1,01E-11 ENSG00000165312 OTUD1 1,09542 1,79E-06 
ENSG00000168398 BDKRB2 1,58376 1,45E-07 ENSG00000196557 CACNA1H 1,39183 0,0142252 ENSG00000103942 HOMER2 1,22519 0,0150194 ENSG00000106266 SNX8 1,09457 8,60E-10 
ENSG00000135063 FAM189A2 1,56722 0,0054252 ENSG00000272031 ANKRD34A 1,38928 0,0025859 ENSG00000056558 TRAF1 1,22156 5,03E-06 ENSG00000144749 LRIG1 1,08875 2,79E-10 
ENSG00000115267 IFIH1 1,56362 1,29E-17 ENSG00000187764 SEMA4D 1,38477 0,0005562 ENSG00000172164 SNTB1 1,21733 0,0159874 ENSG00000277701  1,08484 0,0070857 
ENSG00000177283 FZD8 1,56208 0,0002546 ENSG00000228594 C1orf233 1,37814 0,0146482 ENSG00000187955 COL14A1 1,21192 0,0069929 ENSG00000136002 ARHGEF4 1,08166 0,0164324 
ENSG00000196074 SYCP2 1,56036 0,0044222 ENSG00000117013 KCNQ4 1,37495 0,0153828 ENSG00000064225 ST3GAL6 1,21094 0,0005046 ENSG00000139178 C1RL 1,07989 5,18E-10 
ENSG00000154898 CCDC144CP 1,55871 0,0335259 ENSG00000234449  1,3737 3,88E-07 ENSG00000268903  1,2105 2,75E-05 ENSG00000138944 KIAA1644 1,07814 0,0316279 
ENSG00000102755 FLT1 1,54905 0,0114907 ENSG00000221890 NPTXR 1,37194 0,0007539 ENSG00000090530 LEPREL1 1,20996 0,0288424 ENSG00000179832 MROH1 1,06946 3,06E-13 
ENSG00000142408 CACNG8 1,5447 0,0003426 ENSG00000204519 ZNF551 1,3719 0,0031574 ENSG00000101493 ZNF516 1,20605 0,0082611 ENSG00000183486 MX2 1,06583 5,03E-06 
ENSG00000162595 DIRAS3 1,54425 0,0014975 ENSG00000247228  1,37001 0,0189923 ENSG00000120306 CYSTM1 1,20483 4,16E-05 ENSG00000198796 ALPK2 1,06505 0,001065 
ENSG00000161133 USP41 1,53908 0,0080376 ENSG00000171224 C10orf35 1,36187 0,0003566 ENSG00000105464 GRIN2D 1,20472 1,42E-07 ENSG00000102996 MMP15 1,06476 0,019805 
ENSG00000197943 PLCG2 1,5318 2,48E-05 ENSG00000115648 MLPH 1,36174 0,0209151 ENSG00000119508 NR4A3 1,20154 0,0336943 ENSG00000125945 ZNF436 1,06098 1,93E-09 
ENSG00000104856 RELB 1,53045 1,50E-19 ENSG00000184489 PTP4A3 1,36161 6,57E-07 ENSG00000142494 SLC47A1 1,20093 0,0093421 ENSG00000113070 HBEGF 1,0572 0,0001068 
ENSG00000131459 GFPT2 1,52848 1,88E-13 ENSG00000106804 C5 1,35842 0,008441 ENSG00000230257 NFE4 1,20069 3,72E-07 ENSG00000119917 IFIT3 1,0542 3,19E-09 
ENSG00000203883 SOX18 1,52826 0,0065656 ENSG00000065320 NTN1 1,34907 0,0001134 ENSG00000069424 KCNAB2 1,20014 8,36E-10 ENSG00000164638 SLC29A4 1,0526 0,0009089 
ENSG00000163814 CDCP1 1,52742 3,26E-07 ENSG00000164342 TLR3 1,34641 0,0111929 ENSG00000120129 DUSP1 1,19942 4,46E-19 ENSG00000176406 TTC9 1,04905 0,0180954 
ENSG00000136943 CTSV 1,52428 0,0020089 ENSG00000273151  1,33876 0,001034 ENSG00000173227 SYT12 1,19524 0,0027181 ENSG00000158286 RNF207 1,04775 1,42E-05 
ENSG00000173156 RHOD 1,51798 5,32E-07 ENSG00000204282 TNRC6C-AS1 1,33543 0,0019189 ENSG00000173193 PARP14 1,19323 5,26E-19 ENSG00000146592 CREB5 1,04571 0,000485 
ENSG00000233327 USP32P2 1,50837 0,00126 ENSG00000151067 CACNA1C 1,33428 0,0013259 ENSG00000072832 CRMP1 1,18997 8,52E-10 ENSG00000049769 PPP1R3F 1,03757 0,0175638 
ENSG00000100031 GGT1 1,50259 1,94E-08 ENSG00000159733 ZFYVE28 1,32496 5,38E-06 ENSG00000143452 HORMAD1 1,18896 7,27E-05 ENSG00000196208 GREB1 1,03488 0,0063342 
ENSG00000154358 OBSCN 1,49644 9,44E-17 ENSG00000116016 EPAS1 1,32451 3,03E-20 ENSG00000272419  1,18887 4,23E-05 ENSG00000124216 SNAI1 1,03226 0,0377657 
ENSG00000197599 CCDC154 1,49345 0,0224408 ENSG00000081803 CADPS2 1,3242 0,00407 ENSG00000147804 SLC39A4 1,18545 4,16E-08 ENSG00000196083 IL1RAP 1,03186 0,0004142 
ENSG00000174939 ASPHD1 1,49066 5,02E-10 ENSG00000168685 IL7R 1,32155 3,24E-14 ENSG00000167767 KRT80 1,18306 7,36E-10 ENSG00000110328 GALNT18 1,03015 0,0088157 
ENSG00000130822 PNCK 1,48529 0,0230133 ENSG00000175471 MCTP1 1,3195 0,0225967 ENSG00000164136 IL15 1,18216 0,0006196 ENSG00000134363 FST 1,02873 3,15E-08 
ENSG00000176463 SLCO3A1 1,48418 2,27E-06 ENSG00000178814 OPLAH 1,31786 5,45E-11 ENSG00000183098 GPC6 1,17746 1,63E-05 ENSG00000158769 F11R 1,02832 1,22E-05 
ENSG00000139370 SLC15A4 1,47665 7,02E-08 ENSG00000148344 PTGES 1,31266 0,0012294 ENSG00000008513 ST3GAL1 1,17559 1,98E-09 ENSG00000121406 ZNF549 1,02286 0,0098482 
ENSG00000100167 03-sep 1,47647 1,17E-05 ENSG00000244291 C7orf13 1,30918 0,0022041 ENSG00000196372 ASB13 1,16842 2,36E-05 ENSG00000172893 DHCR7 1,01802 2,30E-10 
ENSG00000112902 SEMA5A 1,47213 3,38E-08 ENSG00000139117 CPNE8 1,30883 0,0001082 ENSG00000048052 HDAC9 1,16725 0,0009654 ENSG00000164855 TMEM184A 1,0177 0,0284719 
ENSG00000135480 KRT7 1,47116 0,0037628 ENSG00000107719 PALD1 1,30864 0,0015712 ENSG00000272016  1,16571 4,77E-05 ENSG00000188827 SLX4 1,01661 0,0002397 
ENSG00000157766 ACAN 1,46912 0,0027581 ENSG00000166165 CKB 1,30641 1,39E-06 ENSG00000178531 CTXN1 1,16498 0,0224408 ENSG00000111266 DUSP16 1,01524 4,15E-07 
ENSG00000137642 SORL1 1,46681 0,0168637 ENSG00000253846 PCDHGA10 1,30564 0,0465621 ENSG00000105255 FSD1 1,1649 0,0001725 ENSG00000149781 FERMT3 1,0094 1,82E-06 
ENSG00000138646 HERC5 1,46172 5,24E-15 ENSG00000133687 TMTC1 1,29963 8,75E-05 ENSG00000008394 MGST1 1,16214 2,77E-11 ENSG00000174705 SH3PXD2B 1,00937 5,05E-09 
ENSG00000147799 ARHGAP39 1,46104 5,82E-09 ENSG00000181790 BAI1 1,29719 0,0191627 ENSG00000036672 USP2 1,15773 0,0421219 ENSG00000123342 MMP19 1,00858 0,0258078 
ENSG00000073060 SCARB1 1,45864 4,07E-16 ENSG00000179698 KIAA1875 1,29538 4,61E-05 ENSG00000270194  1,15661 0,0496256 ENSG00000103202 NME4 1,0079 6,17E-13 
ENSG00000140479 PCSK6 1,45074 0,0002646 ENSG00000134070 IRAK2 1,2825 8,06E-08 ENSG00000146966 DENND2A 1,15287 8,41E-09 ENSG00000126603 GLIS2 1,00758 1,16E-06 
ENSG00000188290 HES4 1,44842 2,19E-19 ENSG00000168961 LGALS9 1,28159 0,0169437 ENSG00000158186 MRAS 1,15282 2,79E-05 ENSG00000156587 UBE2L6 1,00658 5,35E-10 
ENSG00000122863 CHST3 1,44683 5,73E-12 ENSG00000158258 CLSTN2 1,27749 0,0445029 ENSG00000116985 BMP8B 1,1523 0,0007075 ENSG00000161011 SQSTM1 1,0026 1,44E-15 
ENSG00000198346 ZNF813 1,44581 0,0082429 ENSG00000064547 LPAR2 1,27691 0,0001139 ENSG00000160161 CILP2 1,14661 0,0105538 ENSG00000236609 ZNF853 1,00087 0,0039271 
157 
 
 
Table S5. RNASeq gene expression analysis data derived from xenografts removed 30 days post-implantation. Gene expression fold-change (FC) is represented as log2FC and color coded from 
highest (+ values in red, upregulated in low stromal CAV1 xenografts) to lowest (- values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000130962 PRRG1 0,99953 0,0048736 ENSG00000164535 DAGLB 0,90077 2,72E-08 ENSG00000196793 ZNF239 0,77909 0,0404514 ENSG00000101680 LAMA1 0,68206 0,0065475 
ENSG00000185338 SOCS1 0,99887 0,0327104 ENSG00000135736 CCDC102A 0,90049 0,0026837 ENSG00000144339 TMEFF2 0,77893 0,0424974 ENSG00000108771 DHX58 0,68006 0,0021752 
ENSG00000125965 GDF5 0,99599 0,0134942 ENSG00000153815 CMIP 0,89724 1,05E-07 ENSG00000073578 SDHA 0,77782 3,73E-08 ENSG00000132481 TRIM47 0,67798 5,22E-05 
ENSG00000135049 AGTPBP1 0,99105 8,45E-05 ENSG00000166532 RIMKLB 0,89645 2,18E-07 ENSG00000145476 CYP4V2 0,77019 0,0004363 ENSG00000137767 SQRDL 0,67548 0,0295245 
ENSG00000165655 ZNF503 0,9907 5,86E-08 ENSG00000226742 HSBP1L1 0,89494 0,0175638 ENSG00000100342 APOL1 0,76823 0,0001068 ENSG00000145901 TNIP1 0,67539 1,45E-07 
ENSG00000140450 ARRDC4 0,98954 1,72E-06 ENSG00000095739 BAMBI 0,89455 0,0039709 ENSG00000187098 MITF 0,75437 0,0124361 ENSG00000137965 IFI44 0,67482 1,22E-05 
ENSG00000213190 MLLT11 0,98617 7,20E-07 ENSG00000171813 PWWP2B 0,88703 4,79E-06 ENSG00000127415 IDUA 0,75349 0,0005072 ENSG00000172731 LRRC20 0,67291 0,0266941 
ENSG00000216490 IFI30 0,98554 2,48E-05 ENSG00000103148 NPRL3 0,88548 0,0004004 ENSG00000146067 FAM193B 0,75321 1,09E-07 ENSG00000122884 P4HA1 0,66975 1,42E-06 
ENSG00000243509  0,98472 0,0023575 ENSG00000157601 MX1 0,88373 3,95E-05 ENSG00000170525 PFKFB3 0,75095 4,59E-05 ENSG00000091622 PITPNM3 0,66678 0,048009 
ENSG00000130702 LAMA5 0,97988 1,54E-15 ENSG00000171208 NETO2 0,88213 0,0012741 ENSG00000129925 TMEM8A 0,75067 9,57E-06 ENSG00000007384 RHBDF1 0,66671 3,25E-05 
ENSG00000013588 GPRC5A 0,97915 7,24E-13 ENSG00000062282 DGAT2 0,87838 0,0065546 ENSG00000123240 OPTN 0,75024 8,71E-09 ENSG00000165806 CASP7 0,66398 0,0038201 
ENSG00000146072 TNFRSF21 0,97841 1,33E-05 ENSG00000140853 NLRC5 0,87725 0,0001137 ENSG00000104549 SQLE 0,74922 3,51E-07 ENSG00000164916 FOXK1 0,66323 5,09E-07 
ENSG00000107338 SHB 0,97787 7,20E-07 ENSG00000172216 CEBPB 0,87541 3,81E-09 ENSG00000246705 H2AFJ 0,7476 2,87E-05 ENSG00000162104 ADCY9 0,66233 0,0230358 
ENSG00000231584 FAHD2CP 0,97768 0,0359098 ENSG00000113739 STC2 0,8753 9,20E-09 ENSG00000138166 DUSP5 0,74471 2,98E-05 ENSG00000076706 MCAM 0,66224 0,0003211 
ENSG00000204860 FAM201A 0,97583 0,0277855 ENSG00000160190 SLC37A1 0,87449 0,0257222 ENSG00000242802 AP5Z1 0,74469 1,24E-07 ENSG00000263528 IKBKE 0,65817 0,0100538 
ENSG00000111335 OAS2 0,97542 3,03E-05 ENSG00000164877 MICALL2 0,86288 9,20E-11 ENSG00000184371 CSF1 0,74386 2,22E-06 ENSG00000119280 C1orf198 0,65618 4,38E-05 
ENSG00000099194 SCD 0,97422 2,90E-16 ENSG00000128274 A4GALT 0,86012 0,0098052 ENSG00000106346 USP42 0,74256 0,001545 ENSG00000076944 ZNF14 0,65544 0,0004185 
ENSG00000189067 LITAF 0,96663 3,70E-08 ENSG00000131378 RFTN1 0,85988 0,0107941 ENSG00000169131 ZNF354A 0,74238 0,0030361 ENSG00000106012 IQCE 0,65213 0,0012294 
ENSG00000132819 RBM38 0,96618 2,30E-06 ENSG00000136247 ZDHHC4 0,85859 4,97E-08 ENSG00000130066 SAT1 0,74213 1,05E-06 ENSG00000148339 SLC25A25 0,65097 0,0019751 
ENSG00000230606  0,96349 0,002185 ENSG00000105767 CADM4 0,85658 0,0021866 ENSG00000197070 ARRDC1 0,74102 0,0013435 ENSG00000169826 CSGALNACT2 0,64924 0,0018246 
ENSG00000166710 B2M 0,9631 2,35E-16 ENSG00000120594 PLXDC2 0,85582 0,0216067 ENSG00000101255 TRIB3 0,73842 0,0002365 ENSG00000224078 SNHG14 0,64854 0,0026616 
ENSG00000173511 OR7A10 0,96298 1,41E-11 ENSG00000170345 FOS 0,84716 0,0326933 ENSG00000160326 SLC2A6 0,73676 0,0002275 ENSG00000169926 KLF13 0,64834 7,48E-05 
ENSG00000080503 SMARCA2 0,96069 8,38E-07 ENSG00000206337 HCP5 0,84527 0,0067294 ENSG00000125347 IRF1 0,73562 7,21E-05 ENSG00000113269 RNF130 0,64583 0,0002317 
ENSG00000166974 MAPRE2 0,96017 1,84E-05 ENSG00000129757 CDKN1C 0,84155 9,74E-08 ENSG00000168890 TMEM150A 0,73548 0,0342699 ENSG00000134780 DAGLA 0,64519 0,0172627 
ENSG00000197461 PDGFA 0,95886 4,83E-07 ENSG00000149177 PTPRJ 0,84146 6,56E-05 ENSG00000130193 THEM6 0,73404 0,0021907 ENSG00000157827 FMNL2 0,64174 0,0021255 
ENSG00000184979 USP18 0,95849 1,31E-06 ENSG00000151692 RNF144A 0,83966 0,0001892 ENSG00000173334 TRIB1 0,73387 0,0025981 ENSG00000119771 KLHL29 0,64054 0,0122785 
ENSG00000168672 FAM84B 0,95843 0,0003651 ENSG00000159399 HK2 0,83789 2,89E-10 ENSG00000135766 EGLN1 0,73296 3,76E-08 ENSG00000116729 WLS 0,63752 0,001052 
ENSG00000163132 MSX1 0,95615 1,39E-06 ENSG00000165752 STK32C 0,83592 3,91E-05 ENSG00000181381 DDX60L 0,72976 0,0026837 ENSG00000121281 ADCY7 0,63682 0,0381815 
ENSG00000182118 FAM89A 0,95597 0,0098538 ENSG00000103351 CLUAP1 0,8332 0,0013552 ENSG00000188191 PRKAR1B 0,72919 0,0253499 ENSG00000113719 ERGIC1 0,63668 4,65E-05 
ENSG00000170873 MTSS1 0,95488 0,0263428 ENSG00000176485 PLA2G16 0,83211 0,0034904 ENSG00000115380 EFEMP1 0,72828 0,0001057 ENSG00000160447 PKN3 0,6363 6,44E-05 
ENSG00000168404 MLKL 0,94464 0,0010544 ENSG00000101213 PTK6 0,82944 0,0266713 ENSG00000072786 STK10 0,72622 1,09E-05 ENSG00000070404 FSTL3 0,6356 3,07E-06 
ENSG00000110446 SLC15A3 0,94394 0,0037111 ENSG00000077585 GPR137B 0,82669 0,023286 ENSG00000125354 06-sep 0,72279 0,0017904 ENSG00000166833 NAV2 0,63452 0,0001087 
ENSG00000174938 SEZ6L2 0,94268 1,66E-09 ENSG00000185686 PRAME 0,82305 2,95E-08 ENSG00000140859 KIFC3 0,72242 8,89E-08 ENSG00000277586 NEFL 0,63442 0,0314279 
ENSG00000134824 FADS2 0,94023 1,39E-12 ENSG00000051523 CYBA 0,82043 4,57E-08 ENSG00000213853 EMP2 0,72162 0,0115531 ENSG00000197355 UAP1L1 0,63398 1,13E-05 
ENSG00000234745 HLA-B 0,94009 1,27E-16 ENSG00000134901 KDELC1 0,81952 3,46E-05 ENSG00000204261 PSMB8-AS1 0,72002 0,0130258 ENSG00000167766 ZNF83 0,63393 0,0074157 
ENSG00000137959 IFI44L 0,93725 9,21E-08 ENSG00000090661 CERS4 0,81772 0,0019601 ENSG00000185022 MAFF 0,71935 1,27E-05 ENSG00000068971 PPP2R5B 0,63267 0,0001468 
ENSG00000258947  0,93724 1,08E-11 ENSG00000204642 HLA-F 0,81761 3,20E-05 ENSG00000075340 ADD2 0,71772 0,0405177 ENSG00000135899 SP110 0,63237 0,0068558 
ENSG00000277150 F8A3 0,93577 0,000123 ENSG00000134516 DOCK2 0,8176 0,0302679 ENSG00000163568 AIM2 0,71755 0,0403852 ENSG00000136240 KDELR2 0,62979 1,19E-06 
ENSG00000171992 SYNPO 0,93434 3,93E-05 ENSG00000059122 FLYWCH1 0,8137 0,0001955 ENSG00000145147 SLIT2 0,71612 8,96E-05 ENSG00000198576 ARC 0,6293 0,0445381 
ENSG00000132718 SYT11 0,93111 0,0038129 ENSG00000162772 ATF3 0,81271 1,17E-05 ENSG00000163840 DTX3L 0,71511 7,62E-07 ENSG00000185753 CXorf38 0,62729 0,0004941 
ENSG00000185133 INPP5J 0,93092 0,0462389 ENSG00000139182 CLSTN3 0,81175 1,00E-06 ENSG00000197381 ADARB1 0,71443 6,20E-05 ENSG00000130827 PLXNA3 0,62662 6,88E-06 
ENSG00000138642 HERC6 0,93078 5,42E-06 ENSG00000121310 ECHDC2 0,80833 2,66E-05 ENSG00000163874 ZC3H12A 0,71283 0,0005497 ENSG00000141682 PMAIP1 0,6265 0,0004894 
ENSG00000185745 IFIT1 0,92768 5,38E-06 ENSG00000184254 ALDH1A3 0,80329 0,0042769 ENSG00000103742 IGDCC4 0,7107 0,0005285 ENSG00000184232 OAF 0,6244 0,0078997 
ENSG00000001617 SEMA3F 0,92691 0,0066295 ENSG00000178338 ZNF354B 0,80312 0,0158556 ENSG00000154277 UCHL1 0,70732 0,0002578 ENSG00000153066 TXNDC11 0,62289 0,0046242 
ENSG00000205903 ZNF316 0,92634 2,58E-12 ENSG00000138131 LOXL4 0,80212 0,0130218 ENSG00000206503 HLA-A 0,70552 2,99E-09 ENSG00000178764 ZHX2 0,62205 0,0082272 
ENSG00000146083 RNF44 0,92522 5,90E-08 ENSG00000006740 ARHGAP44 0,79763 0,0437269 ENSG00000112972 HMGCS1 0,70303 1,33E-06 ENSG00000170558 CDH2 0,62195 0,0026733 
ENSG00000112096 SOD2 0,92298 2,88E-15 ENSG00000250786 SNHG18 0,79744 0,0343591 ENSG00000153395 LPCAT1 0,70262 0,0002133 ENSG00000166825 ANPEP 0,62079 8,97E-05 
ENSG00000136999 NOV 0,92101 0,0027724 ENSG00000046604 DSG2 0,79632 1,91E-06 ENSG00000261796 ISY1-RAB43 0,69938 0,0041087 ENSG00000184557 SOCS3 0,61822 0,0002432 
ENSG00000161013 MGAT4B 0,91405 2,77E-11 ENSG00000107738 C10orf54 0,7948 0,0045864 ENSG00000069482 GAL 0,69902 0,0070288 ENSG00000132840 BHMT2 0,61607 0,0096665 
ENSG00000166923 GREM1 0,91375 1,18E-08 ENSG00000125257 ABCC4 0,7921 0,0037501 ENSG00000130821 SLC6A8 0,69696 1,45E-07 ENSG00000175416 CLTB 0,61589 0,0006203 
ENSG00000146574 CCZ1B 0,91239 6,69E-06 ENSG00000214357 NEURL1B 0,79201 0,000175 ENSG00000171823 FBXL14 0,69502 0,0353392 ENSG00000140443 IGF1R 0,61256 0,001421 
ENSG00000104998 IL27RA 0,91222 0,0263428 ENSG00000109107 ALDOC 0,79107 0,0009638 ENSG00000206190 ATP10A 0,69468 0,0216067 ENSG00000167508 MVD 0,61185 0,0004638 
ENSG00000165175 MID1IP1 0,91143 1,28E-08 ENSG00000143514 TP53BP2 0,78776 2,34E-08 ENSG00000163291 PAQR3 0,69427 0,0066622 ENSG00000078403 MLLT10 0,61167 0,0040473 
ENSG00000089127 OAS1 0,90739 0,000489 ENSG00000100906 NFKBIA 0,78745 2,41E-09 ENSG00000151552 QDPR 0,69398 0,0015436 ENSG00000186812 ZNF397 0,61053 0,0337048 
ENSG00000132359 RAP1GAP2 0,90507 8,07E-10 ENSG00000156515 HK1 0,78639 4,48E-09 ENSG00000184992 BRI3BP 0,69278 0,0026879 ENSG00000168016 TRANK1 0,6097 0,0127703 
ENSG00000003137 CYP26B1 0,90461 0,0175638 ENSG00000133627 ACTR3B 0,7863 0,0299378 ENSG00000090565 RAB11FIP3 0,69075 0,000151 ENSG00000002822 MAD1L1 0,60937 0,0001681 
ENSG00000154153 FAM134B 0,90408 0,0461299 ENSG00000187608 ISG15 0,78441 4,12E-05 ENSG00000163703 CRELD1 0,69053 0,0019984 ENSG00000187243 MAGED4B 0,60901 8,02E-06 
ENSG00000117245 KIF17 0,90371 0,0496707 ENSG00000102858 GPR84 0,78081 6,69E-05 ENSG00000181625 SLX1B 0,69036 0,0473806 ENSG00000152582 SPEF2 0,60878 0,0330965 
ENSG00000088899  0,90245 4,12E-05 ENSG00000118960 HS1BP3 0,77927 0,000175 ENSG00000158023 WDR66 0,68657 0,0385402 ENSG00000126709 IFI6 0,60831 0,0042578 
ENSG00000188158 NHS 0,90126 1,59E-05 ENSG00000196793 ZNF239 0,77909 0,0404514 ENSG00000107130 NCS1 0,68374 1,41E-06 ENSG00000167779 IGFBP6 0,60654 0,0005208 
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Table S5. RNASeq gene expression analysis data derived from xenografts removed 30 days post-implantation. Gene expression fold-change (FC) is represented as log2FC and color coded from 
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ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000136193 SCRN1 0,60589 3,20E-05 ENSG00000167996 FTH1 0,54089 3,84E-06 ENSG00000038532 CLEC16A 0,49121 0,0420661 ENSG00000122958 VPS26A 0,44062 0,0033761 
ENSG00000185842 DNAH14 0,6021 0,0341458 ENSG00000104522 TSTA3 0,54061 0,0001019 ENSG00000147383 NSDHL 0,48865 0,008088 ENSG00000131652 THOC6 0,44053 0,0410371 
ENSG00000159110 IFNAR2 0,60204 0,0197215 ENSG00000143641 GALNT2 0,54004 9,86E-05 ENSG00000135821 GLUL 0,48685 0,0001886 ENSG00000160972 PPP1R16A 0,44036 0,0138798 
ENSG00000086289 EPDR1 0,59423 0,0255569 ENSG00000142949 PTPRF 0,53987 0,0013732 ENSG00000171608 PIK3CD 0,48668 0,0037362 ENSG00000182325 FBXL6 0,44017 0,0091885 
ENSG00000089486 CDIP1 0,5937 0,0358412 ENSG00000008256 CYTH3 0,5383 0,0012065 ENSG00000115756 HPCAL1 0,48484 0,0014657 ENSG00000134900 TPP2 0,4401 0,0041433 
ENSG00000139146 FAM60A 0,59237 0,0001134 ENSG00000224389 C4B 0,53829 0,0251209 ENSG00000161010 C5orf45 0,48472 0,001084 ENSG00000152684 PELO 0,43767 0,0336616 
ENSG00000185885 IFITM1 0,59103 0,0260345 ENSG00000149485 FADS1 0,53672 0,0002177 ENSG00000168884 TNIP2 0,48287 0,0009142 ENSG00000116133 DHCR24 0,43635 0,0230968 
ENSG00000103187 COTL1 0,58867 2,07E-05 ENSG00000165832 TRUB1 0,53564 0,0244014 ENSG00000136770 DNAJC1 0,48284 0,020997 ENSG00000134371 CDC73 0,43604 0,0213227 
ENSG00000102024 PLS3 0,5885 0,0001725 ENSG00000159128 IFNGR2 0,53469 0,0001876 ENSG00000143774 GUK1 0,48274 0,0002265 ENSG00000176454 LPCAT4 0,43582 0,007829 
ENSG00000178685 PARP10 0,58742 4,20E-05 ENSG00000226210  0,53104 0,0266161 ENSG00000121486 TRMT1L 0,48206 0,0271447 ENSG00000106305 AIMP2 0,43492 0,0165252 
ENSG00000188549 C15orf52 0,58726 0,0006192 ENSG00000182871 COL18A1 0,53006 0,0015436 ENSG00000120885 CLU 0,47957 0,0258078 ENSG00000175309 PHYKPL 0,43354 0,0258078 
ENSG00000227671 MIR3916 0,58597 0,0098529 ENSG00000080819 CPOX 0,52855 0,0116264 ENSG00000138685 FGF2 0,4788 0,002333 ENSG00000152518 ZFP36L2 0,43331 0,0081318 
ENSG00000167994 RAB3IL1 0,58561 0,0338037 ENSG00000119950 MXI1 0,52805 0,0311107 ENSG00000163545 NUAK2 0,47879 0,0122494 ENSG00000153339 TRAPPC8 0,4328 0,0398679 
ENSG00000136238 RAC1 0,58307 3,48E-06 ENSG00000120549 KIAA1217 0,52713 0,0229645 ENSG00000142192 APP 0,47874 0,0001792 ENSG00000145247 OCIAD2 0,43153 0,0317243 
ENSG00000109790 KLHL5 0,58194 0,0172185 ENSG00000063587 ZNF275 0,52549 0,0041659 ENSG00000176171 BNIP3 0,47752 0,0085004 ENSG00000116962 NID1 0,43098 0,004676 
ENSG00000132635 PCED1A 0,58159 0,0001377 ENSG00000213445 SIPA1 0,5253 0,0006441 ENSG00000120539 MASTL 0,47712 0,0157119 ENSG00000127022 CANX 0,42986 0,0078623 
ENSG00000130787 HIP1R 0,58158 0,0085498 ENSG00000178397 FAM220A 0,52523 0,0197235 ENSG00000155545 MIER3 0,4764 0,0300156 ENSG00000122729 ACO1 0,42956 0,0130543 
ENSG00000124006 OBSL1 0,57895 0,0002594 ENSG00000111752 PHC1 0,5251 0,0003136 ENSG00000176788 BASP1 0,47592 0,0015937 ENSG00000080822 CLDND1 0,42925 0,0057972 
ENSG00000059378 PARP12 0,57838 7,04E-05 ENSG00000154640 BTG3 0,52496 0,0002133 ENSG00000167987 VPS37C 0,47484 0,0168101 ENSG00000119537 KDSR 0,42696 0,0223987 
ENSG00000196562 SULF2 0,5779 0,0024946 ENSG00000113569 NUP155 0,52438 0,0018278 ENSG00000221968 FADS3 0,47465 0,0008843 ENSG00000067064 IDI1 0,42687 0,0263652 
ENSG00000138496 PARP9 0,57698 0,0009993 ENSG00000060138 YBX3 0,52361 7,36E-05 ENSG00000119729 RHOQ 0,47455 0,0025369 ENSG00000113552 GNPDA1 0,4266 0,0087439 
ENSG00000105939 ZC3HAV1 0,57644 5,23E-05 ENSG00000142733 MAP3K6 0,52009 0,0069389 ENSG00000122515 ZMIZ2 0,47452 0,00189 ENSG00000113300 CNOT6 0,42619 0,0243788 
ENSG00000136854 STXBP1 0,57605 0,0053218 ENSG00000185033 SEMA4B 0,51994 0,0013259 ENSG00000086232 EIF2AK1 0,47403 0,0005208 ENSG00000160753 RUSC1 0,42594 0,0028281 
ENSG00000168394 TAP1 0,57563 2,47E-05 ENSG00000169398 PTK2 0,51958 0,0001082 ENSG00000131149 GSE1 0,47371 0,0256556 ENSG00000108828 VAT1 0,42581 0,0036366 
ENSG00000132109 TRIM21 0,57556 0,0164691 ENSG00000184216 IRAK1 0,51771 0,0004185 ENSG00000074855 ANO8 0,4728 0,0175638 ENSG00000099290 FAM21A 0,42426 0,012075 
ENSG00000128739 SNRPN 0,57547 0,0002958 ENSG00000116675 DNAJC6 0,51767 0,0462389 ENSG00000145214 DGKQ 0,4721 0,0347809 ENSG00000166444 ST5 0,42259 0,005932 
ENSG00000167632 TRAPPC9 0,57536 0,0047358 ENSG00000178719 GRINA 0,51728 4,78E-05 ENSG00000111676 ATN1 0,47103 0,0008032 ENSG00000164880 INTS1 0,42199 0,0085004 
ENSG00000105835 NAMPT 0,57526 4,52E-06 ENSG00000142089 IFITM3 0,51588 0,0021069 ENSG00000079459 FDFT1 0,46975 0,0010839 ENSG00000110697 PITPNM1 0,42183 0,027132 
ENSG00000143878 RHOB 0,57443 8,79E-06 ENSG00000140044 JDP2 0,51369 0,0411488 ENSG00000104518 GSDMD 0,46892 0,0010769 ENSG00000103126 AXIN1 0,42113 0,0244681 
ENSG00000103326 CAPN15 0,57334 0,0004638 ENSG00000039560 RAI14 0,51259 0,0002364 ENSG00000069399 BCL3 0,46833 0,0095293 ENSG00000166900 STX3 0,4201 0,0410293 
ENSG00000185880 TRIM69 0,5731 0,0087495 ENSG00000134897 BIVM 0,51239 0,0076454 ENSG00000187953 PMS2CL 0,46801 0,0372063 ENSG00000188313 PLSCR1 0,41983 0,0341458 
ENSG00000011275 RNF216 0,57291 6,52E-05 ENSG00000132530 XAF1 0,51233 0,0253804 ENSG00000182095 TNRC18 0,46741 0,0008401 ENSG00000126746 ZNF384 0,41965 0,0053203 
ENSG00000146587 RBAK 0,57169 0,0046183 ENSG00000275993  0,51157 0,0011004 ENSG00000002549 LAP3 0,46731 0,0008956 ENSG00000092010 PSME1 0,41775 0,0026995 
ENSG00000164631 ZNF12 0,56793 0,005648 ENSG00000159674 SPON2 0,51113 0,0002673 ENSG00000196422 PPP1R26 0,46661 0,0043264 ENSG00000167693 NXN 0,41751 0,0098837 
ENSG00000145604 SKP2 0,56663 0,0003664 ENSG00000162522 KIAA1522 0,50918 0,0146404 ENSG00000203879 GDI1 0,46657 0,0006021 ENSG00000106392 C1GALT1 0,41624 0,0439566 
ENSG00000108797 CNTNAP1 0,56642 4,93E-05 ENSG00000166123 GPT2 0,50702 0,0145212 ENSG00000168724 DNAJC21 0,4662 0,0030318 ENSG00000148730 EIF4EBP2 0,41361 0,0038201 
ENSG00000186350 RXRA 0,56613 0,0001551 ENSG00000158470 B4GALT5 0,50585 0,0031266 ENSG00000146576 C7orf26 0,46502 0,0295834 ENSG00000136758 YME1L1 0,41185 0,0125154 
ENSG00000196204 RNF216P1 0,56591 0,0015927 ENSG00000128335 APOL2 0,50424 0,0066703 ENSG00000180104 EXOC3 0,46216 0,0037715 ENSG00000140105 WARS 0,40804 0,0119396 
ENSG00000145390 USP53 0,56544 0,0347206 ENSG00000130640 TUBGCP2 0,50397 0,0001744 ENSG00000160948 VPS28 0,46079 0,0012853 ENSG00000138413 IDH1 0,40672 0,0160447 
ENSG00000105137 SYDE1 0,56385 0,0001504 ENSG00000025039 RRAGD 0,50347 0,0341941 ENSG00000229807 XIST 0,46064 0,0010115 ENSG00000111321 MIF4GD 0,40611 0,0054452 
ENSG00000130589 HELZ2 0,5607 0,0013347 ENSG00000118200 CAMSAP2 0,50131 0,0222035 ENSG00000116984 MTR 0,45987 0,0028249 ENSG00000109501 WFS1 0,40425 0,044553 
ENSG00000157193 LRP8 0,56006 0,0354511 ENSG00000162073 PAQR4 0,50058 0,0344294 ENSG00000080608 KIAA0020 0,45941 0,0161229 ENSG00000134109 EDEM1 0,4039 0,0119701 
ENSG00000188070 C11orf95 0,55948 0,0025307 ENSG00000171552 BCL2L1 0,49985 0,0005726 ENSG00000160439 RDH13 0,45758 0,04839 ENSG00000060982 BCAT1 0,40378 0,035148 
ENSG00000034053 APBA2 0,55641 0,0247257 ENSG00000118900 UBN1 0,49914 0,0095808 ENSG00000184428 TOP1MT 0,45745 0,0040803 ENSG00000037474 NSUN2 0,40369 0,0297204 
ENSG00000164970 FAM219A 0,55545 0,0014611 ENSG00000185187 SIGIRR 0,49909 0,0285822 ENSG00000235655 H3F3AP4 0,45606 0,0498142 ENSG00000052802 MSMO1 0,40298 0,0134796 
ENSG00000122674 CCZ1 0,55373 8,89E-05 ENSG00000197226 TBC1D9B 0,49855 0,0015139 ENSG00000188735 TMEM120B 0,45406 0,0060816 ENSG00000135052 GOLM1 0,40193 0,007829 
ENSG00000111057 KRT18 0,55257 2,93E-05 ENSG00000050748 MAPK9 0,49804 0,0043214 ENSG00000185340 GAS2L1 0,45181 0,0057239 ENSG00000109736 MFSD10 0,40135 0,0091678 
ENSG00000074527 NTN4 0,55246 0,0316279 ENSG00000105270 CLIP3 0,49745 0,0048907 ENSG00000215021 PHB2 0,45173 0,0009638 ENSG00000161714 PLCD3 0,40114 0,0145852 
ENSG00000130779 CLIP1 0,55232 0,0018437 ENSG00000197603 C5orf42 0,49745 0,0369759 ENSG00000173153 ESRRA 0,44923 0,0044219 ENSG00000186480 INSIG1 0,40078 0,0057833 
ENSG00000163661 PTX3 0,55055 0,0193114 ENSG00000068079 IFI35 0,49655 0,0336943 ENSG00000196954 CASP4 0,4488 0,0436436 ENSG00000113460 BRIX1 0,40012 0,0153828 
ENSG00000113240 CLK4 0,54906 0,025868 ENSG00000157181 C1orf27 0,49519 0,0130543 ENSG00000277203 F8A1 0,44842 0,0070288 ENSG00000052126 PLEKHA5 0,39959 0,0455973 
ENSG00000111684 LPCAT3 0,54799 0,0012488 ENSG00000204264 PSMB8 0,49475 0,0008211 ENSG00000103260 METRN 0,44718 0,0139996 ENSG00000151929 BAG3 0,39939 0,0073233 
ENSG00000151693 ASAP2 0,54574 0,0303488 ENSG00000198355 PIM3 0,4941 0,001383 ENSG00000134899 ERCC5 0,44698 0,0045188 ENSG00000109787 KLF3 0,39782 0,0244681 
ENSG00000179526 SHARPIN 0,54525 7,36E-05 ENSG00000168056 LTBP3 0,49409 0,0005208 ENSG00000157954 WIPI2 0,44633 0,0020733 ENSG00000148400 NOTCH1 0,39745 0,0241576 
ENSG00000134352 IL6ST 0,54341 0,0017117 ENSG00000102572 STK24 0,4938 0,0004249 ENSG00000150938 CRIM1 0,44484 0,0046837 ENSG00000184470 TXNRD2 0,39662 0,0127161 
ENSG00000125485 DDX31 0,54309 0,0022786 ENSG00000064932 SBNO2 0,49362 0,0006722 ENSG00000100979 PLTP 0,44414 0,0057162 ENSG00000048828 FAM120A 0,39656 0,0082611 
ENSG00000198753 PLXNB3 0,54253 0,0054252 ENSG00000105339 DENND3 0,49259 0,0384953 ENSG00000144746 ARL6IP5 0,44366 0,0026391 ENSG00000147454 SLC25A37 0,39592 0,0069618 
ENSG00000186193 SAPCD2 0,54185 0,0142125 ENSG00000205726 ITSN1 0,49215 0,0078376 ENSG00000117139 KDM5B 0,44324 0,0090826 ENSG00000180182 MED14 0,39581 0,022801 
ENSG00000132510 KDM6B 0,54134 0,0002298 ENSG00000175130 MARCKSL1 0,49174 0,0006204 ENSG00000249915 PDCD6 0,44149 0,006242 ENSG00000122705 CLTA 0,39519 0,0085498 
ENSG00000196776 CD47 0,541 0,0001442 ENSG00000102178 UBL4A 0,49133 0,0038201 ENSG00000148143 ZNF462 0,4408 0,0324137 ENSG00000146066 HIGD2A 0,39385 0,0125994 
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Table S5. RNASeq gene expression analysis data derived from xenografts removed 30 days post-implantation. Gene expression fold-change (FC) is represented as log2FC and color coded from 
highest (+ values in red, upregulated in low stromal CAV1 xenografts) to lowest (- values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000136205 TNS3 0,39142 0,0160447 ENSG00000231925 TAPBP 0,32675 0,0323659 ENSG00000162627 SNX7 -0,346 0,0377657 ENSG00000104381 GDAP1 -0,3947 0,0344093 
ENSG00000118707 TGIF2 0,38971 0,0341941 ENSG00000143256 PFDN2 0,32228 0,0482065 ENSG00000162408 NOL9 -0,3466 0,0410293 ENSG00000173546 CSPG4 -0,3958 0,0112475 
ENSG00000221869 CEBPD 0,3897 0,0123075 ENSG00000143384 MCL1 0,32176 0,0319558 ENSG00000108799 EZH1 -0,3467 0,0367636 ENSG00000117155 SSX2IP -0,397 0,0303488 
ENSG00000169213 RAB3B 0,38904 0,0374146 ENSG00000148110 HIATL1 0,32008 0,0472217 ENSG00000072121 ZFYVE26 -0,3471 0,0413875 ENSG00000009307 CSDE1 -0,3972 0,0070288 
ENSG00000148824 MTG1 0,38765 0,0190932 ENSG00000102144 PGK1 0,31975 0,0497471 ENSG00000149639 SOGA1 -0,3476 0,0227612 ENSG00000135919 SERPINE2 -0,3984 0,0213227 
ENSG00000221963 APOL6 0,38694 0,0454494 ENSG00000143761 ARF1 0,31966 0,0317254 ENSG00000125686 MED1 -0,3477 0,0344262 ENSG00000105989 WNT2 -0,3997 0,0423378 
ENSG00000116679 IVNS1ABP 0,38537 0,0090826 ENSG00000120694 HSPH1 0,3166 0,0404222 ENSG00000198467 TPM2 -0,348 0,0137662 ENSG00000134986 NREP -0,3998 0,0216305 
ENSG00000127527 SPATA22 0,38535 0,019647 ENSG00000198840 MT-ND3 0,31628 0,0358553 ENSG00000164109 MAD2L1 -0,3485 0,0334589 ENSG00000115414 FN1 -0,4025 0,0011436 
ENSG00000087074 PPP1R15A 0,38362 0,0186831 ENSG00000111669 TPI1 0,30704 0,0463323 ENSG00000121957 GPSM2 -0,3499 0,0320734 ENSG00000168077 SCARA3 -0,4031 0,0282379 
ENSG00000087460 GNAS 0,38319 0,00448 ENSG00000198888 MT-ND1 0,30233 0,0438799 ENSG00000152661 GJA1 -0,3502 0,0244681 ENSG00000128510 CPA4 -0,4038 0,0144166 
ENSG00000161021 MAML1 0,38308 0,0329701 ENSG00000108821 COL1A1 -0,2869 0,0313563 ENSG00000243678 NME1-NME2 -0,3509 0,0119701 ENSG00000117543 DPH5 -0,4047 0,0142252 
ENSG00000006625 GGCT 0,38223 0,0273907 ENSG00000108424 KPNB1 -0,2919 0,0468806 ENSG00000259040 BLOC1S5-TXNDC -0,3517 0,0374146 ENSG00000100106 TRIOBP -0,4075 0,0219366 
ENSG00000110536 PTPMT1 0,38198 0,0320734 ENSG00000100097 LGALS1 -0,3058 0,0424974 ENSG00000173171 MTX1 -0,3525 0,0161229 ENSG00000170921 TANC2 -0,4078 0,0071503 
ENSG00000135968 GCC2 0,38134 0,0308238 ENSG00000204231 RXRB -0,3065 0,0462389 ENSG00000198830 HMGN2 -0,3532 0,0085004 ENSG00000148180 GSN -0,4084 0,0063643 
ENSG00000198853 RUSC2 0,38071 0,0384068 ENSG00000164924 YWHAZ -0,3098 0,0315146 ENSG00000142676 RPL11 -0,3535 0,0090337 ENSG00000177954 RPS27 -0,4101 0,001533 
ENSG00000029993 HMGB3 0,37985 0,0161229 ENSG00000099250 NRP1 -0,3098 0,0471064 ENSG00000198198 SZT2 -0,3539 0,0325313 ENSG00000197457 STMN3 -0,4105 0,0168561 
ENSG00000172661 FAM21C 0,37858 0,0320734 ENSG00000117632 STMN1 -0,3111 0,0388567 ENSG00000090006 LTBP4 -0,3542 0,0496088 ENSG00000168785 TSPAN5 -0,4108 0,0303151 
ENSG00000130560 UBAC1 0,37742 0,0339457 ENSG00000124614 RPS10 -0,3114 0,0325912 ENSG00000119865 CNRIP1 -0,3544 0,0499983 ENSG00000049245 VAMP3 -0,4128 0,0029839 
ENSG00000160949 TONSL 0,37742 0,0230358 ENSG00000184009 ACTG1 -0,313 0,0355777 ENSG00000068097 HEATR6 -0,3556 0,0323659 ENSG00000182158 CREB3L2 -0,4171 0,0164324 
ENSG00000134874 DZIP1 0,37723 0,0195636 ENSG00000239672 NME1 -0,3133 0,0480185 ENSG00000165678 GHITM -0,3566 0,0192881 ENSG00000120318 ARAP3 -0,4175 0,008036 
ENSG00000189043 NDUFA4 0,37488 0,0205344 ENSG00000002586 CD99 -0,3137 0,0495798 ENSG00000142669 SH3BGRL3 -0,3572 0,0229157 ENSG00000137962 ARHGAP29 -0,4208 0,0026806 
ENSG00000112941 PAPD7 0,3745 0,0319678 ENSG00000137309 HMGA1 -0,3157 0,0330965 ENSG00000137818 RPLP1 -0,3579 0,0146404 ENSG00000049192 ADAMTS6 -0,4217 0,0065475 
ENSG00000204525 HLA-C 0,37403 0,0099182 ENSG00000049618 ARID1B -0,3159 0,0410371 ENSG00000151176 PLBD2 -0,3586 0,0344294 ENSG00000134802 SLC43A3 -0,4242 0,0192724 
ENSG00000079332 SAR1A 0,37304 0,0175542 ENSG00000163348 PYGO2 -0,3162 0,0428539 ENSG00000065135 GNAI3 -0,359 0,0144166 ENSG00000166173 LARP6 -0,4247 0,0074157 
ENSG00000164466 SFXN1 0,37178 0,0377852 ENSG00000106683 LIMK1 -0,3176 0,0372272 ENSG00000112144 ICK -0,3591 0,0205386 ENSG00000041988 THAP3 -0,4253 0,0225967 
ENSG00000168653 NDUFS5 0,36938 0,0466268 ENSG00000143545 RAB13 -0,3178 0,0394948 ENSG00000002834 LASP1 -0,3592 0,0123264 ENSG00000115232 ITGA4 -0,4275 0,0139178 
ENSG00000071894 CPSF1 0,36756 0,0157119 ENSG00000167601 AXL -0,3179 0,0336011 ENSG00000172057 ORMDL3 -0,3607 0,0303149 ENSG00000006453 BAIAP2L1 -0,4296 0,0073543 
ENSG00000014164 ZC3H3 0,36742 0,0306798 ENSG00000176890 TYMS -0,318 0,044738 ENSG00000173207 CKS1B -0,3609 0,0146166 ENSG00000101000 PROCR -0,4318 0,0265579 
ENSG00000139197 PEX5 0,36735 0,0447911 ENSG00000244038 DDOST -0,3183 0,0383602 ENSG00000099622 CIRBP -0,3611 0,0183439 ENSG00000269821 KCNQ1OT1 -0,4323 0,029637 
ENSG00000164713 BRI3 0,36699 0,0153126 ENSG00000204392 LSM2 -0,3187 0,0488793 ENSG00000188643 S100A16 -0,3612 0,0269044 ENSG00000264112  -0,4324 0,0026837 
ENSG00000114354 TFG 0,36587 0,0125899 ENSG00000154845 PPP4R1 -0,3188 0,0382874 ENSG00000062716 VMP1 -0,3616 0,0273907 ENSG00000141576 RNF157 -0,433 0,0067294 
ENSG00000198546 ZNF511 0,36387 0,0282137 ENSG00000105810 CDK6 -0,3195 0,0344093 ENSG00000113657 DPYSL3 -0,3623 0,0243944 ENSG00000137831 UACA -0,4339 0,0078376 
ENSG00000160932 LY6E 0,36319 0,0258712 ENSG00000143624 INTS3 -0,3204 0,0345262 ENSG00000224877 C17orf89 -0,3625 0,0485956 ENSG00000204410 MSH5 -0,4355 0,0071272 
ENSG00000112977 DAP 0,36227 0,0185601 ENSG00000156482 RPL30 -0,3217 0,0230358 ENSG00000163297 ANTXR2 -0,3627 0,0152966 ENSG00000213523 SRA1 -0,4369 0,0244397 
ENSG00000185567 AHNAK2 0,36029 0,0461299 ENSG00000120708 TGFBI -0,3222 0,049137 ENSG00000143621 ILF2 -0,3631 0,0085004 ENSG00000148175 STOM -0,4392 0,0133297 
ENSG00000157778 PSMG3 0,35888 0,0433163 ENSG00000160299 PCNT -0,3226 0,0408995 ENSG00000138092 CENPO -0,3643 0,0160447 ENSG00000116670 MAD2L2 -0,4419 0,0082611 
ENSG00000175137 SH3BP5L 0,35664 0,0392601 ENSG00000214736 TOMM6 -0,3228 0,0386998 ENSG00000136451 VEZF1 -0,3654 0,0154369 ENSG00000178031 ADAMTSL1 -0,4428 0,0023503 
ENSG00000116977 LGALS8 0,35551 0,0303488 ENSG00000147526 TACC1 -0,3246 0,0398679 ENSG00000269905  -0,3679 0,0341324 ENSG00000079931 MOXD1 -0,444 0,0021685 
ENSG00000127191 TRAF2 0,3553 0,0348246 ENSG00000196704 AMZ2 -0,3259 0,0354212 ENSG00000256053 APOPT1 -0,368 0,0250775 ENSG00000223749 MIR503HG -0,4442 0,0057902 
ENSG00000265972 TXNIP 0,35527 0,0158002 ENSG00000180340 FZD2 -0,3261 0,0443272 ENSG00000063601 MTMR1 -0,3681 0,0344093 ENSG00000160007 ARHGAP35 -0,4484 0,0017147 
ENSG00000179091 CYC1 0,35484 0,0241713 ENSG00000073969 NSF -0,328 0,0408744 ENSG00000134222 PSRC1 -0,3695 0,0331968 ENSG00000137337 MDC1 -0,4485 0,0007078 
ENSG00000127526 SLC35E1 0,35462 0,0394795 ENSG00000196367 TRRAP -0,3295 0,0388567 ENSG00000067225 PKM -0,3705 0,0245239 ENSG00000144681 STAC -0,4517 0,0191669 
ENSG00000108861 DUSP3 0,35353 0,0258712 ENSG00000128791 TWSG1 -0,33 0,043198 ENSG00000116251 RPL22 -0,3711 0,0065192 ENSG00000159164 SV2A -0,4518 0,0016661 
ENSG00000172638 EFEMP2 0,35252 0,0230133 ENSG00000101335 MYL9 -0,3303 0,0335259 ENSG00000213246 SUPT4H1 -0,373 0,0165252 ENSG00000001461 NIPAL3 -0,4528 0,0074488 
ENSG00000153147 SMARCA5 0,35208 0,0445217 ENSG00000105771 SMG9 -0,3312 0,0415452 ENSG00000163359 COL6A3 -0,3742 0,0086615 ENSG00000145715 RASA1 -0,4571 0,0015139 
ENSG00000213699 SLC35F6 0,35102 0,0443063 ENSG00000180901 KCTD2 -0,3314 0,048815 ENSG00000111348 ARHGDIB -0,376 0,0311304 ENSG00000169946 ZFPM2 -0,4573 0,0131812 
ENSG00000105058 FAM32A 0,34821 0,0337627 ENSG00000164687 FABP5 -0,3316 0,0263652 ENSG00000083168 KAT6A -0,3774 0,0303149 ENSG00000166813 KIF7 -0,4577 0,02022 
ENSG00000197724 PHF2 0,3472 0,0312041 ENSG00000017797 RALBP1 -0,3384 0,0230968 ENSG00000154229 PRKCA -0,3804 0,0116335 ENSG00000167549 CORO6 -0,4578 0,0178917 
ENSG00000168159 RNF187 0,34683 0,0408324 ENSG00000122335 SERAC1 -0,3384 0,0409646 ENSG00000110315 RNF141 -0,3813 0,0432063 ENSG00000197956 S100A6 -0,4584 0,000155 
ENSG00000197746 PSAP 0,34525 0,0273907 ENSG00000122406 RPL5 -0,3384 0,0166418 ENSG00000080823 MOK -0,3819 0,0116481 ENSG00000223865 HLA-DPB1 -0,4616 0,0131403 
ENSG00000165637 VDAC2 0,34034 0,0306959 ENSG00000186575 NF2 -0,3385 0,0299602 ENSG00000270069 MIR222HG -0,3869 0,0232741 ENSG00000184838 PRR16 -0,4618 0,0358687 
ENSG00000068323 TFE3 0,34009 0,0462389 ENSG00000166025 AMOTL1 -0,3385 0,0409646 ENSG00000123689 G0S2 -0,3884 0,0421859 ENSG00000127481 UBR4 -0,4631 0,0061526 
ENSG00000149115 TNKS1BP1 0,33809 0,0266941 ENSG00000168386 FILIP1L -0,3394 0,0482139 ENSG00000213178  -0,3885 0,0084369 ENSG00000142621 FHAD1 -0,4632 0,0018246 
ENSG00000204628 GNB2L1 0,3373 0,0255569 ENSG00000124788 ATXN1 -0,3402 0,0448683 ENSG00000146476 C6orf211 -0,3889 0,0197737 ENSG00000197535 MYO5A -0,4656 0,0045415 
ENSG00000115073 ACTR1B 0,33715 0,044766 ENSG00000112297 AIM1 -0,3409 0,0273907 ENSG00000154734 ADAMTS1 -0,3907 0,0173139 ENSG00000105048 TNNT1 -0,4675 0,0085684 
ENSG00000198910 L1CAM 0,33701 0,0310776 ENSG00000264364 DYNLL2 -0,3413 0,0281305 ENSG00000085719 CPNE3 -0,391 0,0054656 ENSG00000161992 PRR35 -0,4694 0,004288 
ENSG00000198959 TGM2 0,33409 0,0376631 ENSG00000049239 H6PD -0,3434 0,0301635 ENSG00000073050 FOXH1 -0,3919 0,0276638 ENSG00000090539 CHRD -0,47 0,010038 
ENSG00000134884 ARGLU1 0,33194 0,0486857 ENSG00000005156 LIG3 -0,3435 0,0341458 ENSG00000219481 NBPF1 -0,3919 0,0403147 ENSG00000149948 HMGA2 -0,4716 0,0060538 
ENSG00000185122 HSF1 0,33053 0,0375565 ENSG00000111696 NT5DC3 -0,3441 0,0360962 ENSG00000177106 EPS8L2 -0,3919 0,0353795 ENSG00000125726 CD70 -0,4736 0,0266078 
ENSG00000089693 MLF2 0,33003 0,0403863 ENSG00000105341 DDHD2 -0,3448 0,0456545 ENSG00000214114 MYCBP -0,3937 0,0330965 ENSG00000231607 DLEU2 -0,4749 0,048714 
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Table S5. RNASeq gene expression analysis data derived from xenografts removed 30 days post-implantation. Gene expression fold-change (FC) is represented as log2FC and color coded from 
highest (+ values in red, upregulated in low stromal CAV1 xenografts) to lowest (- values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000144057 ST6GAL2 -0,477 0,0329659 ENSG00000105974 CAV1 -2,487 3,81E-114 
ENSG00000171953 ATPAF2 -0,4884 0,0325912 ENSG00000260892  -3,0167 1,11E-05 
ENSG00000140403 DNAJA4 -0,4893 0,0022367 ENSG00000261684  -3,3788 0,0049622 
ENSG00000167074 TEF -0,4912 0,0459255 ENSG00000254721  -3,5463  2,46E-06 
ENSG00000004139 SARM1 -0,4928 0,0019499 ENSG00000270316 C10orf32-ASMT -5,1226 0,0008211 
ENSG00000170989 S1PR1 -0,495 0,0230148     
ENSG00000164318 EGFLAM -0,496 0,0202246     
ENSG00000236824 BCYRN1 -0,4972 0,0071272     
ENSG00000189171 S100A13 -0,4984 0,0001169     
ENSG00000197594 ENPP1 -0,5018 0,0001718     
ENSG00000133816 MICAL2 -0,5073 0,0006441     
ENSG00000145431 PDGFC -0,5075 0,0077018     
ENSG00000128656 CHN1 -0,5208 0,0024668     
ENSG00000085117 CD82 -0,5233 0,0005227     
ENSG00000271529 CICP14 -0,5246 0,0219123     
ENSG00000110429 FBXO3 -0,526 0,0130258     
ENSG00000228696 ARL17B -0,5294 0,044738     
ENSG00000075826 SEC31B -0,531 0,0498277     
ENSG00000117152 RGS4 -0,5482 0,0043646     
ENSG00000159184 HOXB13 -0,5504 0,048815     
ENSG00000205670 SMIM11 -0,5534 0,0154369     
ENSG00000109452 INPP4B -0,5598 0,0401071     
ENSG00000220842  -0,566 0,0008166     
ENSG00000110092 CCND1 -0,5778 4,35E-06     
ENSG00000179163 FUCA1 -0,5867 0,0075778     
ENSG00000112619 PRPH2 -0,5895 0,0049328     
ENSG00000196754 S100A2 -0,5903 3,46E-05     
ENSG00000154736 ADAMTS5 -0,595 0,0001066     
ENSG00000131477 RAMP2 -0,5971 0,02983     
ENSG00000165072 MAMDC2 -0,5987 0,0036436     
ENSG00000213366 GSTM2 -0,61 0,0002909     
ENSG00000243302  -0,6114 0,0085498     
ENSG00000162511 LAPTM5 -0,6181 0,0145798     
ENSG00000173530 TNFRSF10D -0,6222 0,0001406     
ENSG00000188452 CERKL -0,6264 0,0026391     
ENSG00000198768 APCDD1L -0,6419 7,49E-06     
ENSG00000170961 HAS2 -0,6441 0,0002397     
ENSG00000259207 ITGB3 -0,6495 0,0420191     
ENSG00000266086  -0,6534 0,044738     
ENSG00000213058  -0,6762 0,0019381     
ENSG00000231290 APCDD1L-AS1 -0,6859 0,0003866     
ENSG00000185532 PRKG1 -0,6875 0,0232562     
ENSG00000179546 HTR1D -0,7273 0,0223987     
ENSG00000164707 SLC13A4 -0,7395 0,0247219     
ENSG00000154096 THY1 -0,7793 1,88E-07     
ENSG00000268173  -0,7849 0,0039524     
ENSG00000242588  -0,8325 0,005011     
ENSG00000178809 TRIM73 -0,8371 0,0182798     
ENSG00000224114  -0,862 0,0194207     
ENSG00000259024 TVP23C-CDRT4 -0,9252 0,0025704     
ENSG00000172927 MYEOV -0,9425 7,70E-08     
ENSG00000228981  -0,9749 0,0004288     
ENSG00000235373  -1,0456 0,0237084     
ENSG00000267645 POLR2J2 -1,1161 0,0016371     
ENSG00000145681 HAPLN1 -1,3615 0,0024627     
ENSG00000203394  -1,3895 0,0002521     
ENSG00000231822  -1,4499 0,0360759     
ENSG00000277125  -1,6354 0,0242954     
ENSG00000254870 ATP6V1G2-DDX3 -1,8678 1,81E-09     
ENSG00000257594 GALNT4 -2,3427 0,0154369     
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Table S6. RNASeq gene expression analysis data derived from xenografts removed 40 days post-implantation. Gene expression fold-change (FC) is represented as log2FC and color coded from 
highest (+ values in red, upregulated in low stromal CAV1 xenografts) to lowest (- values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000148346 LCN2 2,045596 0,028336 ENSG00000087245 MMP2 0,551171 0,023226 
ENSG00000255152 MSH5-SAPCD1 2,002525 0,033337 ENSG00000182095 TNRC18 0,550441 0,005876 
ENSG00000108342 CSF3 1,964561 0,001048 ENSG00000138166 DUSP5 0,543542 0,00703 
ENSG00000163739 CXCL1 1,470155 0,013832 ENSG00000117569 PTBP2 0,542261 0,022427 
ENSG00000125538 IL1B 1,455739 0,000352 ENSG00000090339 ICAM1 0,542155 0,012035 
ENSG00000060718 COL11A1 1,448327 3,82E-09 ENSG00000185567 AHNAK2 0,536339 0,020896 
ENSG00000136244 IL6 1,295209 0,004125 ENSG00000188157 AGRN 0,534647 0,001519 
ENSG00000135312 HTR1B 1,168583 0,025829 ENSG00000166833 NAV2 0,531536 0,03291 
ENSG00000173432 SAA1 1,146104 0,001047 ENSG00000072310 SREBF1 0,531396 0,009464 
ENSG00000144802 NFKBIZ 1,050571 0,03291 ENSG00000140937 CDH11 0,526859 0,011765 
ENSG00000173918 C1QTNF1 1,044405 0,044886 ENSG00000168140 VASN 0,526535 0,016947 
ENSG00000124102 PI3 0,989606 0,022427 ENSG00000130702 LAMA5 0,517342 0,011765 
ENSG00000169429 CXCL8 0,948367 0,054528 ENSG00000112972 HMGCS1 0,512876 0,007025 
ENSG00000118523 CTGF 0,9375 1,65E-07 ENSG00000142798 HSPG2 0,510781 0,023473 
ENSG00000183889  0,927572 5,45E-05 ENSG00000125730 C3 0,502682 0,030217 
ENSG00000183458  0,91949 0,004409 ENSG00000132182 NUP210 0,501293 0,028336 
ENSG00000139874 SSTR1 0,9072 0,022427 ENSG00000231925 TAPBP 0,495883 0,005876 
ENSG00000111799 COL12A1 0,858208 2,41E-10 ENSG00000167548 KMT2D 0,492876 0,025102 
ENSG00000159167 STC1 0,84278 0,00147 ENSG00000108175 ZMIZ1 0,489382 0,019813 
ENSG00000117525 F3 0,842685 0,025829 ENSG00000127603 MACF1 0,482384 0,01148 
ENSG00000143631 FLG 0,83654 0,000414 ENSG00000006118 TMEM132A 0,47764 0,021264 
ENSG00000184985 SORCS2 0,826184 0,016685 ENSG00000105426 PTPRS 0,477303 0,04965 
ENSG00000255103 KIAA0754 0,802871 0,04268 ENSG00000130635 COL5A1 0,470606 0,036631 
ENSG00000179304 FAM156B 0,775241 0,042317 ENSG00000178209 PLEC 0,466412 0,01148 
ENSG00000164694 FNDC1 0,775123 0,020368 ENSG00000148411 NACC2 0,455201 0,025102 
ENSG00000008710 PKD1 0,772642 0,000257 ENSG00000164916 FOXK1 0,454515 0,022427 
ENSG00000196159 FAT4 0,762888 0,032713 ENSG00000082805 ERC1 0,452872 0,052174 
ENSG00000176697 BDNF 0,761505 0,000629 ENSG00000166825 ANPEP 0,446466 0,022427 
ENSG00000178860 MSC 0,744839 0,009464 ENSG00000116604 MEF2D 0,414583 0,025829 
ENSG00000101825 MXRA5 0,721959 0,029447 ENSG00000169710 FASN 0,408844 0,022427 
ENSG00000139970 RTN1 0,700681 0,013244 ENSG00000196924 FLNA 0,346515 0,000772 
ENSG00000132510 KDM6B 0,698922 0,025672 ENSG00000049245 VAMP3 -0,48163 0,006376 
ENSG00000171951 SCG2 0,671467 0,029138 ENSG00000165678 GHITM -0,50637 0,006376 
ENSG00000121005 CRISPLD1 0,657991 0,001882 ENSG00000166592 RRAD -0,59142 0,01506 
ENSG00000131149 GSE1 0,652473 0,011765 ENSG00000125726 CD70 -0,60244 0,001194 
ENSG00000113739 STC2 0,652137 0,007128 ENSG00000079257 LXN -0,61127 0,047382 
ENSG00000064042 LIMCH1 0,646735 0,000908 ENSG00000224578 HNRNPA1P48 -0,63534 0,018385 
ENSG00000123384 LRP1 0,645181 0,000616 ENSG00000278619 MRM1 -0,63842 0,036631 
ENSG00000145147 SLIT2 0,64103 0,000464 ENSG00000130600 H19 -0,81287 1,91E-08 
ENSG00000164362 TERT 0,635454 0,018996 ENSG00000215784 FAM72D -0,92466 0,011765 
ENSG00000159399 HK2 0,614746 0,013244 ENSG00000004799 PDK4 -1,15946 0,030217 
ENSG00000105429 MEGF8 0,603989 0,022427 ENSG00000213145 CRIP1 -1,21443 0,000672 
ENSG00000130164 LDLR 0,602011 0,000104 ENSG00000167772 ANGPTL4 -1,56635 2,23E-05 
ENSG00000146674 IGFBP3 0,597894 0,032569 ENSG00000180389 ATP5EP2 -1,68601 0,022829 
ENSG00000145934 TENM2 0,592991 0,006376 ENSG00000105974 CAV1 -3,04018 1,8E-152 
ENSG00000116016 EPAS1 0,584937 0,000908 ENSG00000234648  -5,1131 3,35E-11 
ENSG00000138829 FBN2 0,583432 4,68E-05    
ENSG00000108797 CNTNAP1 0,569804 0,006507    
ENSG00000174807 CD248 0,568304 0,029138    
ENSG00000008513 ST3GAL1 0,562145 0,0094    
ENSG00000233369  0,560353 0,005203    
ENSG00000243649 CFB 0,558849 0,006376    
ENSG00000164951 PDP1 0,556529 0,012035     
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Table S7. RNASeq gene expression analysis data derived from in vitro 3D collagen-cultured CAFs. Gene expression fold-change (FC) is represented as log2FC and color coded from highest (positive 
values in red, upregulated in CAFshCAV1 fibroblasts) to lowest (negative values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000232220 AC008440.2 8,23094 7,217E-13 ENSG00000185745 IFIT1 0,48278 0,0031127 ENSG00000006625 GGCT 0,33559 0,0139116 ENSG00000197045 GMFB 0,24394 0,0002641 
ENSG00000226964 RHEBP2 7,96869 1,191E-10 ENSG00000245532 NEAT1 0,48093 4,595E-12 ENSG00000151914 DST 0,33373 1,57E-06 ENSG00000109066 TMEM104 0,24249 0,0064921 
ENSG00000185641 AC034236.1 7,90483 3,253E-09 ENSG00000110888 CAPRIN2 0,48071 0,0157469 ENSG00000119917 IFIT3 0,32854 0,0174358 ENSG00000164823 OSGIN2 0,24235 0,0357298 
ENSG00000269972 AC004542.1 7,66733 3,343E-09 ENSG00000117569 PTBP2 0,47438 0,0001139 ENSG00000125398 SOX9 0,32743 4,187E-07 ENSG00000128591 FLNC 0,2411 0,0005603 
ENSG00000173678 SPDYE2B 4,94491 5,004E-05 ENSG00000198712 MT-CO2 0,47132 5,069E-14 ENSG00000213066 FGFR1OP 0,32537 0,0029905 ENSG00000165055 METTL2B 0,24048 0,0271632 
ENSG00000274615 AC233968.1 3,35893 4,242E-07 ENSG00000198763 MT-ND2 0,4671 4,023E-10 ENSG00000146376 ARHGAP18 0,32057 0,0119896 ENSG00000131711 MAP1B 0,24022 0,0001714 
ENSG00000236552 RPL13AP5 3,27341 0,0021948 ENSG00000262246 CORO7 0,46691 0,0304064 ENSG00000145555 MYO10 0,31926 0,0004643 ENSG00000072274 TFRC 0,23918 2,724E-05 
ENSG00000261052 SULT1A3 3,19128 0,0006393 ENSG00000214548 MEG3 0,46426 0,0016603 ENSG00000185813 PCYT2 0,31341 0,0263757 ENSG00000050165 DKK3 0,23906 0,0094551 
ENSG00000169203  3,14353 3,129E-05 ENSG00000102359 SRPX2 0,46322 0,0179964 ENSG00000119139 TJP2 0,31201 0,0003821 ENSG00000157483 MYO1E 0,23846 0,0010709 
ENSG00000253816  2,49421 0,004115 ENSG00000049249 TNFRSF9 0,46201 0,0006514 ENSG00000006118 TMEM132A 0,31046 0,0079032 ENSG00000068366 ACSL4 0,2382 0,0001979 
ENSG00000277125  2,45126 0,0016727 ENSG00000248527 MTATP6P1 0,45752 1,615E-07 ENSG00000211459 MT-RNR1 0,30903 1,82E-06 ENSG00000168461 RAB31 0,23797 0,0011538 
ENSG00000196167 COLCA1 2,19359 0,0319548 ENSG00000123358 NR4A1 0,45367 0,04168 ENSG00000115107 STEAP3 0,3072 0,0455936 ENSG00000054654 SYNE2 0,2368 0,0226169 
ENSG00000180229 HERC2P3 1,90438 0,0351876 ENSG00000186480 INSIG1 0,43984 8,423E-15 ENSG00000077152 UBE2T 0,30675 0,0099472 ENSG00000156671 SAMD8 0,23604 0,0119896 
ENSG00000196205 EEF1A1P5 1,81226 5,151E-07 ENSG00000198804 MT-CO1 0,43563 1,031E-07 ENSG00000174136 RGMB 0,30549 0,0005229 ENSG00000163297 ANTXR2 0,23595 0,0034906 
ENSG00000270276 HIST2H4A 1,47339 0,0067682 ENSG00000104332 SFRP1 0,42718 6,704E-16 ENSG00000198604 BAZ1A 0,3051 0,0002414 ENSG00000169855 ROBO1 0,23585 0,0142293 
ENSG00000265590  1,42063 0,0402787 ENSG00000176973 KPNA2 0,42658 0,0289955 ENSG00000185947 ZNF267 0,30398 0,008898 ENSG00000196937 FAM3C 0,234 0,0002039 
ENSG00000181625 SLX1B 1,24007 0,0110788 ENSG00000050344 NFE2L3 0,42446 0,015626 ENSG00000112096 SOD2 0,30193 3,37E-08 ENSG00000196776 CD47 0,2331 0,0137888 
ENSG00000101670 LIPG 1,05241 0,03394 ENSG00000126709 IFI6 0,42341 9,475E-06 ENSG00000171608 PIK3CD 0,30166 0,0099466 ENSG00000127914 AKAP9 0,23296 0,0045286 
ENSG00000254996 ANKHD1-EIF4EB 1,02101 0,0021661 ENSG00000076554 TPD52 0,42216 0,0245767 ENSG00000101347 SAMHD1 0,29891 0,0005325 ENSG00000171055 FEZ2 0,23191 0,0349465 
ENSG00000152092 ASTN1 1,01984 0,035955 ENSG00000183722 LHFP 0,42211 0,002372 ENSG00000008710 PKD1 0,29788 0,0004398 ENSG00000123240 OPTN 0,23076 0,0165538 
ENSG00000169429 CXCL8 0,99876 0,0022509 ENSG00000169213 RAB3B 0,42182 5,395E-05 ENSG00000180447 GAS1 0,29724 0,0293885 ENSG00000068912 ERLEC1 0,2305 0,0074038 
ENSG00000156463 SH3RF2 0,87588 0,0279154 ENSG00000184371 CSF1 0,42146 9,375E-11 ENSG00000170776 AKAP13 0,29707 2,234E-06 ENSG00000121060 TRIM25 0,23047 0,0019453 
ENSG00000269547  0,86361 0,0183794 ENSG00000130164 LDLR 0,42099 6,332E-14 ENSG00000138778 CENPE 0,29703 0,0346485 ENSG00000049323 LTBP1 0,22884 0,0006993 
ENSG00000198910 L1CAM 0,83847 1,379E-36 ENSG00000210082 MT-RNR2 0,419 1,207E-16 ENSG00000120875 DUSP4 0,29582 0,0139539 ENSG00000173821 RNF213 0,22725 0,0012745 
ENSG00000125730 C3 0,7798 9,169E-39 ENSG00000041982 TNC 0,41536 8,742E-12 ENSG00000173705 SUSD5 0,29541 0,0162623 ENSG00000035862 TIMP2 0,22265 0,0001234 
ENSG00000065320 NTN1 0,77173 0,0057951 ENSG00000096433 ITPR3 0,41203 3,177E-10 ENSG00000163820 FYCO1 0,29133 0,0025174 ENSG00000188643 S100A16 0,22251 0,0014813 
ENSG00000157601 MX1 0,75286 0,0001082 ENSG00000137965 IFI44 0,40769 0,0207954 ENSG00000166797 FAM96A 0,28942 0,0198118 ENSG00000039560 RAI14 0,22242 0,0255511 
ENSG00000072657 TRHDE 0,70376 0,0002118 ENSG00000170558 CDH2 0,40516 0,0246263 ENSG00000136048 DRAM1 0,28844 1,126E-05 ENSG00000112972 HMGCS1 0,2219 0,0321356 
ENSG00000012171 SEMA3B 0,68862 0,0286696 ENSG00000198727 MT-CYB 0,40345 3,929E-07 ENSG00000177706 FAM20C 0,28655 0,0001225 ENSG00000109787 KLF3 0,22151 0,0479161 
ENSG00000185567 AHNAK2 0,68769 1,752E-08 ENSG00000204580 DDR1 0,40217 5,776E-12 ENSG00000164171 ITGA2 0,28482 0,0125715 ENSG00000101745 ANKRD12 0,2203 0,013153 
ENSG00000272398 CD24 0,66555 0,0274359 ENSG00000212907 MT-ND4L 0,40189 2,807E-05 ENSG00000139880 CDH24 0,28449 0,0293885 ENSG00000160285 LSS 0,21917 0,0138255 
ENSG00000163131 CTSS 0,64642 0,0382972 ENSG00000167191 GPRC5B 0,39882 0,0286696 ENSG00000278540 ACACA 0,28449 1,321E-05 ENSG00000162576 MXRA8 0,21886 0,0023849 
ENSG00000138944 KIAA1644 0,64062 0,0244026 ENSG00000198938 MT-CO3 0,39807 7,413E-11 ENSG00000108797 CNTNAP1 0,28203 0,0047499 ENSG00000113083 LOX 0,2188 0,0012805 
ENSG00000244257 PKD1P1 0,6356 0,0329383 ENSG00000138496 PARP9 0,39804 0,0184978 ENSG00000197321 SVIL 0,28184 0,04168 ENSG00000058668 ATP2B4 0,21828 0,0108965 
ENSG00000243649 CFB 0,62732 1,239E-09 ENSG00000111674 ENO2 0,3971 0,0004288 ENSG00000172216 CEBPB 0,28023 0,0048092 ENSG00000149485 FADS1 0,21749 0,0012816 
ENSG00000115041 KCNIP3 0,60567 0,04168 ENSG00000166833 NAV2 0,39304 9,35E-06 ENSG00000159167 STC1 0,27648 0,0307308 ENSG00000091409 ITGA6 0,21599 0,0026423 
ENSG00000111335 OAS2 0,59333 0,0034906 ENSG00000049130 KITLG 0,3929 0,0227626 ENSG00000109756 RAPGEF2 0,27445 0,0286696 ENSG00000006576 PHTF2 0,21326 0,0068553 
ENSG00000275993  0,59125 0,0017387 ENSG00000198695 MT-ND6 0,39263 0,0026423 ENSG00000011021 CLCN6 0,27197 0,0119896 ENSG00000239264 TXNDC5 0,21286 0,0090958 
ENSG00000138623 SEMA7A 0,58692 4,305E-08 ENSG00000075213 SEMA3A 0,39161 0,0018134 ENSG00000169710 FASN 0,27151 1,272E-06 ENSG00000152332 UHMK1 0,21061 0,0017561 
ENSG00000261796 ISY1-RAB43 0,58335 0,0380798 ENSG00000147100 SLC16A2 0,39026 2,234E-06 ENSG00000115295 CLIP4 0,27092 0,0231069 ENSG00000142156 COL6A1 0,20829 0,0019847 
ENSG00000225630 MTND2P28 0,57618 4,189E-05 ENSG00000147459 DOCK5 0,3897 0,0001058 ENSG00000031691 CENPQ 0,27045 0,0283891 ENSG00000141458 NPC1 0,20656 0,0200808 
ENSG00000114270 COL7A1 0,5753 4,724E-06 ENSG00000188158 NHS 0,38208 0,0050756 ENSG00000134824 FADS2 0,26967 0,0008062 ENSG00000110841 PPFIBP1 0,20529 0,0217095 
ENSG00000136040 PLXNC1 0,57478 0,00023 ENSG00000132561 MATN2 0,37757 2,629E-08 ENSG00000111670 GNPTAB 0,26839 0,0021441 ENSG00000176658 MYO1D 0,20292 0,035955 
ENSG00000100342 APOL1 0,56492 0,0020056 ENSG00000171310 CHST11 0,37736 0,0376443 ENSG00000112769 LAMA4 0,26782 0,0012816 ENSG00000003436 TFPI 0,20184 0,0035621 
ENSG00000072310 SREBF1 0,55849 5,604E-18 ENSG00000163975 MFI2 0,37517 0,0002291 ENSG00000166471 TMEM41B 0,26686 0,0164967 ENSG00000163565 IFI16 0,20055 0,0238458 
ENSG00000144802 NFKBIZ 0,55684 1,999E-05 ENSG00000198899 MT-ATP6 0,37232 0,0002287 ENSG00000163840 DTX3L 0,26443 0,0029727 ENSG00000145623 OSMR 0,20011 0,0249215 
ENSG00000100867 DHRS2 0,5543 0,0003644 ENSG00000228253 MT-ATP8 0,3719 0,0010848 ENSG00000177542 SLC25A22 0,26331 0,045211 ENSG00000105576 TNPO2 0,19916 0,0321356 
ENSG00000099194 SCD 0,55222 4,204E-29 ENSG00000138166 DUSP5 0,36965 0,0167936 ENSG00000146373 RNF217 0,26094 0,021075 ENSG00000170385 SLC30A1 0,19905 0,0388403 
ENSG00000130589 HELZ2 0,55163 3,62E-12 ENSG00000032389 TSSC1 0,36675 0,0310641 ENSG00000143631 FLG 0,25776 0,0050241 ENSG00000148848 ADAM12 0,19851 0,0187369 
ENSG00000187720 THSD4 0,55101 1,326E-06 ENSG00000198886 MT-ND4 0,35694 0,0002837 ENSG00000033867 SLC4A7 0,25731 0,0020389 ENSG00000146676 PURB 0,19722 0,0104196 
ENSG00000157193 LRP8 0,5449 0,0025174 ENSG00000237975 FLG-AS1 0,3568 0,0249215 ENSG00000161091 MFSD12 0,257 0,0106283 ENSG00000130779 CLIP1 0,19628 0,0247746 
ENSG00000125538 IL1B 0,54416 0,0446641 ENSG00000177409 SAMD9L 0,35383 0,0144006 ENSG00000138182 KIF20B 0,2559 0,0018937 ENSG00000173230 GOLGB1 0,19611 0,0249215 
ENSG00000137767 SQRDL 0,54095 0,0340547 ENSG00000144681 STAC 0,35276 0,023027 ENSG00000163597 SNHG16 0,25351 0,0004143 ENSG00000100815 TRIP11 0,19455 0,0147922 
ENSG00000165029 ABCA1 0,53673 5,879E-08 ENSG00000135905 DOCK10 0,35258 0,0026423 ENSG00000123983 ACSL3 0,25175 0,0003821 ENSG00000164951 PDP1 0,19408 0,0081194 
ENSG00000158258 CLSTN2 0,52649 0,0031555 ENSG00000041353 RAB27B 0,35 0,0218139 ENSG00000148730 EIF4EBP2 0,25109 0,0001801 ENSG00000231925 TAPBP 0,193 0,0048355 
ENSG00000111331 OAS3 0,51703 0,021075 ENSG00000165288 BRWD3 0,34765 0,0431162 ENSG00000067064 IDI1 0,25028 0,0151613 ENSG00000117519 CNN3 0,19272 0,0064433 
ENSG00000198888 MT-ND1 0,51115 1,351E-12 ENSG00000176170 SPHK1 0,34628 0,0447515 ENSG00000168077 SCARA3 0,24869 0,0096021 ENSG00000117298 ECE1 0,18955 0,0080874 
ENSG00000108691 CCL2 0,50044 0,0161777 ENSG00000138193 PLCE1 0,34338 0,030053 ENSG00000164465 DCBLD1 0,24724 0,0088939 ENSG00000082641 NFE2L1 0,18936 0,0080874 
ENSG00000168398 BDKRB2 0,48959 5,324E-06 ENSG00000145147 SLIT2 0,3416 0,0018089 ENSG00000136235 GPNMB 0,24626 0,0170382 ENSG00000117724 CENPF 0,18921 0,0287396 
ENSG00000128606 LRRC17 0,4875 0,0039806 ENSG00000198786 MT-ND5 0,33752 0,0015489 ENSG00000109046 WSB1 0,24511 0,0491125 ENSG00000181704 YIPF6 0,18883 0,0460754 
ENSG00000130702 LAMA5 0,48366 7,088E-08 ENSG00000198840 MT-ND3 0,33645 3,469E-07 ENSG00000144674 GOLGA4 0,24398 0,002742 ENSG00000224531 SMIM13 0,18877 0,031493 
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Table S7. RNASeq gene expression analysis data derived from in vitro 3D collagen-cultured CAFs. Gene expression fold-change (FC) is represented as log2FC and color coded from highest (positive 
values in red, upregulated in CAFshCAV1 fibroblasts) to lowest (negative values in green, downregulated) values. Benjamini-Hochberg adjusted p-values for multiple comparisons (adj.P.Val). 
 
 
 
ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val ID hgnc_symbol logFC adj.P.Val 
ENSG00000137177 KIF13A 0,18866 0,0174358 ENSG00000158941 CCAR2 -0,1817 0,0308082 ENSG00000141424 SLC39A6 -0,2562 0,0049507 ENSG00000013619 MAMLD1 -0,3716 0,043977 
ENSG00000100997 ABHD12 0,1857 0,0128471 ENSG00000234851  -0,1827 0,0129579 ENSG00000206418 RAB12 -0,2571 0,0069572 ENSG00000205250 E2F4 -0,3739 0,0029571 
ENSG00000188042 ARL4C 0,18504 0,0363349 ENSG00000011304 PTBP1 -0,1829 0,008898 ENSG00000160953 MUM1 -0,2572 0,0358537 ENSG00000185722 ANKFY1 -0,3758 1,837E-09 
ENSG00000090889 KIF4A 0,18376 0,0474999 ENSG00000227097  -0,184 0,0460754 ENSG00000258232  -0,2603 0,004194 ENSG00000151292 CSNK1G3 -0,3799 4,532E-05 
ENSG00000131016 AKAP12 0,18337 0,0099472 ENSG00000197594 ENPP1 -0,1856 0,0103869 ENSG00000133243 BTBD2 -0,2608 0,0033862 ENSG00000090470 PDCD7 -0,3806 0,0003185 
ENSG00000157106 SMG1 0,18072 0,0286696 ENSG00000167996 FTH1 -0,1863 0,0036263 ENSG00000168255 POLR2J3 -0,2643 0,0200808 ENSG00000128714 HOXD13 -0,3823 0,03394 
ENSG00000055332 EIF2AK2 0,18033 0,021685 ENSG00000177600 RPLP2 -0,1871 0,0031127 ENSG00000113721 PDGFRB -0,2644 0,0079932 ENSG00000158987 RAPGEF6 -0,387 0,0004306 
ENSG00000151893 CACUL1 0,17982 0,0351876 ENSG00000019549 SNAI2 -0,1875 0,015626 ENSG00000101911 PRPS2 -0,2649 0,0006565 ENSG00000056998 GYG2 -0,3875 0,0149889 
ENSG00000116133 DHCR24 0,17973 0,0184396 ENSG00000171150 SOCS5 -0,1894 0,047995 ENSG00000111711 GOLT1B -0,2671 0,0104936 ENSG00000165655 ZNF503 -0,3933 0,0006565 
ENSG00000071054 MAP4K4 0,17924 0,0146752 ENSG00000079805 MUCL1 -0,1895 0,0162332 ENSG00000049245 VAMP3 -0,2683 0,0001223 ENSG00000101224 CDC25B -0,406 8,52E-11 
ENSG00000164733 CTSB 0,17617 0,0050937 ENSG00000175970 UNC119B -0,1898 0,0452733 ENSG00000168916 ZNF608 -0,2687 0,04168 ENSG00000151702 FLI1 -0,4081 0,0226585 
ENSG00000135862 LAMC1 0,17607 0,0118003 ENSG00000119402 FBXW2 -0,1914 0,023027 ENSG00000063438 AHRR -0,2697 0,0045781 ENSG00000198959 TGM2 -0,4299 1,11E-10 
ENSG00000107957 SH3PXD2A 0,17593 0,0249215 ENSG00000136937 NCBP1 -0,1939 0,0293885 ENSG00000243927 MRPS6 -0,2716 0,0298548 ENSG00000169071 ROR2 -0,4342 0,0001738 
ENSG00000158270 COLEC12 0,1751 0,0185072 ENSG00000156639 ZFAND3 -0,1943 0,008296 ENSG00000111799 COL12A1 -0,2716 1,326E-06 ENSG00000038427 VCAN -0,4358 7,018E-14 
ENSG00000108854 SMURF2 0,1744 0,0361327 ENSG00000108821 COL1A1 -0,1943 0,0119896 ENSG00000156531 PHF6 -0,2724 0,000594 ENSG00000184838 PRR16 -0,4373 8,2E-07 
ENSG00000213625 LEPROT 0,17304 0,0418916 ENSG00000162521 RBBP4 -0,1951 0,0045141 ENSG00000164442 CITED2 -0,2756 5,8E-07 ENSG00000168685 IL7R -0,4394 1,155E-08 
ENSG00000184743 ATL3 0,16874 0,0473037 ENSG00000204217 BMPR2 -0,1992 0,0227626 ENSG00000105220 GPI -0,2777 8,241E-07 ENSG00000164761 TNFRSF11B -0,4446 0,0154846 
ENSG00000162909 CAPN2 0,16711 0,0167816 ENSG00000082781 ITGB5 -0,2008 0,002742 ENSG00000047644 WWC3 -0,2782 3,025E-05 ENSG00000085719 CPNE3 -0,4538 4,161E-17 
ENSG00000057019 DCBLD2 0,16536 0,0298666 ENSG00000087245 MMP2 -0,2026 0,0049268 ENSG00000138069 RAB1A -0,2786 2,875E-05 ENSG00000162692 VCAM1 -0,4559 0,0293885 
ENSG00000108179 PPIF 0,16385 0,047034 ENSG00000135372 NAT10 -0,2045 0,0064332 ENSG00000163659 TIPARP -0,2795 0,0128471 ENSG00000113732 ATP6V0E1 -0,4574 4,307E-10 
ENSG00000132824 SERINC3 0,16201 0,0355241 ENSG00000114062 UBE3A -0,205 0,006169 ENSG00000091986 CCDC80 -0,2797 0,000101 ENSG00000117152 RGS4 -0,4606 6,746E-05 
ENSG00000116260 QSOX1 0,1609 0,0434901 ENSG00000106211 HSPB1 -0,2062 0,003805 ENSG00000168778 TCTN2 -0,2833 0,0231484 ENSG00000134986 NREP -0,4635 8,763E-16 
ENSG00000188157 AGRN 0,16056 0,0418916 ENSG00000187498 COL4A1 -0,2095 0,019487 ENSG00000269888  -0,2839 0,0361193 ENSG00000135097 MSI1 -0,4665 0,0161777 
ENSG00000156535 CD109 0,15416 0,0344345 ENSG00000101335 MYL9 -0,2098 0,0021689 ENSG00000064393 HIPK2 -0,2864 2,023E-06 ENSG00000074621 SLC24A1 -0,486 0,0073043 
ENSG00000128595 CALU 0,15105 0,033799 ENSG00000138061 CYP1B1 -0,2113 0,0009146 ENSG00000155760 FZD7 -0,2889 1,904E-05 ENSG00000179387 ELMOD2 -0,4939 2,851E-07 
ENSG00000120708 TGFBI 0,14592 0,043977 ENSG00000147457 CHMP7 -0,2123 0,0379649 ENSG00000166224 SGPL1 -0,2923 0,0011538 ENSG00000166923 GREM1 -0,5064 1,911E-25 
ENSG00000105193 RPS16 -0,1428 0,0490083 ENSG00000136153 LMO7 -0,2138 0,0031855 ENSG00000137075 RNF38 -0,2976 0,0168259 ENSG00000139211 AMIGO2 -0,5227 4,313E-09 
ENSG00000063177 RPL18 -0,1439 0,0445537 ENSG00000143970 ASXL2 -0,2152 0,0366105 ENSG00000233369  -0,2978 4,441E-05 ENSG00000011465 DCN -0,5299 5,395E-05 
ENSG00000148303 RPL7A -0,1442 0,0440839 ENSG00000124766 SOX4 -0,2165 0,021685 ENSG00000106683 LIMK1 -0,2983 3,411E-06 ENSG00000152049 KCNE4 -0,5379 0,0090445 
ENSG00000198431 GML -0,1524 0,0343167 ENSG00000204262 COL5A2 -0,218 0,0002576 ENSG00000157045 NTAN1 -0,3008 0,0002288 ENSG00000106771 TMEM245 -0,539 6,357E-22 
ENSG00000139926 FRMD6 -0,1549 0,0282103 ENSG00000092964 DPYSL2 -0,2183 0,0069572 ENSG00000154222 CC2D1B -0,3086 0,002264 ENSG00000137337 MDC1 -0,5487 2,125E-21 
ENSG00000142534 RPS11 -0,155 0,0227626 ENSG00000185122 HSF1 -0,2215 0,0249215 ENSG00000100335 MIEF1 -0,3102 7,463E-06 ENSG00000104067 TJP1 -0,551 1,161E-12 
ENSG00000204388 HSPA1B -0,1555 0,0263265 ENSG00000129474 AJUBA -0,224 0,0031127 ENSG00000088367 EPB41L1 -0,3141 0,0069572 ENSG00000079102 RUNX1T1 -0,5569 0,0031555 
ENSG00000110880 CORO1C -0,1587 0,0255511 ENSG00000095261 PSMD5 -0,2248 0,0185032 ENSG00000111412 C12orf49 -0,3192 0,0017147 ENSG00000128656 CHN1 -0,5594 1,419E-05 
ENSG00000089157 RPLP0 -0,1621 0,0198664 ENSG00000115380 EFEMP1 -0,2251 0,0010841 ENSG00000162980 ARL5A -0,3196 0,0002641 ENSG00000184232 OAF -0,5833 0,0030497 
ENSG00000169100 SLC25A6 -0,1648 0,0191721 ENSG00000125753 VASP -0,2254 0,0256721 ENSG00000115758 ODC1 -0,3204 3,462E-06 ENSG00000154736 ADAMTS5 -0,5987 9,71E-17 
ENSG00000140988 RPS2 -0,1661 0,0109154 ENSG00000164741 DLC1 -0,226 0,000594 ENSG00000005075 POLR2J -0,321 0,0017147 ENSG00000172260 NEGR1 -0,5995 0,0019438 
ENSG00000142871 CYR61 -0,167 0,0267385 ENSG00000177954 RPS27 -0,2274 0,0031492 ENSG00000101079 NDRG3 -0,3221 0,0044175 ENSG00000149948 HMGA2 -0,6078 1,469E-06 
ENSG00000135677 GNS -0,1679 0,0135152 ENSG00000104823 ECH1 -0,2296 0,0293885 ENSG00000169439 SDC2 -0,3221 2,036E-05 ENSG00000165678 GHITM -0,637 2,999E-30 
ENSG00000184900 SUMO3 -0,1684 0,0293885 ENSG00000198833 UBE2J1 -0,23 0,0034935 ENSG00000234127 TRIM26 -0,3225 8,461E-06 ENSG00000143473 KCNH1 -0,6512 0,0001558 
ENSG00000111817 DSE -0,1689 0,0198118 ENSG00000012232 EXTL3 -0,2318 0,0019472 ENSG00000167693 NXN -0,3238 3,639E-05 ENSG00000172780 RAB43 -0,6623 0,0050201 
ENSG00000147475 ERLIN2 -0,1692 0,0324185 ENSG00000137809 FLRT1 -0,2337 0,0008864 ENSG00000106484 MEST -0,3248 2,891E-09 ENSG00000152377 SPOCK1 -0,7318 3,003E-47 
ENSG00000128510 CPA4 -0,1698 0,0221317 ENSG00000137818 RPLP1 -0,2347 2,497E-05 ENSG00000166402 TUB -0,3272 0,0014635 ENSG00000140299 BNIP2 -0,8122 2,999E-30 
ENSG00000162430 SEPN1 -0,1709 0,0325975 ENSG00000114251 WNT5A -0,2357 0,0012849 ENSG00000106554 CHCHD3 -0,3282 7,193E-07 ENSG00000002834 LASP1 -0,8261 9,964E-56 
ENSG00000163430 FSTL1 -0,1715 0,0070879 ENSG00000144283 PKP4 -0,2383 0,0184931 ENSG00000074219 TEAD2 -0,3286 0,0194613 ENSG00000122694 GLIPR2 -0,8982 0,0006766 
ENSG00000197958 RPL12 -0,1717 0,0102571 ENSG00000177700 POLR2L -0,2389 0,0011988 ENSG00000110492 MDK -0,3311 1,442E-08 ENSG00000269378 ITGB1P1 -0,9737 0,0302535 
ENSG00000186340 THBS2 -0,1718 0,0199249 ENSG00000159267 HLCS -0,2399 0,0501182 ENSG00000123689 G0S2 -0,3335 0,0380798 ENSG00000230409 TCEA1P2 -0,9777 0,007253 
ENSG00000083845 RPS5 -0,1719 0,0221337 ENSG00000163171 CDC42EP3 -0,2399 0,0005303 ENSG00000166340 TPP1 -0,3339 6,765E-08 ENSG00000142178 SIK1 -1,026 0,0293726 
ENSG00000183688 FAM101B -0,173 0,0347705 ENSG00000156052 GNAQ -0,2408 0,0018004 ENSG00000103888 CEMIP -0,3352 9,063E-05 ENSG00000235174 RPL39P3 -1,084 3,291E-06 
ENSG00000241343 RPL36A -0,1751 0,0231069 ENSG00000006042 TMEM98 -0,2423 0,0227626 ENSG00000076770 MBNL3 -0,3357 0,0380798 ENSG00000170667 RASA4B -1,2985 2,428E-05 
ENSG00000124813 RUNX2 -0,1752 0,0191344 ENSG00000105137 SYDE1 -0,2432 0,0227626 ENSG00000116954 RRAGC -0,3455 5,483E-05 ENSG00000259040 BLOC1S5-TXNDC -1,4775 2,619E-63 
ENSG00000197702 PARVA -0,1762 0,0351876 ENSG00000204389 HSPA1A -0,2437 0,0002142 ENSG00000137801 THBS1 -0,3472 5,344E-11 ENSG00000167774  -1,5282 0,0341707 
ENSG00000196313 POM121 -0,1775 0,0447515 ENSG00000162889 MAPKAPK2 -0,2449 0,0007489 ENSG00000143341 HMCN1 -0,3489 0,0186761 ENSG00000242852 ZNF709 -2,0062 0,0168495 
ENSG00000213741 RPS29 -0,178 0,0200808 ENSG00000153904 DDAH1 -0,2484 0,0005303 ENSG00000182492 BGN -0,3547 0,0035342 ENSG00000259952  -2,0332 0,0003031 
ENSG00000106723 SPIN1 -0,179 0,0321592 ENSG00000167513 CDT1 -0,2494 0,0156067 ENSG00000165449 SLC16A9 -0,3578 0,0053141 ENSG00000274570  -2,1424 0,0231484 
ENSG00000101290 CDS2 -0,1793 0,0427825 ENSG00000162734 PEA15 -0,2511 5,317E-05 ENSG00000153721 CNKSR3 -0,3586 8,412E-06 ENSG00000229927 RHEBP1 -2,2732 0,0293885 
ENSG00000150347 ARID5B -0,1797 0,021685 ENSG00000131389 SLC6A6 -0,2513 0,0038883 ENSG00000167244 IGF2 -0,3586 0,0286696 ENSG00000271894  -2,2806 0,0293885 
ENSG00000063245 EPN1 -0,1798 0,0227768 ENSG00000197457 STMN3 -0,2534 0,005984 ENSG00000145919 BOD1 -0,3595 2,428E-05 ENSG00000277971  -2,6263 0,0180433 
ENSG00000149257 SERPINH1 -0,1803 0,0090958 ENSG00000089006 SNX5 -0,254 0,0018004 ENSG00000163935 SFMBT1 -0,362 0,0021745 ENSG00000270136 MINOS1-NBL1 -2,8708 6,858E-12 
ENSG00000058063 ATP11B -0,1807 0,0351876 ENSG00000139329 LUM -0,2549 0,0015396 ENSG00000106052 TAX1BP1 -0,3649 5,89E-09 ENSG00000105974 CAV1 -2,8903 0 
ENSG00000119408 NEK6 -0,1811 0,0240563 ENSG00000084444 KIAA1467 -0,2555 0,0465882 ENSG00000099622 CIRBP -0,3695 1,17E-05 ENSG00000258757  -3,2297 0,0005325  
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Goya Mundus 2012 Grant (UPC/EMES, Summer 2012)  
UFV Scholarship for students with Excellent Academic 
Performance (UFV, 2007 - 2012) 
 
• Course on Microscopy and  Advanced 
Applications (Zeiss, 2014) 
• Animal Experimentation Function A 
(Charles River Laboratories, 2015)  
• Open Water Diver (PADI, 2011) 
• Become a web developer from scratch 
(Udemy, in progress) 
Awards  AIT Student of the Year in BSc in Biotechnology (AIT, Oct 2011) 
Madrid Academic Excellence Scholarship (EMES, 2010 - 2011) 
2012 - 
2012-13 
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2010-11 
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Projects 
 
  
 
 
Drug screening targeting Cav1 in 
pancreatic stromal fibroblasts 
Collaboration with Experimental 
Therapeutics + Gastrointestinal Cancer 
at CNIO (Spanish National Cancer 
Research Center) 
Designed a small 50 drug screening with 
various doses and successfully found 3 
approved drugs capable of decreasing Cav1 
levels.  
Coordinated a team of image analysis 
engineers and high content technicians. 
 
 
Genome editing of Cav1 in NSG mice & 
various cell lines 
Collaboration with Transgenics Unit at 
CNIC 
An NSG Cav1 KO mice colony has been 
established using ZnFinger mediated 
genome editing in record time. 
Deletion of Cav1 gene in cell lines with an 
improved version (designed and modified by 
myself) of the commercial ZnFinger plasmid 
provided by Sigma increasing the efficiency 
of the procedure and decreasing the 
workload. 
 
Role of Cav1 levels in stromal 
fibroblasts in angiogenesis, tumor 
hypoxia & disease progression 
PhD Project at CNIC 
I am using a combination of HCS assays, 
transcriptomics and animal models to unveil 
the effect of the absence of Cav1 in the 
stroma of breast cancer tumors, particularly 
in tumor angiogenesis, hypoxia and 
metastasis (Work in progress) 
 
 
